US20070202186A1 - Apparatus and formulations for suprachoroidal drug delivery - Google Patents
Apparatus and formulations for suprachoroidal drug delivery Download PDFInfo
- Publication number
- US20070202186A1 US20070202186A1 US11/709,941 US70994107A US2007202186A1 US 20070202186 A1 US20070202186 A1 US 20070202186A1 US 70994107 A US70994107 A US 70994107A US 2007202186 A1 US2007202186 A1 US 2007202186A1
- Authority
- US
- United States
- Prior art keywords
- suprachoroidal space
- eye
- drug
- formulation
- needle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0026—Ophthalmic product dispenser attachments to facilitate positioning near the eye
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00736—Instruments for removal of intra-ocular material or intra-ocular injection, e.g. cataract instruments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/48—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for varying, regulating, indicating or limiting injection pressure
- A61M5/486—Indicating injection pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3103—Leak prevention means for distal end of syringes, i.e. syringe end for mounting a needle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0612—Eyes
Definitions
- the invention relates to the field of drug delivery into the eye.
- the eye is a complex organ with a variety of specialized tissues that provide the optical and neurological processes for vision. Accessing the eye for medical treatment is hindered by the small size and delicate nature of the tissues.
- the posterior region of the eye, including the retina, macula and optic nerve, is especially difficult to access due to the recessed position of the eye within the orbital cavity.
- topical eye drops penetrate poorly into the posterior region, further restricting treatment options.
- the suprachoroidal space is a potential space in the eye that is located between the choroid, which is the inner vascular tunic, and the sclera, the outer layer of the eye.
- the suprachoroidal space extends from the anterior portion of the eye near the ciliary body to the posterior end of the eye near the optic nerve. Normally the suprachoroidal space is not evident due to the close apposition of the choroid to the sclera from the intraocular pressure of the eye. Since there is no substantial attachment of the choroid to the sclera, the tissues separate to form the suprachoroidal space when fluid accumulation or other conditions occur.
- the suprachoroidal space provides a potential route of access from the anterior region of the eye to treat the posterior region.
- the present invention is directed to drug formulations for administration to the suprachoroidal space and an apparatus to deliver drugs and other substances in minimally invasive fashion to the suprachoroidal space.
- Drug formulations are provided characterized by a zero shear viscosity of at least 300,000 mPas.
- a subclass of the drug formulations is further characterized by a viscosity of not more than about 400 mPas at 1000 s ⁇ 1 shear rate.
- a biologically active substance for injection into the suprachoroidal space of an eye comprising a biologically active substance and a thixotropic polymeric excipient that acts as a gel-like material to spread after injection and uniformly distribute and localize the drug in a region of the suprachoroidal space.
- gel-like material crosslinks after injection into the suprachoroidal space.
- the biologically active substance may comprise microparticles or microspheres.
- the polymeric excipient may comprise hyaluronic acid, chondroitin sulfate, gelatin, polyhydroxyethylmethacrylate, dermatin sulfate, polyethylene oxide, polyethylene glycol, polypropylene oxide, polypropylene glycol, alginate, starch derivatives, a water soluble chitin derivative, a water soluble cellulose derivative or polyvinylpyrollidone.
- a drug formulation for delivery to the suprachoroidal space of an eye comprising a biologically active substance and microspheres with an outer diameter in the range of about 1 to 33 microns.
- the microparticles or microspheres additionally may comprise a controlled release coating and/or a tissue affinity surface.
- the biologically active substance preferably comprises an antibiotic, a steroid, a non-steroidal anti-inflammatory agent, a neuroprotectant, an anti-VEGF agent, or a neovascularization suppressant.
- Devices are also provided for minimally invasive delivery of a drug formulation into the suprachoroidal space of the eye comprising a needle having a leading tip shaped to allow passage through scleral tissues without damage to the underlying choroidal tissues, and a sensor to guide placement of the tip to deliver the formulation adjacent to or within the suprachoroidal space.
- the sensor may provide an image of the scleral tissues.
- the sensor preferably responds to ultrasound, light, or differential pressure.
- devices for minimally invasive delivery of a drug formulation into the suprachoroidal space of the eye comprising a needle having a leading tip shaped to allow passage through scleral tissues, and an inner tip that provides an inward distending action to the choroid upon contacting the choroid to prevent trauma thereto.
- Methods for administering drugs to the eye comprising placing a formulation comprising a biologically active substance and a polymer excipient in the suprachoroidal space such that the excipient gels after delivery to localize said biologically active substance.
- the formulation may be placed in a posterior or anterior region of the suprachoroidal space.
- method for administering drugs to a posterior region of the eye comprising placing a formulation comprising a biologically active substance comprising microspheres or microparticles with an outer diameter in the range of about 1 to 33 microns in an anterior region of the suprachoroidal space such that the microspheres or microparticles subsequently migrate to the posterior region.
- the formulation preferably comprises a polymer excipient to uniformly disperse the microparticles or microspheres in the suprachoroidal space.
- a method is provided of administering drugs in the suprachoroidal space of the eye comprising the steps of placing a needle in scleral tissues toward the suprachoroidal space at a depth of at least half of the scleral thickness, and injecting a drug formulation through the needle into the sclera such that the formulation dissects the scleral tissues adjacent to the suprachoroidal space and enters the suprachoroidal space.
- the formulation preferably comprises a thixotropic polymer.
- FIG. 1 is an ultrasound image of a portion of the eye after injection by needle into the sclera of a hyaluronic acid surgical viscoelastic material according to Example 9 .
- FIG. 2 is an ultrasonic image of a portion of the eye during injection by needle into the sclera of a 1:1 by volume mixture of the viscoelastic material and 1% solution of polystyrene microspheres according to Example 9.
- FIGS. 3 a and 3 b are diagrams of an embodiment of a delivery device according to the invention having a distending and cutting or ablative tip.
- FIG. 4 is a diagram showing the location of a delivery device according to the invention relative to the target sclera, suprachoroidal space and choroid.
- FIG. 5 is a diagram of an embodiment of a delivery device according to the invention having a stop plate to set the depth and angle of penetration of the needle into the eye.
- FIG. 6 is a diagram of an embodiment of a delivery device according to the invention that accommodates a microendoscope and camera to monitor the location of the cannula tip during surgery.
- FIG. 7 is a diagram of an embodiment of a delivery device having a lumen for delivery of drugs through a catheter into the eye and a fiber optic line connected to an illumination source to illuminate the tip if the cannula.
- FIG. 8 is a diagram of an embodiment of the use of a device according to the invention in conjunction with a high resolution imaging device to monitor the location of the tip of the cannula.
- the present invention comprises drug formulations, devices and related methods to access the suprachoroidal space of an eye for the purpose of delivering drugs to treat the eye.
- the invention relates to drug formulations designed for suprachoroidal space administration to treat the eye, including specific regions of the eye by localization of the delivered drug.
- the invention also relates to the design and methods of use for a minimally invasive device to inject drug formulations and drug containing materials directly into the suprachoroidal space through a small needle.
- a biologically active substance or material is a drug or other substance that affects living organisms or biological processes, including use in the diagnosis, cure, mitigation, treatment, or prevention of disease or use to affect the structure or any function of the body.
- a drug formulation contains a biologically active substance.
- the anterior region of the eye is that region of the eye that is generally readily accessible from the exposed front surface of the eye in its socket.
- the posterior region of the eye is generally the remaining region of the eye that is primarily surgically accessed through a surface of the eye that is unexposed, thus often requiring temporary retraction of the eye to gain access to that surface.
- the drug formulations of the invention provide compatibility with the suprachoroidal space environment and may be formulated to control the distribution of the biologically active substance by migration of the formulation as well as provide for sustained release over time.
- the drug formulation comprises one or more biologically active substances formulated with physiologically compatible excipients that are administered, typically by injection, into the suprachoroidal space of an eye. Suitable biologically active substances include antibiotics to treat infection, steroids and non-steroidal anti-inflammatory compounds to treat inflammation and edema, neuroprotectant agents such as calcium channel blockers to treat the optic nerve and retinal agents such as anti-VEGF compounds or neo-vascular suppressants to treat macular degeneration.
- the drug may be prepared in a formulation to limit migration after delivery and delivered to the region of the lesion. While not intending to be bound by a particular theory, we observe that drug microparticles typically travel toward the posterior region of the suprachoroidal space under physiological conditions, presumably due to uveal-scleral fluid flow within the space. Such drug microparticles may be fabricated with sufficient size and optionally with tissue surface affinity to limit drug migration. Tissue surface affinity may be modified by the addition of polymeric or lipid surface coatings to the microparticles, or by the addition of chemical or biological moieties to the microparticle surface.
- Tissue affinity is thereby obtained from surface charge, hydrophobicity, or biological targeting agents such as antibodies or integrins that may be incorporated to the surface of the microparticles to provide a binding property with the tissues to limit drug migration.
- the drug may be formulated with one or more polymeric excipients to limit drug migration.
- a polymeric excipient may be selected and formulated to act as a viscous gel-like material in-situ and thereby spread into a region of the suprachoroidal space and uniformly distribute and retain the drug.
- the polymer excipient may be selected and formulated to provide the appropriate viscosity, flow and dissolution properties.
- carboxymethylcellulose is a weakly thixotropic water soluble polymer that may be formulated to an appropriate viscosity at zero shear rate to form a gel-like material in the suprachoroidal space.
- the thixotropic effect of the polymer may be enhanced by appropriate chemical modification to the polymer to increase associative properties such as the addition of hydrophobic moieties, the selection of higher molecular weight polymer or by formulation with appropriate surfactants.
- Preferred is the use of highly associative polymeric excipients with strong thixotropic properties such as hyaluronic acid to maximize the localization and drug retaining properties of the drug formulation while allowing the formulation to be injected through a small gauge needle.
- the dissolution properties of the drug formulation may be adjusted by tailoring of the water solubility, molecular weight, and concentration of the polymeric excipient in the range of appropriate thixotropic properties to allow both delivery through a small gauge needle and localization in the suprachoroidal space.
- the polymeric excipient may be formulated to increase in viscosity or to cross-link after delivery to further limit migration or dissolution of the material and incorporated drug.
- a highly thixotropic drug formulation will have a low viscosity during injection through a small gauge needle, but dramatically increases in effective viscosity once in the supra-choroidal space at zero shear conditions.
- Hyaluronic acid a strongly thixotropic natural polymer, when formulated at concentrations of 1 to 2 weight percent demonstrates a viscosity of approximately 300,000 to 7,000,000 mPas at zero shear and viscosity of 150 to 400 mPas at a shear rate of 1000 s ⁇ 1 , typical of injection though a small gauge needle, with the exact viscosity depending of the molecular weight.
- Chemical methods to increase the molecular weight or degree of crosslinking of the polymer excipient may also be used to increase localization of the drug formulation in-situ, for example the formulation of hyaluronic acid with bisepoxide or divinylsulfone crosslinking agents.
- the environment in the suprachoroidal space may also be used to initiate an increase in viscosity or cross-linking of the polymer excipient, for example from the physiologic temperature, pH or ions associated with the suprachoroidal space.
- the gel-like material may also be formulated with surface charge, hydrophobicity or specific tissue affinity to limit migration within the suprachoroidal space.
- Water soluble polymers that are physiologically compatible are suitable for use as polymeric excipients according to the invention include synthetic polymers such as polyvinylalcohol, polyvinylpyrollidone, polyethylene glycol, polyethylene oxide, polyhydroxyethylmethacrylate, polypropylene glycol and propylene oxide, and biological polymers such as cellulose derivatives, chitin derivatives, alginate, gelatin, starch derivatives, hyaluronic acid, chondroiten sulfate, dermatin sulfate, and other glycosoaminoglycans, and mixtures or copolymers of such polymers.
- synthetic polymers such as polyvinylalcohol, polyvinylpyrollidone, polyethylene glycol, polyethylene oxide, polyhydroxyethylmethacrylate, polypropylene glycol and propylene oxide
- biological polymers such as cellulose derivatives, chitin derivatives, alginate, gelatin, starch derivatives, hyalur
- the polymeric excipient is selected to allow dissolution over time, with the rate controlled by the concentration, molecular weight, water solubility, crosslinking, enzyme lability and tissue adhesive properties of the polymer.
- polymer excipients that confer the formulation strong thixotropic properties to enable the drug formulation to exhibit a low viscosity at high shear rates typical of delivery through a small gauge needle to facilitate administration, but exhibit a high viscosity at zero shear to localize the drug in-situ.
- a polymeric excipient to limit drug migration may be combined with a drug and injected into the desired anterior region of the suprachoroidal space.
- One method for treating the posterior region of the eye comprises administration of a drug formulation with localizing properties directly to the posterior region of the suprachoroidal space.
- Drug formulations may be delivered to the posterior region of the suprachoroidal space by using a flexible microcannula placed in an anterior region of the suprachoroidal space with subsequent advancement of the distal tip to the posterior region prior to delivery of the drug and a localizing excipient.
- a flexible microcannula may be advanced to the center of a desired treatment area such as a macular lesion prior to delivery of a drug formulation with properties to localize the administered drug.
- Treatment of a localized region of the eye, especially the posterior region, is facilitated by the use of drug preparations of the present invention in combination with administration devices to deliver the preparation locally to various regions of the suprachoroidal space with a flexible device as described in U.S. patent application 60/566,776 by the common inventors, incorporated by reference herein in its entirety.
- the drug may be prepared in a form to allow migration after delivery and delivered to an anterior region of the suprachoroidal space.
- the drug may be formulated in soluble form, with a rapid dissoluting polymeric excipient or as small microparticles or microspheres to allow drug migration after administration. If a polymeric excipient is used, a low viscosity, rapidly absorbed formulation may be selected to distribute the drug uniformly in the region of administration to minimize areas of overly high drug concentration, and subsequently dissolution of the excipient to allow drug migration to the posterior region of the suprachoroidal space.
- microparticles or microspheres are those with an outer diameter in the range of about 1 to 33 microns.
- the use of drug microparticles, one or more polymeric excipients or a combination of both, may also be applied to confer sustained release properties to the drug formulation.
- the drug release rate from the microparticles may be tailored by adjusting drug solubility or application of a controlled release coating.
- the polymeric excipient may also provide sustained release from incorporated drugs.
- the polymeric excipient may, for example, be selected to limit drug diffusion or provide drug affinity to slow drug release.
- the dissolution rate of the polymeric excipient may also be adjusted to control the kinetics of its effect on sustained release properties.
- a device for minimally invasive delivery of drugs to the suprachoroidal space may comprise a needle for injection of drugs or drug containing materials directly to the suprachoroidal space.
- the device may also comprise elements to advance the needle through the conjunctiva and sclera tissues to or just adjacent to the suprachoroidal space without perforation or trauma to the inner choroid layer.
- the position of the leading tip of the delivery device may be confirmed by non-invasive imaging such as ultrasound or optical coherence tomography, external depth markers or stops on the tissue-contacting portion of the device, depth or location sensors incorporated into the device or a combination of such sensors.
- the delivery device may incorporate a sensor at the leading tip such as a light pipe or ultrasound sensor to determining depth and the location of the choroid or a pressure transducer to determine a change in local fluid pressure from entering the suprachoroidal space.
- the leading tip of the delivery device is preferably shaped to facilitate penetration of the sclera, either by cutting, blunt dissection or a combination of cutting and blunt dissection.
- Features of the device may include energy delivery elements to aid tissue penetration such as ultrasound, high fluid pressure, or tissue ablative energy at the distal tip.
- the outer diameter of the tissue contacting portion of the device is preferably about the size of a 20 to 25 gauge needle (nominal 0.0358 to 0.0203 inch outer diameter) to allow minimally invasive use without requiring additional features for tissue dissection or wound closure.
- Suitable materials for the delivery device include high modulus materials such as metals including stainless steel, tungsten and nickel titanium alloys, and structural polymers such as nylon, polyethylene, polypropylene, polyimide and polyetheretherketone, and ceramics.
- the tissue contacting portions of the device may also comprise surface treatments such as lubricious coatings to assist in tissue penetration or energy reflective or absorptive coatings to aid in location and guidance during medical imaging.
- the needle may be mounted or slidably disposed at a shallow angle to a plate or fixation mechanism to provide for localization and control of the angle and depth of insertion.
- the plate such as shown in FIG. 4 , may contain an injection port to allow advancement of the needle through the plate that has been pre-positioned on the surface of the globe (eye surface).
- the plate may further comprise a vacuum assist seal 12 to provide stabilization of the plate to the target site on the ocular surface.
- An external vacuum source such as a syringe or vacuum pump is connected by line 13 to the plate to provide suction.
- the plate should preferably have a bottom side or bottom flanges which are curved suitably to curvature of the globe.
- the needle 11 is advanced through the sclera 1 until entering the suprachoroidal space 2 but not into choroid 3 .
- Elements to seal the needle tract during injection such as a flexible flange or vacuum seal along the tract may also be incorporated to aid delivery.
- FIG. 4 the location of the delivery device 11 is shown with respect to the target sclera 1 , suprachoroidal space 2 , and choroid 3 by positioning with a vacuum interfacial seal 12 attached to a suction line 13 .
- the device may also comprise elements to mechanically open the suprachoroidal space, in order to allow injection of microparticulate drugs or drug delivery implants which are larger than can be delivered with a small bore needle.
- a delivery device may comprise a first element provided to penetrate the scleral tissue to a specified depth, and a second element, which can advance, and atraumatically distend the choroid inwards, maintaining a pathway to the suprachoroidal space.
- the second element may be disposed within or placed adjacent to the first element.
- FIGS. 3 a and 3 b An embodiment of a device having such elements is shown in FIGS. 3 a and 3 b.
- the delivery device comprises a cutting or ablative tip 4 a choroidal distention tip 8 at the distal end of the device, and an ultrasonic sensor 6 used to guide the device through the tissues.
- a luer connector 7 is provided at the proximal end (away from the cutting tip) of the device.
- the knob 5 is connected to the mechanism for activating the distention tip 8 .
- the device is placed facing the sclera 1 to address the suprachoroidal space 2 adjacent to the choroid 3 . The device is then advanced in scleral tissues using the depth sensor for guidance.
- the distension tip 8 is activated to prevent damage to the choroid.
- the knob 5 has been activated to advance the distention tip to its activated position 9 which results in a distended choroid 10 .
- a pathway to the suprachoroidal space 2 is thereby attained without trauma to the choroid from the ablative tip 4 .
- the delivery device comprises a thin walled needle fabricated with a short, high angle bevel at the leading tip to allow the bevel to be advanced into or through scleral tissues. Maintaining the beveled section with the opening directed inward prevents the drug from being expressed away from the suprachoroidal space.
- Various types of access and delivery may be achieved through the precise placement of the needle tip into or through the scleral tissues. If the needle is advanced through the sclera and into the suprachoroidal space, the needle may then be used for direct injections into the space or to serve as an introducer for the placement of other devices such as a microcannula.
- FIG. 8 An embodiment of a device useful in such manner is shown in FIG. 8 .
- a system to inject a substance into the suprachoroidal space 2 comprises an access cannula 26 and a high resolution imaging device 27 .
- the access cannula may accommodate a hypodermic type needle (not shown) or introducer sheath with a trocar (not shown).
- the access means may comprise a plate as shown in FIG. 4 or FIG. 5 .
- the access cannula incorporates a beveled sharp distal tip suitably shaped for penetration of the tissues.
- the imaging device may comprise real-time modalities such as ultrasound, optical coherence tomography (OCT) or micro-computed tomography (MicroCT). The advancement of the access needle or introducer through the sclera is monitored using the imaging device.
- OCT optical coherence tomography
- MicroCT micro-computed tomography
- the access cannula 26 is advanced until the leading tip is in close proximity to the inner boundary of the sclera 28 , at which point the injection of the drug is made. Injection of drug formulations through the needle will allow fluid dissection or flow through any remaining interposing scleral tissue and delivery to the suprachoroidal space 29 .
- the delivery device may allow a specific angle of entry into the tissues in order to provide a tissue pathway that will maintain the tract within the sclera, or penetrate to the suprachoroidal space without contacting the choroid.
- FIG. 5 an embodiment of the device is shown with a luer connector 7 at the proximal end and a bevel needle tip 14 at the distal end.
- the needle is affixed to an angled stop plate 15 to set the depth and angle of penetration of the needle tip 14 .
- the assembly is advanced until the stop plate encounters the surface of the globe, placing the needle tip at the target depth.
- the mounting plate may also contain sensors for indicating or directing the position of the needle tip.
- a system for obtaining minimally invasive access to the suprachoroidal space comprises an access cannula and an optical device used to determine the location of the access cannula distal tip in the tissue tract providing direct feedback upon entry to the suprachoroidal space.
- the color differential between the sclera (white) and the choroid (brown) may be used to provide location information or OCT methods may be used to determine the distance to the choroid interface from the sclera.
- the optical device may be incorporated within a microcannula, or may be an independent device such as a microendoscope or a fiber-optic sensor and transducer capable of detecting the tissue properties.
- the optical signal may be sent to a camera and monitor for direct visualization, as in the case of an endoscope, or to an optical signal processing system, which will indicate depth by signaling the change in tissue properties at the tip of the optical fiber.
- the access microcannula may be a needle or introducer-type device made of metal or plastic. The distal end of the access cannula is suitable to pierce ocular tissue. If independent, the optical device will be removed from the access microcannula after cannulation to allow access to the space for other devices or for an injectate to administer treatment. An embodiment of such a system is shown in FIG. 6 .
- the optical device comprises a flexible microendoscope 18 , coupled to a CCD camera 16 with the image viewed on a monitor 19 .
- the endoscope is sized to fit slidably in an access cannula 17 that is preferably less than 1 mm in outer diameter.
- the access cannula 17 comprises a beveled sharp distal tip for tissue access.
- the distal tip of the endoscope is positioned at the proximal end of the cannula bevel to provide an image of the cannula tip.
- the cannula is advanced against the ocular surface at the region of the pars plana at a low angle, piercing the sclera 1 , and advancing until the endoscope image shows access into the suprachoridal space 2 .
- the optical device of the system comprises a focal illumination source at the distal tip.
- the amount of light scatter and the intensity of the light will vary depending upon the type of tissues and depth of a small light spot traversing the tissues. The change may be seen from the surface by the observing physician or measured with a sensor.
- the focal spot may be incorporated as an illuminated beacon tip on a microcannula.
- the access device comprises a flexible microcannula or microcatheter 20 , sized suitably for atraumatic access into the suprachoroidal space 2 .
- the microcatheter comprises a lumen 22 for the delivery of materials to the space 2 and a fiber optic 23 to provide for an illuminated distal tip.
- the fiber optic is connected to an illumination source 24 such as a laser diode, superbright LED, incandescent or similar source.
- the microcatheter is slidably disposed within the access cannula 21 . As the access cannula is advanced through the tissues, the light 25 transilluminating the tissues will change. Scleral tissues scatter light from within the sclera tissues to a high degree, however once inside the suprachoroidal space, the light intensity and backscatter seen at the surface diminishes significantly, indicating that the illuminated tip has transited the sclera 1 , and is now in the target location at the suprachoroidal space.
- Drug in microparticulate form are preferred to be substantially smaller than the lumen diameter to prevent lumen obstruction during delivery.
- Microparticles of average outer dimension of approximately 10 to 20% of the device lumen at maximum are preferred.
- a useful formulation includes microspheres or microparticles with an outer diameter in the range of about 1 to 33 microns.
- a polymeric excipient in the drug formulation to enable the formulation to be injected into the scleral tissues adjacent to the suprachoroidal space, with subsequent dissection of the tissue between the distal tip and the suprachoroidal space by the excipient containing fluid to form a flow path for the drug into the suprachoroidal space.
- Formulations with thixotropic properties are advantageous for passage through a small needle lumen as well as for fluid dissection of scleral tissue.
- Fluorescent dyed polystyrene microspheres (FirefliTM, Duke Scientific, Inc., Palo Alto, Calif.) suspended in phosphate-buffered saline were used as model drug to evaluate the size range in which particulates will migrate in the suprachoroidal space from the anterior region to the posterior region.
- the eye was then perfused for 24 hours with phosphate buffered saline at 10 mm Hg pressure by introducing into the anterior chamber a 30 gauge needle attached to a reservoir via infusion tubing.
- the reservoir was placed on a lab jack and elevated to provide constant perfusion pressure.
- the eye was placed into a beaker of glycerin to clarify the scleral tissue by dehydration, allowing direct visualization of the suprachoroidal space.
- microspheres were visualized using a stereofluorescence microscope (Model MZ-16, Leica, Inc.) with fluorescence filters selected for the microsphere fluorescence. Under low magnification (7 to 35 ⁇ ) the microspheres could be clearly seen in a stream-like pattern running from the site of instillation back toward the optic nerve region, collecting primarily in the posterior region of the suprachoroidal space.
- the experiment was repeated using microsphere suspensions of 1, 6, 10, 15, 24 and 33 micron diameter with the same resulting pattern of migration and distribution to the posterior region of the eye.
- Example 1 The experiment of Example 1 was repeated, except that a mixture of 6 and 33 micron diameter fluorescent microspheres as a model drug was suspended in a polymeric excipient comprising a surgical viscoelastic (Healon 5, Advanced Medical Optics, Inc.), a 2.3% concentration of sodium hyaluronic acid of 4,000,000 Daltons molecular weight, with thixotropic properties of a zero shear viscosity of 7,000,000 mPas and 400 mPas viscosity at 1000 s ⁇ 1 shear rate.
- the mixture was introduced into the suprachoroidal space in the manner of Example 1. After 24 hour perfusion, the microspheres resided solely in the suprachoroidal space at the anterior instillation site and did not show evidence of migration, demonstrating the localizing effect of the thixotropic polymeric excipient.
- Example 1 To demonstrate the effect of polymeric excipient viscosity on drug localization, the experiment of Example 1 was repeated, except that bevacizumab (AvastinTM, Genentech), an anti-VEG antibody, was adsorbed onto 5 micron diameter carboxylated fluorescent microspheres and mixed at equal volumes with one of three hyaluronic acid based surgical viscoelastics (Healon, Healon GV, Healon 5, Advanced Medical Optics, Inc.), each with a different viscosity and thixotropic properties.
- bevacizumab AvastinTM, Genentech
- an anti-VEG antibody an anti-VEG antibody
- the microspheres in Healon and Healon GV were found to be in process of migration to the posterior region of the suprachoroidal space with the formulation found at both the pars plana site of instillation and the posterior pole.
- the microspheres in Healon 5 remained dispersed in the viscoelastic localized at the original injection site in the pars plana region of the suprachoroidal space.
- Example 1 The experiment of Example 1 was repeated, except that bevacizumab (AvastinTM, Genentech) was covalently crosslinked using 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide (EDAC, Sigma-Aldrich) onto 5 micron diameter carboxylated fluorescent microspheres and mixed at equal volumes with one of three surgical viscoelastics (Healon, Healon GV, Healon 5, Advanced Medical Optics, Inc.), each with a different viscosity and thixotropic properties as in Example 3.
- the mixture was introduced into the suprachoroidal space at the pars plana in the manner of Example 1. After 24 hour perfusion the microspheres remained exclusively in the pars plana region of the suprachoroidal space for all viscoelastic carriers.
- Example 1 To demonstrate the effect of a crosslinking polymeric excipient on drug localization, the experiment of Example 1 was repeated, except that 10 micron diameter fluorescent microspheres were mixed into a 4% alginate solution and introduced into the suprachoroidal space at the pars plana region. Before sealing the incision site an equal volume of 1 M CaCl2 solution was instilled at the site of the microsphere/alginate suspension to initiate crosslinking of the alginate excipient. The mixture was allowed to gel for 5 minutes before perfusing as in Example 1. The microspheres remained exclusively at the site of instillation, dispersed in the crosslinked polymer excipient.
- a drug containing injectate was prepared by suspending 1.5 mg of Triamcinolone acetonide in microparticulate form, in 15 microliters of Healon viscoelastic (Advanced Medical Optics, Irvine, Calif.) with a zero shear viscosity of 300,000 mPas and a viscosity of 150 mPas at a shear rate of 1000 s ⁇ 1.
- Forty porcine subjects were placed under anesthesia and the right eye prepared and draped in a sterile manner.
- a conjunctival peritomy was made near the superior limbus, exposing and providing surgical access to a region of sclera.
- a small radial incision was made in the sclera, exposing bare choroid.
- a flexible microcannula with a 360 micron diameter tip and 325 micron diameter body was inserted in to the scleral incision and advanced in a posterior direction to a target region behind the macula.
- the drug suspension was injected into the posterior region of the suprachoroidal space, and was observed to form a layer between the choroid and sclera at the target region.
- the microcannula was retracted and the scleral and conjunctival incisions closed with 7-0 Vicryl suture.
- the subjects were observed and eyes tissues recovered at 12 hours, 24 hours, 48 hours, 4 days, 7 days, 14 days, 30 days and 90 days.
- Angiographic, histologic, and photographic studies of the subjects demonstrated no sign of posterior segment pathology. Recovered samples of choroid demonstrated significant concentration of the drug, in the range of at least 1 mg per gram of tissue at all recovery time periods.
- a drug-containing formulation comprising 20 mL Healon 5 and 50 mL (1.5 mg) bevacizumab (AvastinTM, Genentech) was prepared. Eighteen porcine subjects were anesthetized and the right eye prepared and draped in a sterile manner. A conjunctival peritomy was made near the superior limbus, exposing and providing surgical access to a region of sclera. A small radial incision was made in the sclera, exposing bare choroid.
- a flexible microcannula with a 360 micron diameter tip and 325 micron diameter body (iTrack microcannula, iScience Interventional Corp.) was inserted in to the scleral incision and advanced in a posterior direction to a target region behind the macula.
- the drug formulation was injected into the posterior region of the suprachoroidal space, and was observed to form a layer between the choroid and sclera at the target region.
- the microcannula was retracted and the scleral and conjunctival incisions closed with 7-0 Vicryl suture.
- Another 18 porcine subjects were anesthetized and each received a 50 mL bolus of bevacizumab via injection into the vitreous.
- Example 1 The experiment of Example 1 was repeated, except a drug formulation 0.2 mL of Healon 5, 0.6 mL of Avastin, and 24 mg of triamcinolone acetonide was prepared to provide a treatment with both anti-inflammatory and anti-VEGF properties.
- An approximately 5 mm long incision was made longitudinally in the pars plana region transecting the sclera, exposing the choroid of a cadaver globe that had been clarified by immersion in glycerol for approximately 30 minutes and perfused with saline at 12 mm Hg pressure.
- the flexible microcannula of Example 6 was primed with the drug formulation and the microcannula tip was inserted into the suprachoroidal space through the scleral incision.
- the distal end of the microcannula was steered toward the posterior pole of the globe, stopping approximately 5 mm short of the optic nerve.
- a Viscoelastic Injector iScience Interventional
- 70 microliters of the drug formulation was injected into the posterior region of the suprachoroidal space.
- the microcannula was removed by withdrawing though the pars plana incision.
- the mixture was visible though the clarified sclera, and formed a deposit near the optic nerve with the mixture also following the catheter track.
- the incision was sealed with cyanoacrylate (Locktite 4011) and the globe perfused again with saline at 12 mm Hg for 3 hours.
- the sclera was re-cleared by immersion in glycerol to examine the administered drug formulation.
- the drug formulation was observed by microscopy to have formed a layer of dispersed drug within the polymer excipient in the posterior region of the suprachoroidal space.
- Human cadaver eyes were obtained from an eye bank and were prepared by inflating the eyes to approximately 20 mm Hg pressure with phosphate buffered saline (PBS).
- PBS phosphate buffered saline
- a delivery needle was fabricated using stainless steel hypodermic tubing, 255 mm ID ⁇ 355 mm OD. The needle distal tip was ground into a bi-faceted short bevel point, 400 um in length and at an angle of 50°. The fabricated needle was then silver-soldered into a standard 25 gauge ⁇ 1 inch hypodermic needle to complete the assembly.
- the needle was gently advanced into scleral tissue at an acute angle ( ⁇ 10°) with respect to the surface of the eye.
- the needle entry was started in the pars plana region approximately 4 mm from the limbus, and the needle advanced posteriorly in scleral tissue to create a tract between 5 and 6 mm long without penetrating through the sclera into the suprachoroidal space.
- a high resolution ultrasound system iUltrasound, iScience Surgical Corp. was used to guide and verify placement of the needle tip within scleral tissues and to document the injections.
- a polymeric excipient alone comprising a hyaluronic acid surgical viscoelastic Healon 5, Advanced Medical Optics, Inc
- Healon 5, Advanced Medical Optics, Inc a hyaluronic acid surgical viscoelastic
- the viscoelastic was mixed in a 1:1 ratio with a 1% aqueous solution of 10 micron diameter polystyrene microspheres (Duke Scientific, Inc) to represent a model microparticulate drug.
- the viscoelastic and the mixture were delivered through the needle using a screw driven syringe (ViscoInjector, iScience Surgical Corp.) in order to control delivery volume and injection pressure.
- the injections were made with the needle bevel turned inwards towards the center of the globe. Multiple locations on three cadaver eyes were used for the experiments.
- the needle tract was approximately 3 to 4 mm in length and the injectate was observed to flow back out the tract.
- higher injection pressure was obtained and allowed the injectate to dissect through the remaining interposing layers of the sclera and deliver to the suprachoroidal space.
- FIG. 1 shows the needle tract 30 clearly visible (after removal of the needle) and a region 31 of the suprachoroidal space filled with injectate.
- the sclera 1 and choroid 3 are shown.
- FIG. 2 shows a region 33 of the suprachoroidal space filled with the microsphere and hyaluronic acid excipient containing injectate, and the tip of the needle 4 in the sclera and needle shadow 32 .
- micro-endoscopic imaging was performed to allow minimally invasive access to the suprachoroidal space in a human cadaver eye.
- a custom fabricated, flexible micro-endoscope (Endoscopy Support Services, Brewster, N.Y.) with an outer diameter of 350 microns containing an imaging bundle with 1200 pixels was mounted on a micrometer adjusted stage. The stage was mounted on a vertical stand allowing for controlled up and down travel of the endoscope.
- the micro-endoscope was attached to a 1 ⁇ 2′′ chip CCD camera and then to a video monitor.
- a 20 gauge hypodermic needle was placed over the endoscope to provide a means for piercing the tissues for access.
- the camera was turned on and an external light source with a light pipe (Model MI-150, Dolan Jenner, Boxborough, Mass.) was used to provide transcleral imaging illumination.
- the needle was advanced until the distal tip was in contact with the scleral surface of a human cadaver whole globe approximately 4 mm posterior of the limbus.
- the micro-endoscope was then lowered until the white scleral surface could be seen through the end of the needle.
- the needle was then slowly advanced into the scleral tissue by slight back-and-forth rotation. As the needle was advanced in this manner, the endoscope was lowered to follow the tract created by the needle. At or within the sclera, the endoscopic image was seen as white or whitish-grey. As the needle pierced the scleral tissues, the image color changed to dark brown indicating the presence of the dark choroidal tissues, demonstrating surgical access of the suprachoroidal space.
- a flexible microcannula with an illuminated distal tip (iTrack-250A, iScience Interventional, Menlo Park, Calif.) was placed into a 25 gauge hypodermic needle.
- the microcannula comprised a plastic optical fiber that allowed for illumination of the distal tip.
- the microcatheter fiber connector was attached to a 635 nm (red) laser diode fiber optic illuminator (iLumin, iScience Interventional) and the illuminator turned on to provide a steady red light emanating for the microcannula tip.
- the microcannula was fed through the 25 gauge needle up to the distal bevel of the needle but not beyond.
- the needle was slowly advanced in the pars plana region of a human cadaver whole globe until the needle tip was sufficiently embedded in the scleral tissues to allow a slight advancement of the microcannula.
- the illumination from the microcannula tip was seen clearly as the scleral tissues diffused the light to a significant extent.
- the microcannula was pushed forward at the same time.
- the hypodermic needle tip pierced through sufficient scleral tissue to reach the suprachoroidal space, the red light of the microcannula tip immediately dimmed as the illuminated tip passed out of the diffusional scleral tissues and into the space beneath.
- the microcannula was advanced while keeping the needle stationary, thereby placing the microcannula tip into the suprachoroidal space. Further advancement of the microcannula in a posterior direction in the suprachoroidal space could be seen transclerally as a focal red spot without the broad light diffusion seen when the tip was inside the scleral tissues. Using a high frequency ultrasound system (iUltraSound, iScience Interventional), the location of the microcannula in the suprachoroidal space was confirmed.
- a high frequency ultrasound system iUltraSound, iScience Interventional
Abstract
Description
- The priority of provisional U.S. application Ser. No. 60/776,903, filed Feb. 22, 2006 is claimed pursuant to 35 USC 119(e). The provisional application is incorporated herein by reference in its entirety.
- The invention relates to the field of drug delivery into the eye.
- The eye is a complex organ with a variety of specialized tissues that provide the optical and neurological processes for vision. Accessing the eye for medical treatment is hindered by the small size and delicate nature of the tissues. The posterior region of the eye, including the retina, macula and optic nerve, is especially difficult to access due to the recessed position of the eye within the orbital cavity. In addition, topical eye drops penetrate poorly into the posterior region, further restricting treatment options.
- The suprachoroidal space is a potential space in the eye that is located between the choroid, which is the inner vascular tunic, and the sclera, the outer layer of the eye. The suprachoroidal space extends from the anterior portion of the eye near the ciliary body to the posterior end of the eye near the optic nerve. Normally the suprachoroidal space is not evident due to the close apposition of the choroid to the sclera from the intraocular pressure of the eye. Since there is no substantial attachment of the choroid to the sclera, the tissues separate to form the suprachoroidal space when fluid accumulation or other conditions occur. The suprachoroidal space provides a potential route of access from the anterior region of the eye to treat the posterior region.
- The present invention is directed to drug formulations for administration to the suprachoroidal space and an apparatus to deliver drugs and other substances in minimally invasive fashion to the suprachoroidal space.
- Drug formulations are provided characterized by a zero shear viscosity of at least 300,000 mPas. A subclass of the drug formulations is further characterized by a viscosity of not more than about 400 mPas at 1000 s−1 shear rate.
- For injection into the suprachoroidal space of an eye comprising a biologically active substance and a thixotropic polymeric excipient that acts as a gel-like material to spread after injection and uniformly distribute and localize the drug in a region of the suprachoroidal space. In one embodiment, gel-like material crosslinks after injection into the suprachoroidal space. The biologically active substance may comprise microparticles or microspheres. The polymeric excipient may comprise hyaluronic acid, chondroitin sulfate, gelatin, polyhydroxyethylmethacrylate, dermatin sulfate, polyethylene oxide, polyethylene glycol, polypropylene oxide, polypropylene glycol, alginate, starch derivatives, a water soluble chitin derivative, a water soluble cellulose derivative or polyvinylpyrollidone.
- In another embodiment, a drug formulation is provided for delivery to the suprachoroidal space of an eye comprising a biologically active substance and microspheres with an outer diameter in the range of about 1 to 33 microns. The microparticles or microspheres additionally may comprise a controlled release coating and/or a tissue affinity surface.
- The biologically active substance preferably comprises an antibiotic, a steroid, a non-steroidal anti-inflammatory agent, a neuroprotectant, an anti-VEGF agent, or a neovascularization suppressant.
- Devices are also provided for minimally invasive delivery of a drug formulation into the suprachoroidal space of the eye comprising a needle having a leading tip shaped to allow passage through scleral tissues without damage to the underlying choroidal tissues, and a sensor to guide placement of the tip to deliver the formulation adjacent to or within the suprachoroidal space.
- The sensor may provide an image of the scleral tissues. The sensor preferably responds to ultrasound, light, or differential pressure.
- In another embodiment, devices are provided for minimally invasive delivery of a drug formulation into the suprachoroidal space of the eye comprising a needle having a leading tip shaped to allow passage through scleral tissues, and an inner tip that provides an inward distending action to the choroid upon contacting the choroid to prevent trauma thereto.
- Methods are provided for administering drugs to the eye comprising placing a formulation comprising a biologically active substance and a polymer excipient in the suprachoroidal space such that the excipient gels after delivery to localize said biologically active substance. The formulation may be placed in a posterior or anterior region of the suprachoroidal space.
- In another embodiment, method are provided for administering drugs to a posterior region of the eye comprising placing a formulation comprising a biologically active substance comprising microspheres or microparticles with an outer diameter in the range of about 1 to 33 microns in an anterior region of the suprachoroidal space such that the microspheres or microparticles subsequently migrate to the posterior region. The formulation preferably comprises a polymer excipient to uniformly disperse the microparticles or microspheres in the suprachoroidal space.
- In another embodiment, a method is provided of administering drugs in the suprachoroidal space of the eye comprising the steps of placing a needle in scleral tissues toward the suprachoroidal space at a depth of at least half of the scleral thickness, and injecting a drug formulation through the needle into the sclera such that the formulation dissects the scleral tissues adjacent to the suprachoroidal space and enters the suprachoroidal space.
- In the methods disclosed herein, the formulation preferably comprises a thixotropic polymer.
-
FIG. 1 is an ultrasound image of a portion of the eye after injection by needle into the sclera of a hyaluronic acid surgical viscoelastic material according to Example 9. -
FIG. 2 is an ultrasonic image of a portion of the eye during injection by needle into the sclera of a 1:1 by volume mixture of the viscoelastic material and 1% solution of polystyrene microspheres according to Example 9. -
FIGS. 3 a and 3 b are diagrams of an embodiment of a delivery device according to the invention having a distending and cutting or ablative tip. -
FIG. 4 is a diagram showing the location of a delivery device according to the invention relative to the target sclera, suprachoroidal space and choroid. -
FIG. 5 is a diagram of an embodiment of a delivery device according to the invention having a stop plate to set the depth and angle of penetration of the needle into the eye. -
FIG. 6 is a diagram of an embodiment of a delivery device according to the invention that accommodates a microendoscope and camera to monitor the location of the cannula tip during surgery. -
FIG. 7 is a diagram of an embodiment of a delivery device having a lumen for delivery of drugs through a catheter into the eye and a fiber optic line connected to an illumination source to illuminate the tip if the cannula. -
FIG. 8 is a diagram of an embodiment of the use of a device according to the invention in conjunction with a high resolution imaging device to monitor the location of the tip of the cannula. - The present invention comprises drug formulations, devices and related methods to access the suprachoroidal space of an eye for the purpose of delivering drugs to treat the eye. Specifically, the invention relates to drug formulations designed for suprachoroidal space administration to treat the eye, including specific regions of the eye by localization of the delivered drug. The invention also relates to the design and methods of use for a minimally invasive device to inject drug formulations and drug containing materials directly into the suprachoroidal space through a small needle.
- A biologically active substance or material is a drug or other substance that affects living organisms or biological processes, including use in the diagnosis, cure, mitigation, treatment, or prevention of disease or use to affect the structure or any function of the body. A drug formulation contains a biologically active substance.
- As used herein, the anterior region of the eye is that region of the eye that is generally readily accessible from the exposed front surface of the eye in its socket. The posterior region of the eye is generally the remaining region of the eye that is primarily surgically accessed through a surface of the eye that is unexposed, thus often requiring temporary retraction of the eye to gain access to that surface.
- Formulations:
- The drug formulations of the invention provide compatibility with the suprachoroidal space environment and may be formulated to control the distribution of the biologically active substance by migration of the formulation as well as provide for sustained release over time. The drug formulation comprises one or more biologically active substances formulated with physiologically compatible excipients that are administered, typically by injection, into the suprachoroidal space of an eye. Suitable biologically active substances include antibiotics to treat infection, steroids and non-steroidal anti-inflammatory compounds to treat inflammation and edema, neuroprotectant agents such as calcium channel blockers to treat the optic nerve and retinal agents such as anti-VEGF compounds or neo-vascular suppressants to treat macular degeneration.
- Formulations for Localized Treatment:
- For treatment of a localized region of the eye, for example, to treat a macular lesion, the posterior retina, or the optic nerve, the drug may be prepared in a formulation to limit migration after delivery and delivered to the region of the lesion. While not intending to be bound by a particular theory, we observe that drug microparticles typically travel toward the posterior region of the suprachoroidal space under physiological conditions, presumably due to uveal-scleral fluid flow within the space. Such drug microparticles may be fabricated with sufficient size and optionally with tissue surface affinity to limit drug migration. Tissue surface affinity may be modified by the addition of polymeric or lipid surface coatings to the microparticles, or by the addition of chemical or biological moieties to the microparticle surface. Tissue affinity is thereby obtained from surface charge, hydrophobicity, or biological targeting agents such as antibodies or integrins that may be incorporated to the surface of the microparticles to provide a binding property with the tissues to limit drug migration. Alternatively or in combination, the drug may be formulated with one or more polymeric excipients to limit drug migration. A polymeric excipient may be selected and formulated to act as a viscous gel-like material in-situ and thereby spread into a region of the suprachoroidal space and uniformly distribute and retain the drug. The polymer excipient may be selected and formulated to provide the appropriate viscosity, flow and dissolution properties. For example, carboxymethylcellulose is a weakly thixotropic water soluble polymer that may be formulated to an appropriate viscosity at zero shear rate to form a gel-like material in the suprachoroidal space. The thixotropic effect of the polymer may be enhanced by appropriate chemical modification to the polymer to increase associative properties such as the addition of hydrophobic moieties, the selection of higher molecular weight polymer or by formulation with appropriate surfactants. Preferred is the use of highly associative polymeric excipients with strong thixotropic properties such as hyaluronic acid to maximize the localization and drug retaining properties of the drug formulation while allowing the formulation to be injected through a small gauge needle. The dissolution properties of the drug formulation may be adjusted by tailoring of the water solubility, molecular weight, and concentration of the polymeric excipient in the range of appropriate thixotropic properties to allow both delivery through a small gauge needle and localization in the suprachoroidal space. The polymeric excipient may be formulated to increase in viscosity or to cross-link after delivery to further limit migration or dissolution of the material and incorporated drug. For example, a highly thixotropic drug formulation will have a low viscosity during injection through a small gauge needle, but dramatically increases in effective viscosity once in the supra-choroidal space at zero shear conditions. Hyaluronic acid, a strongly thixotropic natural polymer, when formulated at concentrations of 1 to 2 weight percent demonstrates a viscosity of approximately 300,000 to 7,000,000 mPas at zero shear and viscosity of 150 to 400 mPas at a shear rate of 1000 s−1, typical of injection though a small gauge needle, with the exact viscosity depending of the molecular weight. Chemical methods to increase the molecular weight or degree of crosslinking of the polymer excipient may also be used to increase localization of the drug formulation in-situ, for example the formulation of hyaluronic acid with bisepoxide or divinylsulfone crosslinking agents. The environment in the suprachoroidal space may also be used to initiate an increase in viscosity or cross-linking of the polymer excipient, for example from the physiologic temperature, pH or ions associated with the suprachoroidal space. The gel-like material may also be formulated with surface charge, hydrophobicity or specific tissue affinity to limit migration within the suprachoroidal space.
- Water soluble polymers that are physiologically compatible are suitable for use as polymeric excipients according to the invention include synthetic polymers such as polyvinylalcohol, polyvinylpyrollidone, polyethylene glycol, polyethylene oxide, polyhydroxyethylmethacrylate, polypropylene glycol and propylene oxide, and biological polymers such as cellulose derivatives, chitin derivatives, alginate, gelatin, starch derivatives, hyaluronic acid, chondroiten sulfate, dermatin sulfate, and other glycosoaminoglycans, and mixtures or copolymers of such polymers. The polymeric excipient is selected to allow dissolution over time, with the rate controlled by the concentration, molecular weight, water solubility, crosslinking, enzyme lability and tissue adhesive properties of the polymer. Especially advantageous are polymer excipients that confer the formulation strong thixotropic properties to enable the drug formulation to exhibit a low viscosity at high shear rates typical of delivery through a small gauge needle to facilitate administration, but exhibit a high viscosity at zero shear to localize the drug in-situ.
- To treat an anterior region of the eye, a polymeric excipient to limit drug migration may be combined with a drug and injected into the desired anterior region of the suprachoroidal space.
- One method for treating the posterior region of the eye comprises administration of a drug formulation with localizing properties directly to the posterior region of the suprachoroidal space. Drug formulations may be delivered to the posterior region of the suprachoroidal space by using a flexible microcannula placed in an anterior region of the suprachoroidal space with subsequent advancement of the distal tip to the posterior region prior to delivery of the drug and a localizing excipient. Similarly, a flexible microcannula may be advanced to the center of a desired treatment area such as a macular lesion prior to delivery of a drug formulation with properties to localize the administered drug.
- Treatment of a localized region of the eye, especially the posterior region, is facilitated by the use of drug preparations of the present invention in combination with administration devices to deliver the preparation locally to various regions of the suprachoroidal space with a flexible device as described in U.S. patent application 60/566,776 by the common inventors, incorporated by reference herein in its entirety.
- Formulations for Migration to a Posterior Region:
- For treatment of the posterior region of the eye, for example, to treat the entire macula, choroid or the optic nerve, the drug may be prepared in a form to allow migration after delivery and delivered to an anterior region of the suprachoroidal space. The drug may be formulated in soluble form, with a rapid dissoluting polymeric excipient or as small microparticles or microspheres to allow drug migration after administration. If a polymeric excipient is used, a low viscosity, rapidly absorbed formulation may be selected to distribute the drug uniformly in the region of administration to minimize areas of overly high drug concentration, and subsequently dissolution of the excipient to allow drug migration to the posterior region of the suprachoroidal space. Of particular utility is the use of such a polymeric excipient in combination with drug microparticles or microspheres. Such use of drug migration is advantageous as the drug may be injected into an anterior region of the eye easily accessible by the physician, and used to treat a posterior region distant from the injection site such as, the posterior choroid and macula. Preferred microparticles or microspheres are those with an outer diameter in the range of about 1 to 33 microns.
- Sustained Release:
- The use of drug microparticles, one or more polymeric excipients or a combination of both, may also be applied to confer sustained release properties to the drug formulation. The drug release rate from the microparticles may be tailored by adjusting drug solubility or application of a controlled release coating. The polymeric excipient may also provide sustained release from incorporated drugs. The polymeric excipient may, for example, be selected to limit drug diffusion or provide drug affinity to slow drug release. The dissolution rate of the polymeric excipient may also be adjusted to control the kinetics of its effect on sustained release properties.
- Delivery Devices:
- A device for minimally invasive delivery of drugs to the suprachoroidal space may comprise a needle for injection of drugs or drug containing materials directly to the suprachoroidal space. The device may also comprise elements to advance the needle through the conjunctiva and sclera tissues to or just adjacent to the suprachoroidal space without perforation or trauma to the inner choroid layer. The position of the leading tip of the delivery device may be confirmed by non-invasive imaging such as ultrasound or optical coherence tomography, external depth markers or stops on the tissue-contacting portion of the device, depth or location sensors incorporated into the device or a combination of such sensors. For example, the delivery device may incorporate a sensor at the leading tip such as a light pipe or ultrasound sensor to determining depth and the location of the choroid or a pressure transducer to determine a change in local fluid pressure from entering the suprachoroidal space.
- The leading tip of the delivery device is preferably shaped to facilitate penetration of the sclera, either by cutting, blunt dissection or a combination of cutting and blunt dissection. Features of the device may include energy delivery elements to aid tissue penetration such as ultrasound, high fluid pressure, or tissue ablative energy at the distal tip. The outer diameter of the tissue contacting portion of the device is preferably about the size of a 20 to 25 gauge needle (nominal 0.0358 to 0.0203 inch outer diameter) to allow minimally invasive use without requiring additional features for tissue dissection or wound closure. Suitable materials for the delivery device include high modulus materials such as metals including stainless steel, tungsten and nickel titanium alloys, and structural polymers such as nylon, polyethylene, polypropylene, polyimide and polyetheretherketone, and ceramics. The tissue contacting portions of the device may also comprise surface treatments such as lubricious coatings to assist in tissue penetration or energy reflective or absorptive coatings to aid in location and guidance during medical imaging.
- The needle may be mounted or slidably disposed at a shallow angle to a plate or fixation mechanism to provide for localization and control of the angle and depth of insertion. The plate, such as shown in
FIG. 4 , may contain an injection port to allow advancement of the needle through the plate that has been pre-positioned on the surface of the globe (eye surface). The plate may further comprise a vacuum assistseal 12 to provide stabilization of the plate to the target site on the ocular surface. An external vacuum source such as a syringe or vacuum pump is connected byline 13 to the plate to provide suction. The plate should preferably have a bottom side or bottom flanges which are curved suitably to curvature of the globe. Theneedle 11 is advanced through thesclera 1 until entering thesuprachoroidal space 2 but not intochoroid 3. - Elements to seal the needle tract during injection such as a flexible flange or vacuum seal along the tract may also be incorporated to aid delivery. Referring to
FIG. 4 , the location of thedelivery device 11 is shown with respect to thetarget sclera 1,suprachoroidal space 2, andchoroid 3 by positioning with a vacuuminterfacial seal 12 attached to asuction line 13. - The device may also comprise elements to mechanically open the suprachoroidal space, in order to allow injection of microparticulate drugs or drug delivery implants which are larger than can be delivered with a small bore needle. In one embodiment, such a delivery device may comprise a first element provided to penetrate the scleral tissue to a specified depth, and a second element, which can advance, and atraumatically distend the choroid inwards, maintaining a pathway to the suprachoroidal space. The second element may be disposed within or placed adjacent to the first element. An embodiment of a device having such elements is shown in
FIGS. 3 a and 3 b. - Referring to
FIG. 3 a a delivery device with a distending tip is shown. The delivery device comprises a cutting or ablative tip 4 achoroidal distention tip 8 at the distal end of the device, and anultrasonic sensor 6 used to guide the device through the tissues. Aluer connector 7 is provided at the proximal end (away from the cutting tip) of the device. Theknob 5 is connected to the mechanism for activating thedistention tip 8. The device is placed facing thesclera 1 to address thesuprachoroidal space 2 adjacent to thechoroid 3. The device is then advanced in scleral tissues using the depth sensor for guidance. When the depth sensor indicates that thetip 4 is to or just adjacent to thesuprachoroidal space 2, thedistension tip 8 is activated to prevent damage to the choroid. Referring toFIG. 3 b, theknob 5 has been activated to advance the distention tip to its activatedposition 9 which results in adistended choroid 10. A pathway to thesuprachoroidal space 2 is thereby attained without trauma to the choroid from theablative tip 4. - In another embodiment, the delivery device comprises a thin walled needle fabricated with a short, high angle bevel at the leading tip to allow the bevel to be advanced into or through scleral tissues. Maintaining the beveled section with the opening directed inward prevents the drug from being expressed away from the suprachoroidal space. Various types of access and delivery may be achieved through the precise placement of the needle tip into or through the scleral tissues. If the needle is advanced through the sclera and into the suprachoroidal space, the needle may then be used for direct injections into the space or to serve as an introducer for the placement of other devices such as a microcannula. If the needle is placed in close proximity to the inner boundary of the sclera, injection of drug formulations through the needle will allow fluid dissection or flow through any remaining interposing scleral tissue and delivery to the suprachoroidal space. An embodiment of a device useful in such manner is shown in
FIG. 8 . - In
FIG. 8 , a system to inject a substance into thesuprachoroidal space 2 comprises anaccess cannula 26 and a highresolution imaging device 27. The access cannula may accommodate a hypodermic type needle (not shown) or introducer sheath with a trocar (not shown). Furthermore, the access means may comprise a plate as shown inFIG. 4 orFIG. 5 . The access cannula incorporates a beveled sharp distal tip suitably shaped for penetration of the tissues. The imaging device may comprise real-time modalities such as ultrasound, optical coherence tomography (OCT) or micro-computed tomography (MicroCT). The advancement of the access needle or introducer through the sclera is monitored using the imaging device. Theaccess cannula 26 is advanced until the leading tip is in close proximity to the inner boundary of thesclera 28, at which point the injection of the drug is made. Injection of drug formulations through the needle will allow fluid dissection or flow through any remaining interposing scleral tissue and delivery to thesuprachoroidal space 29. - In one embodiment, the delivery device may allow a specific angle of entry into the tissues in order to provide a tissue pathway that will maintain the tract within the sclera, or penetrate to the suprachoroidal space without contacting the choroid. Referring to
FIG. 5 , an embodiment of the device is shown with aluer connector 7 at the proximal end and abevel needle tip 14 at the distal end. The needle is affixed to anangled stop plate 15 to set the depth and angle of penetration of theneedle tip 14. The assembly is advanced until the stop plate encounters the surface of the globe, placing the needle tip at the target depth. The mounting plate may also contain sensors for indicating or directing the position of the needle tip. - In one embodiment, a system for obtaining minimally invasive access to the suprachoroidal space comprises an access cannula and an optical device used to determine the location of the access cannula distal tip in the tissue tract providing direct feedback upon entry to the suprachoroidal space. The color differential between the sclera (white) and the choroid (brown) may be used to provide location information or OCT methods may be used to determine the distance to the choroid interface from the sclera. The optical device may be incorporated within a microcannula, or may be an independent device such as a microendoscope or a fiber-optic sensor and transducer capable of detecting the tissue properties. The optical signal may be sent to a camera and monitor for direct visualization, as in the case of an endoscope, or to an optical signal processing system, which will indicate depth by signaling the change in tissue properties at the tip of the optical fiber. The access microcannula may be a needle or introducer-type device made of metal or plastic. The distal end of the access cannula is suitable to pierce ocular tissue. If independent, the optical device will be removed from the access microcannula after cannulation to allow access to the space for other devices or for an injectate to administer treatment. An embodiment of such a system is shown in
FIG. 6 . The optical device comprises aflexible microendoscope 18, coupled to aCCD camera 16 with the image viewed on amonitor 19. The endoscope is sized to fit slidably in anaccess cannula 17 that is preferably less than 1 mm in outer diameter. Theaccess cannula 17 comprises a beveled sharp distal tip for tissue access. The distal tip of the endoscope is positioned at the proximal end of the cannula bevel to provide an image of the cannula tip. The cannula is advanced against the ocular surface at the region of the pars plana at a low angle, piercing thesclera 1, and advancing until the endoscope image shows access into thesuprachoridal space 2. - In another embodiment, the optical device of the system comprises a focal illumination source at the distal tip. The amount of light scatter and the intensity of the light will vary depending upon the type of tissues and depth of a small light spot traversing the tissues. The change may be seen from the surface by the observing physician or measured with a sensor. The focal spot may be incorporated as an illuminated beacon tip on a microcannula. Referring to
FIG. 7 , the access device comprises a flexible microcannula ormicrocatheter 20, sized suitably for atraumatic access into thesuprachoroidal space 2. The microcatheter comprises alumen 22 for the delivery of materials to thespace 2 and afiber optic 23 to provide for an illuminated distal tip. The fiber optic is connected to anillumination source 24 such as a laser diode, superbright LED, incandescent or similar source. The microcatheter is slidably disposed within theaccess cannula 21. As the access cannula is advanced through the tissues, the light 25 transilluminating the tissues will change. Scleral tissues scatter light from within the sclera tissues to a high degree, however once inside the suprachoroidal space, the light intensity and backscatter seen at the surface diminishes significantly, indicating that the illuminated tip has transited thesclera 1, and is now in the target location at the suprachoroidal space. - Of particular utility with a delivery device are drug formulations as previously described that are compatible with the delivery device. Drug in microparticulate form are preferred to be substantially smaller than the lumen diameter to prevent lumen obstruction during delivery. Microparticles of average outer dimension of approximately 10 to 20% of the device lumen at maximum are preferred. A useful formulation includes microspheres or microparticles with an outer diameter in the range of about 1 to 33 microns. Also preferred is the use of a polymeric excipient in the drug formulation to enable the formulation to be injected into the scleral tissues adjacent to the suprachoroidal space, with subsequent dissection of the tissue between the distal tip and the suprachoroidal space by the excipient containing fluid to form a flow path for the drug into the suprachoroidal space. Formulations with thixotropic properties are advantageous for passage through a small needle lumen as well as for fluid dissection of scleral tissue.
- The following examples are provided only for illustrative purposes and are not intended to limit the invention in any way.
- Fluorescent dyed polystyrene microspheres (Firefli™, Duke Scientific, Inc., Palo Alto, Calif.) suspended in phosphate-buffered saline were used as model drug to evaluate the size range in which particulates will migrate in the suprachoroidal space from the anterior region to the posterior region.
- An enucleated human cadaver eye was radially incised to the choroid in the pars plana region, which is in the anterior portion of the eye. Using a syringe terminated with a blunt 27 gauge needle, 0.15 mL of a 1% by volume microsphere suspension (mean
diameter 6 micron) was delivered into the anterior region of the suprachoroidal space. The needle was withdrawn and the incision sealed with cyanoacrylate adhesive. - The eye was then perfused for 24 hours with phosphate buffered saline at 10 mm Hg pressure by introducing into the anterior chamber a 30 gauge needle attached to a reservoir via infusion tubing. The reservoir was placed on a lab jack and elevated to provide constant perfusion pressure. Several hours prior to examination, the eye was placed into a beaker of glycerin to clarify the scleral tissue by dehydration, allowing direct visualization of the suprachoroidal space.
- The microspheres were visualized using a stereofluorescence microscope (Model MZ-16, Leica, Inc.) with fluorescence filters selected for the microsphere fluorescence. Under low magnification (7 to 35×) the microspheres could be clearly seen in a stream-like pattern running from the site of instillation back toward the optic nerve region, collecting primarily in the posterior region of the suprachoroidal space.
- The experiment was repeated using microsphere suspensions of 1, 6, 10, 15, 24 and 33 micron diameter with the same resulting pattern of migration and distribution to the posterior region of the eye.
- The experiment of Example 1 was repeated, except that a mixture of 6 and 33 micron diameter fluorescent microspheres as a model drug was suspended in a polymeric excipient comprising a surgical viscoelastic (
Healon 5, Advanced Medical Optics, Inc.), a 2.3% concentration of sodium hyaluronic acid of 4,000,000 Daltons molecular weight, with thixotropic properties of a zero shear viscosity of 7,000,000 mPas and 400 mPas viscosity at 1000 s−1 shear rate. The mixture was introduced into the suprachoroidal space in the manner of Example 1. After 24 hour perfusion, the microspheres resided solely in the suprachoroidal space at the anterior instillation site and did not show evidence of migration, demonstrating the localizing effect of the thixotropic polymeric excipient. - To demonstrate the effect of polymeric excipient viscosity on drug localization, the experiment of Example 1 was repeated, except that bevacizumab (Avastin™, Genentech), an anti-VEG antibody, was adsorbed onto 5 micron diameter carboxylated fluorescent microspheres and mixed at equal volumes with one of three hyaluronic acid based surgical viscoelastics (Healon, Healon GV,
Healon 5, Advanced Medical Optics, Inc.), each with a different viscosity and thixotropic properties. (Healon, 300,000 mPas viscoscity at zero shear rate, 150 mPas viscosity at 1000 s−1 shear rate; Healon GV, 3,000,000 mPas viscosity at zero shear rate, 200 mPas at 1000 s−1 shear rate;Healon 5, 7,000,000 mPas viscosity at zero shear rate, 400 mPas viscosity at 1000 s−1 shear rate.) Each mixture was introduced into the anterior region of the suprachoroidal space at the pars plana in the anterior region of the eye in the manner of Example 1. After 24 hours perfusion, the microspheres in Healon and Healon GV were found to be in process of migration to the posterior region of the suprachoroidal space with the formulation found at both the pars plana site of instillation and the posterior pole. The microspheres inHealon 5 remained dispersed in the viscoelastic localized at the original injection site in the pars plana region of the suprachoroidal space. - The experiment of Example 1 was repeated, except that bevacizumab (Avastin™, Genentech) was covalently crosslinked using 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide (EDAC, Sigma-Aldrich) onto 5 micron diameter carboxylated fluorescent microspheres and mixed at equal volumes with one of three surgical viscoelastics (Healon, Healon GV,
Healon 5, Advanced Medical Optics, Inc.), each with a different viscosity and thixotropic properties as in Example 3. The mixture was introduced into the suprachoroidal space at the pars plana in the manner of Example 1. After 24 hour perfusion the microspheres remained exclusively in the pars plana region of the suprachoroidal space for all viscoelastic carriers. - To demonstrate the effect of a crosslinking polymeric excipient on drug localization, the experiment of Example 1 was repeated, except that 10 micron diameter fluorescent microspheres were mixed into a 4% alginate solution and introduced into the suprachoroidal space at the pars plana region. Before sealing the incision site an equal volume of 1 M CaCl2 solution was instilled at the site of the microsphere/alginate suspension to initiate crosslinking of the alginate excipient. The mixture was allowed to gel for 5 minutes before perfusing as in Example 1. The microspheres remained exclusively at the site of instillation, dispersed in the crosslinked polymer excipient.
- A drug containing injectate was prepared by suspending 1.5 mg of Triamcinolone acetonide in microparticulate form, in 15 microliters of Healon viscoelastic (Advanced Medical Optics, Irvine, Calif.) with a zero shear viscosity of 300,000 mPas and a viscosity of 150 mPas at a shear rate of 1000 s−1. Forty porcine subjects were placed under anesthesia and the right eye prepared and draped in a sterile manner. A conjunctival peritomy was made near the superior limbus, exposing and providing surgical access to a region of sclera. A small radial incision was made in the sclera, exposing bare choroid. A flexible microcannula with a 360 micron diameter tip and 325 micron diameter body (iTrack microcannula, iScience Interventional Corp.) was inserted in to the scleral incision and advanced in a posterior direction to a target region behind the macula. The drug suspension was injected into the posterior region of the suprachoroidal space, and was observed to form a layer between the choroid and sclera at the target region. The microcannula was retracted and the scleral and conjunctival incisions closed with 7-0 Vicryl suture. The subjects were observed and eyes tissues recovered at 12 hours, 24 hours, 48 hours, 4 days, 7 days, 14 days, 30 days and 90 days. Angiographic, histologic, and photographic studies of the subjects demonstrated no sign of posterior segment pathology. Recovered samples of choroid demonstrated significant concentration of the drug, in the range of at least 1 mg per gram of tissue at all recovery time periods.
- A drug-containing formulation comprising 20
mL Healon 5 and 50 mL (1.5 mg) bevacizumab (Avastin™, Genentech) was prepared. Eighteen porcine subjects were anesthetized and the right eye prepared and draped in a sterile manner. A conjunctival peritomy was made near the superior limbus, exposing and providing surgical access to a region of sclera. A small radial incision was made in the sclera, exposing bare choroid. A flexible microcannula with a 360 micron diameter tip and 325 micron diameter body (iTrack microcannula, iScience Interventional Corp.) was inserted in to the scleral incision and advanced in a posterior direction to a target region behind the macula. The drug formulation was injected into the posterior region of the suprachoroidal space, and was observed to form a layer between the choroid and sclera at the target region. The microcannula was retracted and the scleral and conjunctival incisions closed with 7-0 Vicryl suture. Another 18 porcine subjects were anesthetized and each received a 50 mL bolus of bevacizumab via injection into the vitreous. Both groups of test subjects were evaluated and sacrificed at 0.5, 7, 30, 60, 90, and 120 days post-injection. Serum samples were taken and tested for bevacizumab using an enzyme-based immunoassay. Higher plasma levels of bevacizumab were found in the intravitreally injected subjects and for longer duration of time than the suprachoroidal delivery group. The right globes were removed and dissected in order to quanitate bevacizumab in specific tissues and regions using an enzyme-based immunoassay. The enzyme immunoassay demonstrated that bevacizumab delivered via intravitreal injection was distributed throughout eye, but when delivered suprachoroidally remained largely in the retina and choroid, with little found in the vitreous and anterior chamber. - The experiment of Example 1 was repeated, except a drug formulation 0.2 mL of
Healon 5, 0.6 mL of Avastin, and 24 mg of triamcinolone acetonide was prepared to provide a treatment with both anti-inflammatory and anti-VEGF properties. An approximately 5 mm long incision was made longitudinally in the pars plana region transecting the sclera, exposing the choroid of a cadaver globe that had been clarified by immersion in glycerol for approximately 30 minutes and perfused with saline at 12 mm Hg pressure. The flexible microcannula of Example 6 was primed with the drug formulation and the microcannula tip was inserted into the suprachoroidal space through the scleral incision. With the aid of the fiber optic beacon at the microcannula tip, the distal end of the microcannula was steered toward the posterior pole of the globe, stopping approximately 5 mm short of the optic nerve. Using a Viscoelastic Injector (iScience Interventional), 70 microliters of the drug formulation was injected into the posterior region of the suprachoroidal space. The microcannula was removed by withdrawing though the pars plana incision. The mixture was visible though the clarified sclera, and formed a deposit near the optic nerve with the mixture also following the catheter track. The incision was sealed with cyanoacrylate (Locktite 4011) and the globe perfused again with saline at 12 mm Hg for 3 hours. The sclera was re-cleared by immersion in glycerol to examine the administered drug formulation. The drug formulation was observed by microscopy to have formed a layer of dispersed drug within the polymer excipient in the posterior region of the suprachoroidal space. - A series of experiments were performed to evaluate minimally invasive delivery of substances to the suprachoroidal space. The goal of the experiments was to use non-invasive imaging and fluid dissection as a means of delivering substances through scleral tissue and into the suprachoroidal space, without having direct penetration into the suprachoroidal space.
- Human cadaver eyes were obtained from an eye bank and were prepared by inflating the eyes to approximately 20mm Hg pressure with phosphate buffered saline (PBS). A delivery needle was fabricated using stainless steel hypodermic tubing, 255 mm ID×355 mm OD. The needle distal tip was ground into a bi-faceted short bevel point, 400 um in length and at an angle of 50°. The fabricated needle was then silver-soldered into a standard 25 gauge×1 inch hypodermic needle to complete the assembly.
- The needle was gently advanced into scleral tissue at an acute angle (<10°) with respect to the surface of the eye. The needle entry was started in the pars plana region approximately 4 mm from the limbus, and the needle advanced posteriorly in scleral tissue to create a tract between 5 and 6 mm long without penetrating through the sclera into the suprachoroidal space. A high resolution ultrasound system (iUltrasound, iScience Surgical Corp.) was used to guide and verify placement of the needle tip within scleral tissues and to document the injections.
- In the first set of experiments, a polymeric excipient alone comprising a hyaluronic acid surgical viscoelastic (
Healon 5, Advanced Medical Optics, Inc) was injected. In a second set of experiments, the viscoelastic was mixed in a 1:1 ratio with a 1% aqueous solution of 10 micron diameter polystyrene microspheres (Duke Scientific, Inc) to represent a model microparticulate drug. The viscoelastic and the mixture were delivered through the needle using a screw driven syringe (ViscoInjector, iScience Surgical Corp.) in order to control delivery volume and injection pressure. The injections were made with the needle bevel turned inwards towards the center of the globe. Multiple locations on three cadaver eyes were used for the experiments. - In the first experiments, the needle tract was approximately 3 to 4 mm in length and the injectate was observed to flow back out the tract. With placement of the needle tip in a longer tract, higher injection pressure was obtained and allowed the injectate to dissect through the remaining interposing layers of the sclera and deliver to the suprachoroidal space. Through trials it was found that needle tip placement in the outer layers of the sclera (<½ scleral thickness) resulted in the delivery of the viscoelastic into an intra-scleral pocket or sometimes through to the outer surface of the globe. With the needle tip approaching the basement of the sclera, the injections dissected through the remaining interposing scleral tissue, entered the suprachoroidal space and spread to fill the suprachoroidal space in the region of the injection.
FIG. 1 shows theneedle tract 30 clearly visible (after removal of the needle) and aregion 31 of the suprachoroidal space filled with injectate. Thesclera 1 andchoroid 3 are shown.FIG. 2 shows aregion 33 of the suprachoroidal space filled with the microsphere and hyaluronic acid excipient containing injectate, and the tip of theneedle 4 in the sclera andneedle shadow 32. - An experiment was performed to use micro-endoscopic imaging to allow minimally invasive access to the suprachoroidal space in a human cadaver eye. A custom fabricated, flexible micro-endoscope (Endoscopy Support Services, Brewster, N.Y.) with an outer diameter of 350 microns containing an imaging bundle with 1200 pixels was mounted on a micrometer adjusted stage. The stage was mounted on a vertical stand allowing for controlled up and down travel of the endoscope. The micro-endoscope was attached to a ½″ chip CCD camera and then to a video monitor. A 20 gauge hypodermic needle was placed over the endoscope to provide a means for piercing the tissues for access.
- The camera was turned on and an external light source with a light pipe (Model MI-150, Dolan Jenner, Boxborough, Mass.) was used to provide transcleral imaging illumination. The needle was advanced until the distal tip was in contact with the scleral surface of a human cadaver whole globe approximately 4 mm posterior of the limbus. The micro-endoscope was then lowered until the white scleral surface could be seen through the end of the needle. The needle was then slowly advanced into the scleral tissue by slight back-and-forth rotation. As the needle was advanced in this manner, the endoscope was lowered to follow the tract created by the needle. At or within the sclera, the endoscopic image was seen as white or whitish-grey. As the needle pierced the scleral tissues, the image color changed to dark brown indicating the presence of the dark choroidal tissues, demonstrating surgical access of the suprachoroidal space.
- An experiment was performed to use fiber-optic illuminated guidance to allow minimally invasive access to the suprachoroidal space in a human cadaver eye. A flexible microcannula with an illuminated distal tip (iTrack-250A, iScience Interventional, Menlo Park, Calif.) was placed into a 25 gauge hypodermic needle. The microcannula comprised a plastic optical fiber that allowed for illumination of the distal tip. The microcatheter fiber connector was attached to a 635 nm (red) laser diode fiber optic illuminator (iLumin, iScience Interventional) and the illuminator turned on to provide a steady red light emanating for the microcannula tip. The microcannula was fed through the 25 gauge needle up to the distal bevel of the needle but not beyond.
- The needle was slowly advanced in the pars plana region of a human cadaver whole globe until the needle tip was sufficiently embedded in the scleral tissues to allow a slight advancement of the microcannula. The illumination from the microcannula tip was seen clearly as the scleral tissues diffused the light to a significant extent. As the needle was advanced slowly, the microcannula was pushed forward at the same time. When the hypodermic needle tip pierced through sufficient scleral tissue to reach the suprachoroidal space, the red light of the microcannula tip immediately dimmed as the illuminated tip passed out of the diffusional scleral tissues and into the space beneath. The microcannula was advanced while keeping the needle stationary, thereby placing the microcannula tip into the suprachoroidal space. Further advancement of the microcannula in a posterior direction in the suprachoroidal space could be seen transclerally as a focal red spot without the broad light diffusion seen when the tip was inside the scleral tissues. Using a high frequency ultrasound system (iUltraSound, iScience Interventional), the location of the microcannula in the suprachoroidal space was confirmed.
Claims (25)
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/709,941 US20070202186A1 (en) | 2006-02-22 | 2007-02-21 | Apparatus and formulations for suprachoroidal drug delivery |
AU2007221105A AU2007221105A1 (en) | 2006-02-22 | 2007-02-22 | Apparatus and formulations for suprachoroidal drug delivery |
EP07751620.1A EP1986605B1 (en) | 2006-02-22 | 2007-02-22 | Apparatus and formulations for suprachoroidal drug delivery |
JP2008556462A JP2009531298A (en) | 2006-02-22 | 2007-02-22 | Devices and formulations for suprachoroidal drug delivery |
KR1020087020946A KR20080099285A (en) | 2006-02-22 | 2007-02-22 | Apparatus and formulations for suprachoroidal drug delivery |
EP18176149.5A EP3446679A1 (en) | 2006-02-22 | 2007-02-22 | Apparatus and formulations for suprachoroidal drug delivery |
PCT/US2007/004874 WO2007100745A2 (en) | 2006-02-22 | 2007-02-22 | Apparatus and formulations for suprachoroidal drug delivery |
BRPI0708133-2A BRPI0708133A2 (en) | 2006-02-22 | 2007-02-22 | drug formulation, device for minimally invasive dispensing of a drug formulation into the supracorodial space of the eye; and, methods for dispensing drugs to the eye, posterior region of the eye, and supracoroidal eye space |
CN2007800145013A CN101426473B (en) | 2006-02-22 | 2007-02-22 | Apparatus and formulations for suprachoroidal drug delivery |
CN2011100936446A CN102247239B (en) | 2006-02-22 | 2007-02-22 | Apparatus and formulations for suprachoroidal drug delivery |
CA002643019A CA2643019A1 (en) | 2006-02-22 | 2007-02-22 | Apparatus and formulations for suprachoroidal drug delivery |
US13/842,288 US20130245600A1 (en) | 2006-02-22 | 2013-03-15 | Apparatus and formulations for suprachoridal drug delivery |
US13/842,218 US20130216623A1 (en) | 2006-02-22 | 2013-03-15 | Apparatus and formulations for suprachoridal drug delivery |
US15/358,908 US20170290702A1 (en) | 2006-02-22 | 2016-11-22 | Apparatus and formulations for suprachoroidal drug delivery |
US15/398,538 US20170340560A1 (en) | 2006-02-22 | 2017-01-04 | Apparatus and formulations for suprachoroidal drug delivery |
US16/741,473 US20200390692A1 (en) | 2006-02-22 | 2020-01-13 | Apparatus and formulations for suprachoroidal drug delivery |
US17/217,455 US20210212940A1 (en) | 2006-02-22 | 2021-03-30 | Apparatus and formulations for suprachoroidal drug delivery |
US17/711,495 US11752101B2 (en) | 2006-02-22 | 2022-04-01 | Ocular injector and methods for accessing suprachoroidal space of the eye |
US18/365,024 US20230372235A1 (en) | 2006-02-22 | 2023-08-03 | Ocular injector and methods for accessing suprachoroidal space of the eye |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77690306P | 2006-02-22 | 2006-02-22 | |
US11/709,941 US20070202186A1 (en) | 2006-02-22 | 2007-02-21 | Apparatus and formulations for suprachoroidal drug delivery |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/842,288 Continuation US20130245600A1 (en) | 2006-02-22 | 2013-03-15 | Apparatus and formulations for suprachoridal drug delivery |
US13/842,218 Division US20130216623A1 (en) | 2006-02-22 | 2013-03-15 | Apparatus and formulations for suprachoridal drug delivery |
US16/741,473 Continuation US20200390692A1 (en) | 2006-02-22 | 2020-01-13 | Apparatus and formulations for suprachoroidal drug delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070202186A1 true US20070202186A1 (en) | 2007-08-30 |
Family
ID=38444302
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/709,941 Abandoned US20070202186A1 (en) | 2006-02-22 | 2007-02-21 | Apparatus and formulations for suprachoroidal drug delivery |
US13/842,218 Abandoned US20130216623A1 (en) | 2006-02-22 | 2013-03-15 | Apparatus and formulations for suprachoridal drug delivery |
US13/842,288 Abandoned US20130245600A1 (en) | 2006-02-22 | 2013-03-15 | Apparatus and formulations for suprachoridal drug delivery |
US15/358,908 Abandoned US20170290702A1 (en) | 2006-02-22 | 2016-11-22 | Apparatus and formulations for suprachoroidal drug delivery |
US15/398,538 Abandoned US20170340560A1 (en) | 2006-02-22 | 2017-01-04 | Apparatus and formulations for suprachoroidal drug delivery |
US16/741,473 Abandoned US20200390692A1 (en) | 2006-02-22 | 2020-01-13 | Apparatus and formulations for suprachoroidal drug delivery |
US17/217,455 Abandoned US20210212940A1 (en) | 2006-02-22 | 2021-03-30 | Apparatus and formulations for suprachoroidal drug delivery |
US17/711,495 Active US11752101B2 (en) | 2006-02-22 | 2022-04-01 | Ocular injector and methods for accessing suprachoroidal space of the eye |
US18/365,024 Pending US20230372235A1 (en) | 2006-02-22 | 2023-08-03 | Ocular injector and methods for accessing suprachoroidal space of the eye |
Family Applications After (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/842,218 Abandoned US20130216623A1 (en) | 2006-02-22 | 2013-03-15 | Apparatus and formulations for suprachoridal drug delivery |
US13/842,288 Abandoned US20130245600A1 (en) | 2006-02-22 | 2013-03-15 | Apparatus and formulations for suprachoridal drug delivery |
US15/358,908 Abandoned US20170290702A1 (en) | 2006-02-22 | 2016-11-22 | Apparatus and formulations for suprachoroidal drug delivery |
US15/398,538 Abandoned US20170340560A1 (en) | 2006-02-22 | 2017-01-04 | Apparatus and formulations for suprachoroidal drug delivery |
US16/741,473 Abandoned US20200390692A1 (en) | 2006-02-22 | 2020-01-13 | Apparatus and formulations for suprachoroidal drug delivery |
US17/217,455 Abandoned US20210212940A1 (en) | 2006-02-22 | 2021-03-30 | Apparatus and formulations for suprachoroidal drug delivery |
US17/711,495 Active US11752101B2 (en) | 2006-02-22 | 2022-04-01 | Ocular injector and methods for accessing suprachoroidal space of the eye |
US18/365,024 Pending US20230372235A1 (en) | 2006-02-22 | 2023-08-03 | Ocular injector and methods for accessing suprachoroidal space of the eye |
Country Status (9)
Country | Link |
---|---|
US (9) | US20070202186A1 (en) |
EP (2) | EP1986605B1 (en) |
JP (1) | JP2009531298A (en) |
KR (1) | KR20080099285A (en) |
CN (2) | CN101426473B (en) |
AU (1) | AU2007221105A1 (en) |
BR (1) | BRPI0708133A2 (en) |
CA (1) | CA2643019A1 (en) |
WO (1) | WO2007100745A2 (en) |
Cited By (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070118147A1 (en) * | 2002-03-15 | 2007-05-24 | Smedley Gregory T | Combined treatment for cataract and glaucoma treatment |
US20070129693A1 (en) * | 2005-11-11 | 2007-06-07 | Hunter Ian W | Controlled needle-free eye injector |
US20080200860A1 (en) * | 2001-04-07 | 2008-08-21 | Glaukos Corporation | System for treating ocular disorders and methods thereof |
US20100087774A1 (en) * | 2002-09-21 | 2010-04-08 | Glaukos Corporation | Ocular implant with anchoring mechanism and multiple outlets |
WO2010132751A1 (en) * | 2009-05-15 | 2010-11-18 | Iscience Interventional Corporation | Methods and apparatus for sub-retinal catheterization |
US20110105987A1 (en) * | 2000-04-14 | 2011-05-05 | Glaukos Corporation | System and method for treating an ocular disorder |
WO2011139713A2 (en) | 2010-04-26 | 2011-11-10 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
US8118768B2 (en) | 2001-04-07 | 2012-02-21 | Dose Medical Corporation | Drug eluting ocular implant with anchor and methods thereof |
US8142364B2 (en) | 2001-05-02 | 2012-03-27 | Dose Medical Corporation | Method of monitoring intraocular pressure and treating an ocular disorder |
WO2012051575A3 (en) * | 2010-10-15 | 2012-06-14 | Iscience Interventional Corporation | Device for ocular access |
US8348877B2 (en) | 2000-04-14 | 2013-01-08 | Dose Medical Corporation | Ocular implant with therapeutic agents and methods thereof |
US8409606B2 (en) | 2009-02-12 | 2013-04-02 | Incept, Llc | Drug delivery through hydrogel plugs |
US8506515B2 (en) | 2006-11-10 | 2013-08-13 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US8512404B2 (en) | 2007-11-20 | 2013-08-20 | Ivantis, Inc. | Ocular implant delivery system and method |
US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
US8529494B2 (en) | 2008-03-05 | 2013-09-10 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
US8551166B2 (en) | 2007-11-20 | 2013-10-08 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
WO2014074823A1 (en) * | 2012-11-08 | 2014-05-15 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
US8734377B2 (en) | 2007-09-24 | 2014-05-27 | Ivantis, Inc. | Ocular implants with asymmetric flexibility |
US20140194834A1 (en) * | 2013-01-08 | 2014-07-10 | University Of South Florida | Auto-Regulation System for Intraocular Pressure |
US8808222B2 (en) | 2007-11-20 | 2014-08-19 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
WO2014159889A1 (en) * | 2013-03-14 | 2014-10-02 | Lumoptik, Inc. | Insertion tool guidance system for ocular access |
US20140316326A1 (en) * | 2011-08-16 | 2014-10-23 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Device for the treatment of an ocular disease |
WO2015015467A1 (en) * | 2013-08-02 | 2015-02-05 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | A device for delivery of compositions to the eye |
US20150051581A1 (en) * | 2013-05-03 | 2015-02-19 | Clearside Biomedical, Inc. | Apparatus and methods for ocular injection |
US8961447B2 (en) | 2007-09-24 | 2015-02-24 | Ivantis, Inc. | Glaucoma treatment method |
WO2015095772A3 (en) * | 2013-12-20 | 2015-08-13 | Emory University | Formulations and methods for targeted ocular delivery of therapeutic agents |
US9205181B2 (en) | 2014-01-09 | 2015-12-08 | Rainbow Medical, Ltd. | Injectable hydrogel implant for treating glaucoma |
US9211213B2 (en) | 2009-07-09 | 2015-12-15 | Ivantis, Inc. | Ocular implants and methods for delivering ocular implants into the eye |
USD750223S1 (en) | 2014-10-14 | 2016-02-23 | Clearside Biomedical, Inc. | Medical injector for ocular injection |
WO2016042162A1 (en) * | 2014-09-19 | 2016-03-24 | Medterials, Inc. | Ophthalmic delivery device |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
US9402767B2 (en) | 2007-09-24 | 2016-08-02 | Ivantis, Inc. | Ocular implant architectures |
US20160256320A1 (en) * | 2010-11-15 | 2016-09-08 | Aquesys, Inc. | Intraocular shunt placement in the suprachoroidal space |
US20160256323A1 (en) * | 2011-12-08 | 2016-09-08 | Aquesys, Inc. | Intrascleral shunt placement |
US20160270894A1 (en) * | 2013-11-01 | 2016-09-22 | Atrium Medical Corporation | Positioning agent and method of using the same |
US20160302965A1 (en) * | 2013-12-06 | 2016-10-20 | Forsight Vision4, Inc. | Implantable therapeutic devices |
US9510973B2 (en) | 2010-06-23 | 2016-12-06 | Ivantis, Inc. | Ocular implants deployed in schlemm's canal of the eye |
US20170038284A1 (en) * | 1998-10-23 | 2017-02-09 | Babak Nemati | Systems for augmenting optical transmission through biological tissues |
US9579234B2 (en) | 2009-10-23 | 2017-02-28 | Ivantis, Inc. | Ocular implant system and method |
US20170172797A1 (en) * | 2013-11-14 | 2017-06-22 | Aquesys, Inc. | Intraocular shunt insertion techniques |
US9693899B2 (en) | 2009-07-09 | 2017-07-04 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
EP3157463A4 (en) * | 2014-06-17 | 2018-02-21 | Clearside Biomedical, Inc. | Methods and devices for treating posterior ocular disorders |
US9956114B2 (en) | 2014-06-20 | 2018-05-01 | Clearside Biomedical, Inc. | Variable diameter cannula and methods for controlling insertion depth for medicament delivery |
US9980854B2 (en) | 2010-11-15 | 2018-05-29 | Aquesys, Inc. | Shunt placement through the sclera |
US10004638B2 (en) | 2010-11-15 | 2018-06-26 | Aquesys, Inc. | Intraocular shunt delivery |
US10010447B2 (en) | 2013-12-18 | 2018-07-03 | Novartis Ag | Systems and methods for subretinal delivery of therapeutic agents |
US10085884B2 (en) | 2006-06-30 | 2018-10-02 | Aquesys, Inc. | Intraocular devices |
CN108653818A (en) * | 2018-05-24 | 2018-10-16 | 上海其胜生物制剂有限公司 | A kind of reversible collagen stimulation filler and preparation method thereof |
CN109073653A (en) * | 2016-04-22 | 2018-12-21 | 国立癌中心 | For marking the injection composition of lesion |
US10188550B2 (en) | 2013-06-03 | 2019-01-29 | Clearside Biomedical, Inc. | Apparatus and methods for drug delivery using multiple reservoirs |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
US20190110924A1 (en) * | 2017-10-18 | 2019-04-18 | Jesus Moreno | Opthalmic microsurgical instrument |
US10285852B2 (en) | 2010-12-02 | 2019-05-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd., The Chaim Sheba Medical Center | Subretinal delivery of therapeutic compositions |
IL265620A (en) * | 2012-01-23 | 2019-05-30 | Allergan Inc | Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation |
US10307293B2 (en) | 2010-11-15 | 2019-06-04 | Aquesys, Inc. | Methods for intraocular shunt placement |
EP3345642A4 (en) * | 2015-09-03 | 2019-07-10 | Pusan National University Hospital | Optically induced injection device |
US10369048B2 (en) | 2013-06-28 | 2019-08-06 | Aquesys, Inc. | Intraocular shunt implantation |
US10390901B2 (en) | 2016-02-10 | 2019-08-27 | Clearside Biomedical, Inc. | Ocular injection kit, packaging, and methods of use |
US10463537B2 (en) | 2015-06-03 | 2019-11-05 | Aquesys Inc. | Ab externo intraocular shunt placement |
US10524959B2 (en) | 2013-02-27 | 2020-01-07 | Aquesys, Inc. | Intraocular shunt implantation methods and devices |
US10568762B2 (en) | 1999-04-26 | 2020-02-25 | Glaukos Corporation | Stent for treating ocular disorders |
EP3487586A4 (en) * | 2016-07-20 | 2020-03-04 | Emory University | Formulations for the suprachoroidal space of an eye and methods |
US10617558B2 (en) | 2012-11-28 | 2020-04-14 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
US10667947B2 (en) | 2016-06-02 | 2020-06-02 | Aquesys, Inc. | Intraocular drug delivery |
US10709547B2 (en) | 2014-07-14 | 2020-07-14 | Ivantis, Inc. | Ocular implant delivery system and method |
US10813789B2 (en) | 2009-05-18 | 2020-10-27 | Dose Medical Corporation | Drug eluting ocular implant |
US10952898B2 (en) | 2018-03-09 | 2021-03-23 | Aquesys, Inc. | Intraocular shunt inserter |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US10973681B2 (en) | 2016-08-12 | 2021-04-13 | Clearside Biomedical, Inc. | Devices and methods for adjusting the insertion depth of a needle for medicament delivery |
US11135089B2 (en) | 2018-03-09 | 2021-10-05 | Aquesys, Inc. | Intraocular shunt inserter |
US11154420B2 (en) | 2015-09-17 | 2021-10-26 | Oxular Limited | Ophthalmic injection device |
US11197779B2 (en) | 2015-08-14 | 2021-12-14 | Ivantis, Inc. | Ocular implant with pressure sensor and delivery system |
US11246753B2 (en) | 2017-11-08 | 2022-02-15 | Aquesys, Inc. | Manually adjustable intraocular flow regulation |
US11273072B2 (en) | 2017-01-13 | 2022-03-15 | Gyroscope Therapeutics Limited | Suprachoroidal injection device |
US11318043B2 (en) | 2016-04-20 | 2022-05-03 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
US11363951B2 (en) | 2011-09-13 | 2022-06-21 | Glaukos Corporation | Intraocular physiological sensor |
US20220347014A1 (en) * | 2006-02-22 | 2022-11-03 | Clearside Biomedical, Inc. | Ocular injector and methods for accessing suprachoroidal space of the eye |
US11540940B2 (en) | 2021-01-11 | 2023-01-03 | Alcon Inc. | Systems and methods for viscoelastic delivery |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
US11576816B2 (en) * | 2017-10-18 | 2023-02-14 | Jesus Moreno | Opthalmic microsurgical instrument |
US11596545B2 (en) | 2016-05-02 | 2023-03-07 | Clearside Biomedical, Inc. | Systems and methods for ocular drug delivery |
US11622884B2 (en) | 2016-03-16 | 2023-04-11 | Oxular Limited | Ophthalmic delivery device and ophthalmic drug compositions |
US11744734B2 (en) | 2007-09-24 | 2023-09-05 | Alcon Inc. | Method of implanting an ocular implant |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7909789B2 (en) | 2006-06-26 | 2011-03-22 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
US8642067B2 (en) * | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
US8529622B2 (en) | 2010-02-05 | 2013-09-10 | Sight Sciences, Inc. | Intraocular implants and related kits and methods |
EP2559443A1 (en) | 2011-08-16 | 2013-02-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject |
US9962287B2 (en) | 2011-08-16 | 2018-05-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Device for the treatment of an ocular disease |
EP4302734A3 (en) | 2012-03-20 | 2024-03-20 | Sight Sciences, Inc. | Ocular delivery systems and methods |
CN103767822A (en) * | 2012-10-24 | 2014-05-07 | 鸿富锦精密工业(深圳)有限公司 | Auxiliary device and method for feeding eye drops through auxiliary device |
WO2015126694A1 (en) | 2014-02-12 | 2015-08-27 | Ethicon Endo-Surgery, Inc. | Method and apparatus for suprachoroidal administration of therapeutic agent |
US9925088B2 (en) | 2014-06-06 | 2018-03-27 | Janssen Biotech, Inc. | Sub-retinal tangential needle catheter guide and introducer |
US9949874B2 (en) | 2014-06-06 | 2018-04-24 | Janssen Biotech, Inc. | Therapeutic agent delivery device with convergent lumen |
US10219936B2 (en) | 2014-09-11 | 2019-03-05 | Orbit Biomedical Limited | Therapeutic agent delivery device with advanceable cannula and needle |
US10258502B2 (en) | 2014-09-18 | 2019-04-16 | Orbit Biomedical Limited | Therapeutic agent delivery device |
CN117695204A (en) * | 2014-09-19 | 2024-03-15 | 奥叙拉尔有限公司 | Ophthalmic pharmaceutical composition |
US10550187B2 (en) | 2014-10-24 | 2020-02-04 | Incept, Llc | Extra luminal scaffold |
US10299958B2 (en) | 2015-03-31 | 2019-05-28 | Sight Sciences, Inc. | Ocular delivery systems and methods |
US10478553B2 (en) | 2016-03-09 | 2019-11-19 | Orbit Biomedical Limited | Apparatus for subretinal administration of therapeutic agent via a curved needle |
CN106691681B (en) * | 2016-05-25 | 2019-03-22 | 天津优视眼科技术有限公司 | It is a kind of for treating the surgery device of open-angle glaucoma |
US11000410B2 (en) | 2016-06-17 | 2021-05-11 | Gyroscope Therapeutics Limited | Guide apparatus for tangential entry into suprachoroidal space |
US10646374B2 (en) | 2016-06-17 | 2020-05-12 | Orbit Biomedical Limited | Apparatus and method to form entry bleb for subretinal delivery of therapeutic agent |
US10806629B2 (en) * | 2016-06-17 | 2020-10-20 | Gyroscope Therapeutics Limited | Injection device for subretinal delivery of therapeutic agent |
US11413397B2 (en) | 2016-12-16 | 2022-08-16 | The Brigham And Women's Hospital, Inc. | System and method for resistance-dependent, self-regulated medical penetration |
US11076984B2 (en) | 2017-03-13 | 2021-08-03 | Gyroscope Therapeutics Limited | Method of performing subretinal drainage and agent delivery |
AU2018240375C1 (en) | 2017-03-22 | 2024-02-01 | Ascendis Pharma A/S | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
US20200061357A1 (en) * | 2017-05-02 | 2020-02-27 | Georgia Tech Research Corporation | Targeted drug delivery methods using a microneedle |
CN111712228A (en) | 2017-09-15 | 2020-09-25 | 奥叙拉尔有限公司 | Ophthalmic pharmaceutical composition |
EP3687464A4 (en) * | 2017-09-27 | 2021-09-29 | REGENXBIO Inc. | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
CN109009657A (en) * | 2018-09-10 | 2018-12-18 | 天津医科大学总医院 | A kind of choroid restorer |
CN109692072B (en) * | 2019-01-09 | 2021-07-09 | 中南大学湘雅二医院 | Suprachoroidal space pressurized hydrogel balloon device for rhegmatogenous retinal detachment |
US11504270B1 (en) | 2019-09-27 | 2022-11-22 | Sight Sciences, Inc. | Ocular delivery systems and methods |
CN111228034A (en) * | 2020-01-16 | 2020-06-05 | 贵州省人民医院 | Drug-loading controlled-release lacrimal duct embolus and preparation method thereof |
WO2022236778A1 (en) * | 2021-05-13 | 2022-11-17 | Beijing Sightnovo Medical Technology Co., Ltd | Medical penetration device and system |
CN114366712B (en) * | 2022-01-25 | 2023-10-24 | 上海交通大学医学院附属第九人民医院 | Pharmaceutical gel mixture for treating choroidal neovascularization |
Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4377897A (en) * | 1981-08-04 | 1983-03-29 | Ocular Associates | Ophthalmic needle and method for manufacturing the same |
US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
US5273530A (en) * | 1990-11-14 | 1993-12-28 | The University Of Rochester | Intraretinal delivery and withdrawal instruments |
US5312361A (en) * | 1991-09-13 | 1994-05-17 | Zadini Filiberto P | Automatic cannulation device |
US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5632740A (en) * | 1991-01-30 | 1997-05-27 | Ceram Optec Industries, Inc. | Illuminated leading probe device |
US5792099A (en) * | 1995-02-14 | 1998-08-11 | Decamp; Dennis | Syringe and cannula for insertion of viscoelastic material into an eye and method of using same |
US5952378A (en) * | 1994-08-24 | 1999-09-14 | Pharmacia & Upjohn Ab | Methods and means for drug administration |
US20010008961A1 (en) * | 1998-08-03 | 2001-07-19 | Hecker Karl I. | Injection apparatus and method of using same |
US20020042594A1 (en) * | 1998-03-30 | 2002-04-11 | Paul Lum | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
US20030171722A1 (en) * | 2001-01-04 | 2003-09-11 | Michel Paques | Microsurgical injection and/or distending instruments and surgical method and apparatus utilizing same |
US20040039253A1 (en) * | 2002-08-20 | 2004-02-26 | Peyman Gholam A. | Treatment of retinal detachment |
US20050089545A1 (en) * | 2002-02-22 | 2005-04-28 | Mitsuaki Kuwano | Drug delivery system for the subconjunctival administration of fine grains |
US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
US20050137525A1 (en) * | 2003-06-04 | 2005-06-23 | Georgia Tech Research Corporation | Drilling microneedle device |
US20050171507A1 (en) * | 2004-01-23 | 2005-08-04 | Christian Jeffrey J. | Composite ophthalmic microcannula |
US6936053B1 (en) * | 1998-07-02 | 2005-08-30 | Jeffrey N. Weiss | Ocular implant needle |
US20050244462A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Devices and methods for treating a mammalian eye |
US20060233858A1 (en) * | 2005-03-08 | 2006-10-19 | Allergan, Inc. | Systems and methods providing targeted intraocular drug delivery |
US20080033351A1 (en) * | 2006-08-04 | 2008-02-07 | Allergan, Inc. | Ocular implant delivery assemblies with distal caps |
Family Cites Families (555)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1527291A (en) | 1923-07-09 | 1925-02-24 | Zorraquin Guillermo | Safety-pressure-indicating needle |
US2187259A (en) | 1936-07-11 | 1940-01-16 | George E Barnhart | Hypodermic needle |
US2623521A (en) | 1951-03-12 | 1952-12-30 | Rose Shaw | Indicating stylet needle |
US2841145A (en) | 1956-05-07 | 1958-07-01 | John A Epps | Syringe |
US2939459A (en) | 1957-01-11 | 1960-06-07 | Jorge A Lazarte | Tandem syringe |
US3477432A (en) | 1964-07-21 | 1969-11-11 | Joseph Denman Shaw | Combination mixing and injecting medical syringe |
US3376999A (en) | 1967-05-31 | 1968-04-09 | Gen Dynamics Corp | Packaging, mixing and dispensing apparatus |
US3892311A (en) | 1969-01-31 | 1975-07-01 | Vincent R Sneider | Disposable syringe kit |
AT318132B (en) | 1969-08-01 | 1974-09-25 | Dentaire Ivoclar Ets | Mixing container for holding substances that react with one another for the production of ready-to-use paste-like dental preparations |
US3762540A (en) | 1970-05-19 | 1973-10-02 | Dentaire Ivoclar Ets | Receptacle having at least three chambers |
US3964482A (en) | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
US3838690A (en) | 1971-07-14 | 1974-10-01 | B Friedman | Replaceable cartridge hypodermic syringe having sterile maintenance of needle |
US3788320A (en) | 1972-02-25 | 1974-01-29 | Kendall & Co | Spinal needle |
US3962430A (en) | 1974-08-07 | 1976-06-08 | Merck & Co., Inc. | Sterilization of solid non-electrolyte medicinal agents employing sodium chloride |
US4230112A (en) | 1978-08-07 | 1980-10-28 | Smith Philip E | Syringe-type liquid container dispenser adapter |
US4303071A (en) | 1978-08-07 | 1981-12-01 | Baxa Corporation | Syringe-type liquid container dispenser adapter |
US4226328A (en) | 1979-04-09 | 1980-10-07 | Baxter Travenol Laboratories, Inc. | Catheterization package |
US4383530A (en) | 1981-06-05 | 1983-05-17 | John Bruno | Hypodermic needle and method of making needles |
US4432964A (en) | 1981-08-24 | 1984-02-21 | Alza Corporation | Topical composition containing steroid in two forms released independently from polymeric carrier |
JPS5828535B2 (en) | 1981-09-22 | 1983-06-16 | 茨城県 | Temperature sensor |
US4525346A (en) | 1981-09-28 | 1985-06-25 | Alcon Laboratories, Inc. | Aqueous antimicrobial ophthalmic solutions |
JPS5875563A (en) | 1981-10-30 | 1983-05-07 | テルモ株式会社 | Connector for stationary cathetel |
US4564016A (en) | 1982-05-24 | 1986-01-14 | The Board Of Trustees Of The Leland Stanford Junior University | Apparatus for introducing ionized drugs into the posterior segment of the eye and method |
US4615331A (en) | 1983-06-28 | 1986-10-07 | Sterimed Gesellschaft Fur Medizinischen Bedarf Mbh | Medical instruments with aid to introduction |
US4573993A (en) | 1983-09-29 | 1986-03-04 | Instafil, Inc. | Fluid transfer apparatus |
US4501363A (en) | 1983-10-25 | 1985-02-26 | Isbey Jr Edward K | Surgical kit |
NZ212899A (en) | 1984-07-31 | 1987-10-30 | Phillips Pty Ltd N J | Piston operated adjustable volume dose injector for animals |
US4708147A (en) | 1985-02-25 | 1987-11-24 | Haaga John R | Universal biopsy needle |
US4826871A (en) | 1985-03-13 | 1989-05-02 | Gressel Philip D | Topical ophthalmic compositions containing one or more retinoids |
US4689040A (en) | 1985-04-29 | 1987-08-25 | Thompson Robert J | Tip for a phacoemulsification needle |
US4689042A (en) | 1985-05-20 | 1987-08-25 | Survival Technology, Inc. | Automatic medicament ingredient mixing and injecting apparatus |
US4662870A (en) | 1985-07-15 | 1987-05-05 | Augustine Scott D | Needle penetration indicator and guide |
US4826490A (en) | 1985-07-29 | 1989-05-02 | National Research Development Corporation | Safety device for hypodermic needle or the like |
US4601708A (en) | 1985-09-09 | 1986-07-22 | Pavel Jordan | Automatic injection for syringe needle, and assembly |
US4662878A (en) | 1985-11-13 | 1987-05-05 | Patents Unlimited Ltd. | Medicine vial adaptor for needleless injector |
US5023087A (en) | 1986-02-10 | 1991-06-11 | Liposome Technology, Inc. | Efficient method for preparation of prolonged release liposome-based drug delivery system |
US4736850A (en) | 1986-10-17 | 1988-04-12 | W. L. Gore & Associates, Inc. | Endothelial cell harvesting kit |
US4966773A (en) | 1986-11-25 | 1990-10-30 | Alcon Laboratories, Inc. | Topical ophthalmic compositions containing microfine retinoid particles |
US4795432A (en) | 1987-02-19 | 1989-01-03 | Karczmer Claude M | Shield assembly for hypodermic injection devices |
US4804371A (en) | 1987-05-06 | 1989-02-14 | Vaillancourt Vincent L | Post-injection needle sheath |
EP0443630B1 (en) | 1987-07-10 | 1993-12-29 | B. Braun Melsungen AG | Cannula |
DE3802158A1 (en) | 1987-08-11 | 1989-02-23 | Hoechst Ag | DEVICE FOR APPLICATION OF IMPLANTS |
US5547467A (en) | 1988-01-21 | 1996-08-20 | Massachusettes Institute Of Technology | Method for rapid temporal control of molecular transport across tissue |
US5100394A (en) | 1988-01-25 | 1992-03-31 | Baxter International Inc. | Pre-slit injection site |
US5211638A (en) | 1988-01-25 | 1993-05-18 | Baxter International Inc. | Pre-slit injection site |
US5066276A (en) | 1988-06-21 | 1991-11-19 | Alcon Laboratories, Inc. | Method and apparatus for injecting viscous fluid into the eye to lift pre-retinal and post-retinal membrane with linear pressure control |
US5137447A (en) | 1988-09-23 | 1992-08-11 | Frank Hunter | Oral hygiene |
US5057072A (en) | 1988-10-28 | 1991-10-15 | Medtronic, Inc. | Iontophoresis electrode |
CA2001444C (en) | 1988-10-28 | 2000-07-25 | Darrel F. Untereker | Iontophoresis electrode |
US5817075A (en) | 1989-08-14 | 1998-10-06 | Photogenesis, Inc. | Method for preparation and transplantation of planar implants and surgical instrument therefor |
US5025811A (en) | 1990-02-16 | 1991-06-25 | Dobrogowski Michael J | Method for focal destruction of eye tissue by electroablation |
US5024662A (en) | 1990-03-13 | 1991-06-18 | Menes Cesar M | Resistance syringe for epidural anesthesia |
US5015240A (en) | 1990-05-01 | 1991-05-14 | Ian Campbell Cree | Hypodermic needle shield |
US5098389A (en) | 1990-06-28 | 1992-03-24 | Becton, Dickinson And Company | Hypodermic needle assembly |
ES2023597A6 (en) | 1990-11-05 | 1992-01-16 | Rodiera Olive Jose Javier | Epidural cannula. |
US5284474A (en) | 1990-12-11 | 1994-02-08 | Adair Edwin Lloyd | Trochar system for laparoscopy |
US5569288A (en) | 1990-12-18 | 1996-10-29 | Yoon; Inbae | Safety penetrating instrument |
GB9103291D0 (en) | 1991-02-15 | 1991-04-03 | Waverley Pharma Ltd | Transfer adaptor |
US5206267A (en) | 1991-05-09 | 1993-04-27 | Morton Shulman | Pain controlling composition and method of preparation |
US5181909A (en) | 1991-05-15 | 1993-01-26 | Mcfarlane Richard H | Ampule-container medical syringe and methods |
GB9111049D0 (en) | 1991-05-22 | 1991-07-17 | Parkin Adrian | Hypodermic needle |
DE4120173A1 (en) | 1991-06-19 | 1992-12-24 | Hoechst Ag | POSITIVELY WORKING RADIATION-SENSITIVE MIXTURE AND PRODUCTION OF RADIATION-SENSITIVE RECORDING MATERIAL THEREFOR |
US5104381A (en) | 1991-08-30 | 1992-04-14 | Origin Medsystems, Inc. | Pneumoneedle with removable stylet assembly |
US5172807A (en) | 1991-09-30 | 1992-12-22 | Centrix, Inc. | Cement mixing capsule |
AU4282793A (en) | 1992-04-10 | 1993-11-18 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | A microneedle for injection of ocular blood vessels |
US5767079A (en) | 1992-07-08 | 1998-06-16 | Celtrix Pharmaceuticals, Inc. | Method of treating ophthalmic disorders using TGF -β |
EP0651650A4 (en) | 1992-07-08 | 1996-04-17 | Celtrix Pharma | METHOD OF TREATING OPHTHALMIC DISORDERS USING TGF--g(b). |
US5295972A (en) | 1992-08-04 | 1994-03-22 | Metatech Corporation | Hypodermic syringe with protective cap |
US5279564A (en) | 1992-09-11 | 1994-01-18 | Edward Weck Incorporated | Cannula retention device |
US5300084A (en) | 1992-11-23 | 1994-04-05 | United States Surgical Corporation | Pneumoperitoneum needle |
CA2150554A1 (en) | 1992-12-02 | 1994-06-09 | Sheng-Wan Tsao | Cyclodextrin and polymer based drug delivery system |
US5320609A (en) | 1992-12-07 | 1994-06-14 | Habley Medical Technology Corporation | Automatic pharmaceutical dispensing syringe |
US5681825A (en) * | 1993-03-15 | 1997-10-28 | Lindqvist; Bengt | Surgical method |
US5399159A (en) | 1993-03-30 | 1995-03-21 | Origin Medsystems, Inc. | Apparatus and method for hand-held insufflation |
US5358489A (en) | 1993-05-27 | 1994-10-25 | Washington Biotech Corporation | Reloadable automatic or manual emergency injection system |
US5407070A (en) | 1993-08-18 | 1995-04-18 | Bascos; Christine M. | One-time resealable package for needled medical devices |
US5415629A (en) | 1993-09-15 | 1995-05-16 | Henley; Julian L. | Programmable apparatus for the transdermal delivery of drugs and method |
US5354286A (en) | 1993-12-07 | 1994-10-11 | Survival Technology, Inc. | Injection device having polyparaxylylene coated container |
US5397313A (en) | 1994-01-27 | 1995-03-14 | The Kendall Company | Low friction syringe |
US5527306A (en) | 1994-04-18 | 1996-06-18 | Haining; Michael L. | Vial adapter |
US5658256A (en) | 1994-08-22 | 1997-08-19 | Shields; Jack W. | Universal sharps shield |
WO1996009838A1 (en) | 1994-09-28 | 1996-04-04 | Celtrix Pharmaceuticals, Inc. | METHOD OF TREATING MACULAR DEGENERATION USING TGF-$g(b) |
IL114960A0 (en) | 1995-03-20 | 1995-12-08 | Medimop Medical Projects Ltd | Flow control device |
US5779668A (en) | 1995-03-29 | 1998-07-14 | Abbott Laboratories | Syringe barrel for lyophilization, reconstitution and administration |
US5575780A (en) | 1995-04-28 | 1996-11-19 | Saito; Yoshikuni | Medical hollow needle and a method of producing thereof |
US5968022A (en) | 1995-04-28 | 1999-10-19 | Saito; Yoshikuni | Medical hollow needle and method of production |
US5839715A (en) | 1995-05-16 | 1998-11-24 | Alaris Medical Systems, Inc. | Medical adapter having needleless valve and sharpened cannula |
USD383049S (en) | 1995-06-30 | 1997-09-02 | Fiskars Inc. | Tool handle grip |
US6280470B1 (en) | 1995-10-20 | 2001-08-28 | Gholam A. Peyman | Intrastromal corneal modification |
US6039093A (en) | 1995-10-20 | 2000-03-21 | Schering Aktiengesellschaft | Adapter for extracting a liquid from a container closed with a stopper |
DK0928182T3 (en) | 1996-01-11 | 2002-08-26 | Duoject Inc | Delivery system for medicines packed in pharmaceutical bottles |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
US5766198A (en) | 1996-06-10 | 1998-06-16 | Li; Bing | Surgical knife employing a vacuum to ensure precise depth of incisions |
US5752942A (en) | 1996-06-20 | 1998-05-19 | Becton Dickinson And Company | Five beveled point geometry for a hypodermic needle |
US5788679A (en) | 1996-06-26 | 1998-08-04 | Gravlee, Jr.; Joseph F. | Phacoemulsification needle |
US5976573A (en) | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
US5911223A (en) | 1996-08-09 | 1999-06-15 | Massachusetts Institute Of Technology | Introduction of modifying agents into skin by electroporation |
US5951520A (en) | 1996-12-19 | 1999-09-14 | Bio-Plexus, Inc. | Self-blunting needle medical devices and methods of manufacture thereof |
GB9701413D0 (en) | 1997-01-24 | 1997-03-12 | Smithkline Beecham Biolog | Novel device |
US5919158A (en) | 1997-02-13 | 1999-07-06 | Emory University | Method and apparatus for preventing and clearing condensation on the lens during a fluid-gas exchange portion of a pars plana vitrectomy |
EA199901013A1 (en) | 1997-05-16 | 2000-06-26 | Амген Инк. | GELS OF PROLONGED ACTION |
AUPO940697A0 (en) | 1997-09-23 | 1997-10-16 | Kaal, Joseph Hermes | Retractable syringe |
FR2773320B1 (en) | 1998-01-05 | 2000-03-03 | Optisinvest | DEVICE FOR INTRAOCULAR TRANSFER OF ACTIVE PRODUCTS BY IONTOPHORESIS |
WO1999034858A1 (en) | 1998-01-12 | 1999-07-15 | Georgia Tech Research Corporation | Assessment and control of acoustic tissue effects |
US6003566A (en) | 1998-02-26 | 1999-12-21 | Becton Dickinson And Company | Vial transferset and method |
US6059111A (en) | 1998-03-04 | 2000-05-09 | Medtronic, Inc. | Medical device packaging system |
US6309347B1 (en) | 1998-03-17 | 2001-10-30 | Fuji Photo Optical Co., Ltd. | Air and water supply system for endoscopes |
JP2951938B1 (en) | 1998-03-19 | 1999-09-20 | 日本ケミカルリサーチ株式会社 | Syringe with built-in drug dissolution mechanism |
US6957745B2 (en) | 1998-04-20 | 2005-10-25 | Becton, Dickinson And Company | Transfer set |
US6209738B1 (en) | 1998-04-20 | 2001-04-03 | Becton, Dickinson And Company | Transfer set for vials and medical containers |
US6378714B1 (en) | 1998-04-20 | 2002-04-30 | Becton Dickinson And Company | Transferset for vials and other medical containers |
US6540725B1 (en) | 1998-06-04 | 2003-04-01 | Biosense Webster, Inc. | Injection catheter with controllably extendable injection needle |
US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
FR2784034B1 (en) | 1998-10-01 | 2000-12-15 | Marc Brunel | SINGLE USE INJECTION DEVICE FOR PRE-FILLED |
US6219575B1 (en) | 1998-10-23 | 2001-04-17 | Babak Nemati | Method and apparatus to enhance optical transparency of biological tissues |
US20040141925A1 (en) | 1998-11-12 | 2004-07-22 | Elan Pharma International Ltd. | Novel triamcinolone compositions |
US6670321B1 (en) | 1998-12-30 | 2003-12-30 | The Children's Medical Center Corporation | Prevention and treatment for retinal ischemia and edema |
JP5483789B2 (en) | 1999-01-05 | 2014-05-07 | ザ フリンダーズ ユニバーシティ オブ サウス オーストラリア | Novel drugs and methods for treating and diagnosing eye disorders |
JP3492543B2 (en) | 1999-03-15 | 2004-02-03 | 金子工業有限会社 | Injection needle and its manufacturing method |
DE19916979A1 (en) | 1999-04-15 | 2000-11-02 | Sican Gmbh | Level measurement method and level sensor |
DE60043734D1 (en) | 1999-04-20 | 2010-03-11 | Jms Co Ltd | CONTAINER CAP FOR TANK AND LIQUID TRANSFER DEVICE |
US6699210B2 (en) | 1999-04-27 | 2004-03-02 | The Arizona Board Of Regents | Glaucoma shunt and a method of making and surgically implanting the same |
US6159218A (en) | 1999-05-19 | 2000-12-12 | Aramant; Robert B. | Retinal tissue implantation tool |
US6319240B1 (en) | 1999-05-25 | 2001-11-20 | Iomed, Inc. | Methods and apparatus for ocular iontophoresis |
US6611707B1 (en) | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
US6743211B1 (en) | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
FR2794650B1 (en) | 1999-06-10 | 2001-09-14 | Marc Brunel | SINGLE USE INJECTION DEVICE |
US6738526B1 (en) | 1999-07-30 | 2004-05-18 | Microsoft Corporation | Method and apparatus for filtering and caching data representing images |
JP2003508163A (en) | 1999-09-03 | 2003-03-04 | ファーマスペック、コーポレーション | Multicannula catheter for administering drugs to isolated sites in a vein where fluid flow near the catheter is obstructed |
US6569123B2 (en) | 1999-10-14 | 2003-05-27 | Becton, Dickinson And Company | Prefillable intradermal injector |
US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
EP1221918B1 (en) | 1999-10-21 | 2005-03-16 | Alcon Inc. | Sub-tenon drug delivery |
FR2801795B1 (en) | 1999-12-07 | 2002-07-05 | Plastef Investissements | SAFETY SUPPORT DEVICE FOR A SYRINGE AND ASSEMBLY OF SUCH A DEVICE AND A SYRINGE |
US20020072673A1 (en) | 1999-12-10 | 2002-06-13 | Yamamoto Ronald K. | Treatment of ocular disease |
US20010051798A1 (en) | 1999-12-28 | 2001-12-13 | Hochman Mark N. | Method of performing an injection using a bi-directional rotational insertion technique |
US6726676B2 (en) | 2000-01-05 | 2004-04-27 | Grieshaber & Co. Ag Schaffhausen | Method of and device for improving the flow of aqueous humor within the eye |
US6139534A (en) | 2000-01-24 | 2000-10-31 | Bracco Diagnostics, Inc. | Vial access adapter |
US6544246B1 (en) | 2000-01-24 | 2003-04-08 | Bracco Diagnostics, Inc. | Vial access adapter and vial combination |
US6832994B2 (en) | 2000-01-24 | 2004-12-21 | Bracco Diagnostics Inc. | Table top drug dispensing vial access adapter |
US6503240B1 (en) | 2000-01-24 | 2003-01-07 | Brocco Diagnostics, Inc. | Vial access adapter |
US7799009B2 (en) | 2000-01-24 | 2010-09-21 | Bracco Diagnostics Inc. | Tabletop drug dispensing vial access adapter |
RU14351U1 (en) | 2000-02-15 | 2000-07-20 | Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" | GUIDEL NEEDLE FOR RETROBULBAR SPACE |
US6558361B1 (en) | 2000-03-09 | 2003-05-06 | Nanopass Ltd. | Systems and methods for the transport of fluids through a biological barrier and production techniques for such systems |
IL134997A0 (en) | 2000-03-09 | 2001-05-20 | Yehoshua Yeshurun | Health care system based on micro device |
US6491670B1 (en) * | 2000-04-04 | 2002-12-10 | Duke University | Miniaturized surgical instruments especially useful for the opthalmologic surgical procedures and methods of making the same |
JP4372310B2 (en) | 2000-04-10 | 2009-11-25 | ニプロ株式会社 | Adapter for mixed injection |
US6622864B1 (en) | 2000-06-01 | 2003-09-23 | Osteotech, Inc. | Moisture resistant package for storing sterile items |
GB0017999D0 (en) | 2000-07-21 | 2000-09-13 | Smithkline Beecham Biolog | Novel device |
US6530904B1 (en) | 2000-08-15 | 2003-03-11 | Evan T. Edwards | Medical injector |
JP4187922B2 (en) | 2000-09-14 | 2008-11-26 | テルモ株式会社 | Liquid injection needle and liquid injection device |
US6546283B1 (en) | 2000-10-18 | 2003-04-08 | Iomed, Inc. | High current density iontophoretic device and method of use thereof |
EP1339348A2 (en) | 2000-10-31 | 2003-09-03 | Smith & Nephew, Inc. | Packaging and delivery system for bone graft particles |
US20030060447A1 (en) * | 2002-04-24 | 2003-03-27 | Mutlu Karakelle | Non-aspirating transitional viscoelastics for use in surgery |
JP2002177392A (en) | 2000-11-08 | 2002-06-25 | West Pharmaceutical Services Inc | Safety device of syringe |
US6915901B2 (en) | 2000-12-11 | 2005-07-12 | Marc Feinberg | Packaging assembly for surgical use |
WO2002064193A2 (en) | 2000-12-14 | 2002-08-22 | Georgia Tech Research Corporation | Microneedle devices and production thereof |
US6387078B1 (en) | 2000-12-21 | 2002-05-14 | Gillespie, Iii Richard D. | Automatic mixing and injecting apparatus |
EP2335660B1 (en) | 2001-01-18 | 2018-03-28 | The Regents of The University of California | Minimally invasive glaucoma surgical instrument |
JP4083425B2 (en) | 2001-01-25 | 2008-04-30 | テルモ株式会社 | Liquid injection needle and liquid injection device |
US6656433B2 (en) | 2001-03-07 | 2003-12-02 | Churchill Medical Systems, Inc. | Vial access device for use with various size drug vials |
US7052829B2 (en) | 2001-03-30 | 2006-05-30 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Prevascularized constructs for implantation to provide blood perfusion |
US20090088721A1 (en) | 2001-04-17 | 2009-04-02 | Eyegate Pharma S.A.S. | Enhanced retinal delivery of a nucleic acid through iontophoresis |
US8337419B2 (en) | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7025774B2 (en) | 2001-06-12 | 2006-04-11 | Pelikan Technologies, Inc. | Tissue penetration device |
US20030073609A1 (en) | 2001-06-29 | 2003-04-17 | Pinkerton Thomas C. | Enhanced pharmacokinetic profile of intradermally delivered substances |
US6749792B2 (en) | 2001-07-09 | 2004-06-15 | Lifescan, Inc. | Micro-needles and methods of manufacture and use thereof |
CA2455525C (en) | 2001-07-24 | 2007-12-04 | Artes Medical Usa, Inc. | Elongated syringe |
JP2003052819A (en) | 2001-08-10 | 2003-02-25 | Seikagaku Kogyo Co Ltd | Drug filling syringe package and sterilization or bactericidal method for it |
AU2002333554C1 (en) | 2001-09-12 | 2008-12-11 | Becton, Dickinson And Company | Microneedle-based pen device for drug delivery and method for using same |
WO2003024507A2 (en) | 2001-09-19 | 2003-03-27 | Biovalve Technologies, Inc. | Microneedles, microneedle arrays, and systems and methods relating to same |
WO2003024508A2 (en) | 2001-09-21 | 2003-03-27 | Biovalve Technologies, Inc. | Gas pressure actuated microneedle arrays, and systems and methods relating to same |
WO2003039369A1 (en) | 2001-09-26 | 2003-05-15 | Roche Diagnostics Gmbh | Method and apparatus for sampling bodily fluid |
US6715520B2 (en) | 2001-10-11 | 2004-04-06 | Carmel Pharma Ab | Method and assembly for fluid transfer |
US7429258B2 (en) | 2001-10-26 | 2008-09-30 | Massachusetts Institute Of Technology | Microneedle transport device |
US7349733B2 (en) | 2001-11-02 | 2008-03-25 | Ceramatel, Inc. | Iontophoretic drug delivery systems |
US7569035B1 (en) | 2001-11-02 | 2009-08-04 | Meridian Medical Technologies, Inc. | Automatic injector with anti-coring needle |
CN1315544C (en) | 2001-11-09 | 2007-05-16 | 阿尔扎公司 | Pneumatic powered autoinjector |
EP1810645B1 (en) | 2001-11-22 | 2010-07-28 | Eduard Anton Haefliger | Device and method for performing ophthalmologic operations |
GB0127983D0 (en) | 2001-11-22 | 2002-01-16 | Neutec Pharma Plc | Treatment of micro-organism infection |
US7204823B2 (en) | 2001-12-19 | 2007-04-17 | Medtronic Minimed, Inc. | Medication delivery system and monitor |
US6821286B1 (en) | 2002-01-23 | 2004-11-23 | Cardica, Inc. | System for preparing a graft vessel for anastomosis |
US6875205B2 (en) | 2002-02-08 | 2005-04-05 | Alaris Medical Systems, Inc. | Vial adapter having a needle-free valve for use with vial closures of different sizes |
CA2476076C (en) | 2002-02-15 | 2012-03-27 | Antares Pharma, Inc. | Injector with bypass channel |
US20050033230A1 (en) | 2002-02-15 | 2005-02-10 | Alchas Paul G. | Prefillable intradermal delivery device with hidden needle and passive shielding |
AU2003212337B2 (en) | 2002-03-13 | 2009-06-11 | Janssen Pharmaceutica N.V. | Amino-derivatives as novel inhibitors of histone deacetylase |
CN1658848A (en) | 2002-04-12 | 2005-08-24 | 细胞基因公司 | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
US7226461B2 (en) | 2002-04-19 | 2007-06-05 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
CA2486005C (en) | 2002-05-16 | 2008-08-26 | Scott Laboratories, Inc. | Drug container entry mechanisms and method |
US6979316B1 (en) | 2002-05-23 | 2005-12-27 | Seedlings Life Science Ventures Llc | Apparatus and method for rapid auto-injection of medication |
WO2004000389A2 (en) | 2002-06-25 | 2003-12-31 | Sung-Yun Kwon | Rapidly dissolving micro-perforator for drug delivery and other applications |
US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
WO2004006998A1 (en) | 2002-07-11 | 2004-01-22 | Tecpharma Licensing Ag | Needle-free injection device |
DE10242984B4 (en) | 2002-09-17 | 2010-09-23 | Sanatis Gmbh | Device for producing mixtures of two components |
JP3688287B1 (en) | 2002-09-18 | 2005-08-24 | アラーガン、インコーポレイテッド | Device for delivering an ophthalmic implant |
US20040106904A1 (en) | 2002-10-07 | 2004-06-03 | Gonnelli Robert R. | Microneedle array patch |
IL152271A (en) | 2002-10-13 | 2006-04-10 | Meir Hefetz | Microneedles structures and production methods |
US6883222B2 (en) | 2002-10-16 | 2005-04-26 | Bioject Inc. | Drug cartridge assembly and method of manufacture |
CN101336887A (en) | 2002-12-04 | 2009-01-07 | 参天制药株式会社 | Drug delivery system using subconjunctival depot |
JP2004196787A (en) | 2002-12-04 | 2004-07-15 | Santen Pharmaceut Co Ltd | Drug delivery system with subconjunctival depot |
EP1589901A4 (en) | 2002-12-20 | 2006-08-09 | Generipharm Inc | Intracutaneous injection |
KR100563330B1 (en) | 2003-01-16 | 2006-03-22 | 포스트마이크로 주식회사 | Method for manufacturing of polymer micro needle array with liga process |
EP1590024B1 (en) | 2003-01-21 | 2016-04-27 | Carmel Pharma AB | A needle for penetrating a membrane |
GB0301934D0 (en) | 2003-01-28 | 2003-02-26 | Sundar Satish | Delivery apparatus and location method |
WO2004082745A1 (en) | 2003-02-24 | 2004-09-30 | Becton Dickinson France | Plate for holding a group of syringe body objects |
US7578954B2 (en) | 2003-02-24 | 2009-08-25 | Corium International, Inc. | Method for manufacturing microstructures having multiple microelements with through-holes |
DK1454609T3 (en) | 2003-03-05 | 2013-02-11 | Csl Behring Gmbh | Transmission facility |
US20040186084A1 (en) | 2003-03-21 | 2004-09-23 | Akorn, Inc. | Triamcinolone formulations and methods for their preparation and use |
US20050070819A1 (en) | 2003-03-31 | 2005-03-31 | Rosedale Medical, Inc. | Body fluid sampling constructions and techniques |
US20040199130A1 (en) * | 2003-04-03 | 2004-10-07 | Chornenky Victor I. | Apparatus and method for treatment of macular degeneration |
US7533514B2 (en) | 2003-04-25 | 2009-05-19 | Boston Scientific Scimed, Inc. | Method and apparatus for automated handling of medical devices during manufacture |
US7435237B2 (en) | 2003-06-02 | 2008-10-14 | Boston Scientific Scimed, Inc. | Mixing syringes with breakable septums |
US8403941B2 (en) | 2003-06-02 | 2013-03-26 | Abbott Medical Optics Inc. | Intraocular lens and cartridge packaging with lens-loading function |
FR2855761B1 (en) | 2003-06-03 | 2006-02-24 | Optis France Sa | OCULAR DEVICE FOR VARIABLE DELIVERY OF ACTIVE PRINCIPLES BY IONTOPHORESIS |
US7025389B2 (en) | 2003-06-06 | 2006-04-11 | Baxter International Inc. | Method and device for transferring fluid |
DE10327119A1 (en) | 2003-06-13 | 2004-12-30 | Aventis Pharma Deutschland Gmbh | Injection cap |
US7914803B2 (en) | 2003-06-13 | 2011-03-29 | Alcon, Inc. | Ophthalmic compositions containing a synergistic combination of three polymers |
CA2529495C (en) | 2003-06-16 | 2013-02-05 | Solx, Inc. | Shunt for the treatment of glaucoma |
KR20060029162A (en) | 2003-06-30 | 2006-04-04 | 알자 코포레이션 | Method for coating skin piercing microprojections |
USD499153S1 (en) | 2003-07-08 | 2004-11-30 | Test Rite International Company, Ltd | Handle for jump rope |
US20050009910A1 (en) | 2003-07-10 | 2005-01-13 | Allergan, Inc. | Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug |
CN1852700A (en) | 2003-09-23 | 2006-10-25 | 爱尔康公司 | Triamcinolone acetonide and anecortave acetate formulations for injection |
US7481818B2 (en) | 2003-10-20 | 2009-01-27 | Lifescan | Lancing device with a floating probe for control of penetration depth |
WO2005044364A1 (en) | 2003-11-10 | 2005-05-19 | Agency For Science, Technology And Research | Microneedles and microneedle fabrication |
US20050101882A1 (en) | 2003-11-12 | 2005-05-12 | Leira Enrique C. | Safety pressure device for body fluid extraction |
US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
US20060141049A1 (en) | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
US20090148527A1 (en) | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
CA2552966C (en) | 2004-01-12 | 2012-10-30 | Iscience Surgical Corporation | Injector for viscous materials |
CA2553381C (en) | 2004-01-20 | 2011-03-22 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
JP2007520496A (en) * | 2004-02-04 | 2007-07-26 | レットメッド ピーティーワイ リミテッド | Sustained release steroid composition |
US7678077B2 (en) | 2004-02-20 | 2010-03-16 | Boston Scientific Scimed, Inc. | Variable depth injection device and method |
US20050256499A1 (en) | 2004-03-03 | 2005-11-17 | Pettis Ronald J | Methods and devices for improving delivery of a substance to skin |
US7819822B2 (en) | 2004-03-06 | 2010-10-26 | Roche Diagnostics Operations, Inc. | Body fluid sampling device |
US7108679B2 (en) | 2004-03-11 | 2006-09-19 | Becton, Dickinson And Company | Intradermal syringe and needle assembly |
US20050203575A1 (en) | 2004-03-15 | 2005-09-15 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Skin microactivation system and method |
US7361168B2 (en) | 2004-04-21 | 2008-04-22 | Acclarent, Inc. | Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders |
US20080058704A1 (en) * | 2004-04-29 | 2008-03-06 | Michael Hee | Apparatus and Method for Ocular Treatment |
US20100173866A1 (en) | 2004-04-29 | 2010-07-08 | Iscience Interventional Corporation | Apparatus and method for ocular treatment |
KR20070036044A (en) * | 2004-04-29 | 2007-04-02 | 아이싸이언스 인터벤셔날 코포레이션 | Apparatus and method for ocular treatment |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
BRPI0509334A (en) | 2004-04-30 | 2007-10-16 | Eyegate Pharma S A | ocular iontophoresis device, which reduces irritation |
US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
US8690865B2 (en) | 2004-05-28 | 2014-04-08 | Georgia Tech Research Corporation | Methods and devices for thermal treatment |
US8323227B2 (en) | 2004-07-02 | 2012-12-04 | C. R. Bard, Inc. | Tip configurations for a multi-lumen catheter |
EP2216026B1 (en) | 2004-07-12 | 2016-04-20 | Allergan, Inc. | Ophthalmic compositions and uses for treating ophthalmic conditions |
US7615041B2 (en) | 2004-07-29 | 2009-11-10 | Boston Scientific Scimed, Inc. | Vial adaptor |
US7503920B2 (en) | 2004-08-11 | 2009-03-17 | Tzony Siegal | Spinal surgery system and method |
US7722669B2 (en) | 2004-08-13 | 2010-05-25 | Richard Foulkes | Method and insert for modifying eye color |
JP4771043B2 (en) | 2004-09-06 | 2011-09-14 | 日本電気株式会社 | Thin film semiconductor device, driving circuit thereof, and apparatus using them |
US8114110B2 (en) | 2004-09-22 | 2012-02-14 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Transseptal puncture needle and needle assemblies |
US7947267B2 (en) | 2004-10-08 | 2011-05-24 | Potentia Pharmaceuticals, Inc. | Viral complement control proteins for eye disorders |
US7627938B2 (en) | 2004-10-15 | 2009-12-08 | Board Of Regents, The Univeristy Of Texas System | Tapered hollow metallic microneedle array assembly and method of making and using the same |
US7097776B2 (en) | 2004-10-22 | 2006-08-29 | Hewlett-Packard Development Company, L.P. | Method of fabricating microneedles |
US7604647B2 (en) | 2004-10-22 | 2009-10-20 | Medical Instrument Development Laboratories, Inc. | Ophthalmic cannula insertion tool and method |
CA2588433A1 (en) | 2004-11-17 | 2006-05-26 | Michael R. Robinson | Steroid formulation and methods of treatment using same |
US7648482B2 (en) | 2004-11-22 | 2010-01-19 | Intelliject, Inc. | Devices, systems, and methods for medicament delivery |
US7229468B2 (en) | 2004-11-23 | 2007-06-12 | Wong Jr Edward K | Medical device and method for temperature control and treatment of the eye and surrounding tissues |
US8262715B2 (en) | 2004-11-23 | 2012-09-11 | Eye Delivery System, Llc | Medical device and method for temperature control and treatment of the eye and surrounding tissues via magnetic drug therapy |
US20060173418A1 (en) | 2004-12-13 | 2006-08-03 | Arrow International, Inc. | Loss of resistance syringe |
CA2592459C (en) | 2004-12-16 | 2017-08-22 | Iscience Interventional Corporation | Ophthalmic implant for treatment of glaucoma |
US20060169664A1 (en) | 2004-12-28 | 2006-08-03 | Holopack International Corp. | Vial for filling a syringe |
US7803142B2 (en) | 2005-02-02 | 2010-09-28 | Summit Access Llc | Microtaper needle and method of use |
TW200640443A (en) | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
MX2007010608A (en) | 2005-03-11 | 2007-10-19 | Alcon Inc | Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma. |
US20070060904A1 (en) | 2005-03-14 | 2007-03-15 | Becton, Dickinson And Company | Filling system and method for syringes with short needles |
EP1868661A1 (en) * | 2005-04-08 | 2007-12-26 | SurModics, Inc. | Sustained release implants for subretinal delivery |
US7722581B2 (en) | 2005-04-11 | 2010-05-25 | Gholam A. Peyman | Crystalline lens drug delivery |
US7645264B2 (en) | 2005-04-11 | 2010-01-12 | Becton, Dickinson And Company | Injection device with secondary reservoir |
ES2367921T3 (en) | 2005-04-18 | 2011-11-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | PROCEDURE AND DEVICES FOR THE SUPPLY OF A THERAPEUTIC PRODUCT TO THE EYE SPHERE OF A PATIENT. |
EP2457546A3 (en) | 2005-04-26 | 2013-02-20 | Biolase, Inc. | Methods for treating eye conditions |
US20060259008A1 (en) | 2005-04-27 | 2006-11-16 | Allergan, Inc. | Apparatus and methods useful for intravitreal injection of drugs |
CN100463668C (en) | 2005-05-09 | 2009-02-25 | 凌沛学 | Reversibly hot gelified water soluble medicine composition |
WO2006124756A2 (en) | 2005-05-13 | 2006-11-23 | Bob Rogers | Medical substance transfer system |
US20080269666A1 (en) | 2005-05-25 | 2008-10-30 | Georgia Tech Research Corporation | Microneedles and Methods for Microinfusion |
EP1893216A4 (en) | 2005-06-08 | 2012-08-08 | Targegen Inc | Methods and compositions for the treatment of ocular disorders |
EP1893130A4 (en) | 2005-06-17 | 2015-08-26 | Georgia Tech Res Inst | Coated microstructures and method of manufacture thereof |
CN100430069C (en) | 2005-07-28 | 2008-11-05 | 凌沛学 | Reversible heat gelling aquatic pharmaceutical composition of a Chinese medicine and compound prescription thereof |
JP2009504230A (en) | 2005-08-11 | 2009-02-05 | メディモップ・メディカル・プロジェクツ・リミテッド | Liquid drug transfer device that snap-fits accurately and securely into pharmaceutical vials |
US20070082841A1 (en) | 2005-09-27 | 2007-04-12 | Aciont, Inc. | Ocular administration of immunosuppressive agents |
US20090082321A1 (en) | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Steroid containing drug delivery systems |
US8634907B2 (en) | 2005-10-24 | 2014-01-21 | Aciont, Inc. | Intraocular iontophoretic device and associated methods |
US20070093877A1 (en) | 2005-10-26 | 2007-04-26 | Beecham Michael C | System for maintaining normal health of retinal cells and promoting regeneration of retinal cells |
CA2627392A1 (en) | 2005-11-14 | 2007-05-24 | Pactiv Corporation | Container having internal reservoir |
FR2893852B1 (en) | 2005-11-29 | 2010-09-03 | Eyegate Pharma Sa | OCULAR IONTOPHORESIS DEVICE |
US8099162B2 (en) | 2005-11-29 | 2012-01-17 | Eyegate Pharma, S.A.S. | Ocular iontophoresis device |
US20070123947A1 (en) | 2005-11-30 | 2007-05-31 | Wenger William K | Medical device packaging system |
JP2007159658A (en) | 2005-12-09 | 2007-06-28 | Fujifilm Corp | Blood collecting needle |
JP4358821B2 (en) | 2005-12-15 | 2009-11-04 | オリンパス株式会社 | Intra-subject introduction device |
EP1971386B1 (en) | 2005-12-23 | 2013-11-13 | Cathrx Ltd | Irrigation catheter |
US7981101B2 (en) | 2005-12-30 | 2011-07-19 | Carefusion 303, Inc. | Medical vial adapter with reduced diameter cannula and enlarged vent lumen |
US9084662B2 (en) | 2006-01-17 | 2015-07-21 | Transcend Medical, Inc. | Drug delivery treatment device |
ES2762239T3 (en) | 2006-01-17 | 2020-05-22 | Alcon Inc | Glaucoma treatment device |
US20070185495A1 (en) | 2006-01-30 | 2007-08-09 | Howmedica International S. De R. L. | Plug-in syringe stand |
EP1820485B1 (en) | 2006-02-16 | 2009-11-11 | F.Hoffmann-La Roche Ag | System and apparatus for extracting drugs |
US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
US20080015539A1 (en) | 2006-02-28 | 2008-01-17 | Robert Pieroni | Bottle with adapter for receiving needleless syringe |
FR2898812B1 (en) | 2006-03-24 | 2008-06-13 | Technoflex Sa | LUER CONNECTOR, MEDICAL CONNECTOR AND TRANSFER SET COMPRISING SUCH A CONNECTOR |
US7547300B2 (en) | 2006-04-12 | 2009-06-16 | Icu Medical, Inc. | Vial adaptor for regulating pressure |
ES2355937T3 (en) | 2006-04-27 | 2011-04-01 | Ecolab Inc. | ASSEMBLY OF DISTRIBUTION OF SOLID PRODUCTS. |
US8197435B2 (en) | 2006-05-02 | 2012-06-12 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
US20210393436A1 (en) | 2006-05-02 | 2021-12-23 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
US7918814B2 (en) | 2006-05-02 | 2011-04-05 | Georgia Tech Research Corporation | Method for drug delivery to ocular tissue using microneedle |
US20070270768A1 (en) | 2006-05-17 | 2007-11-22 | Bruno Dacquay | Mechanical Linkage Mechanism For Ophthalmic Injection Device |
US20070270745A1 (en) | 2006-05-18 | 2007-11-22 | Camran Nezhat | Vacuum actuated tissue lifting device |
USD598543S1 (en) | 2006-06-13 | 2009-08-18 | Angiomed Gmbh & Co. Medizintechnik Kg | Handle for a medical delivery device |
US8668676B2 (en) | 2006-06-19 | 2014-03-11 | Allergan, Inc. | Apparatus and methods for implanting particulate ocular implants |
US20070299386A1 (en) | 2006-06-23 | 2007-12-27 | Minu, L.L.C. | Delivery of an ocular agent using iontophoresis |
US8802128B2 (en) | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US8852137B2 (en) | 2010-11-15 | 2014-10-07 | Aquesys, Inc. | Methods for implanting a soft gel shunt in the suprachoroidal space |
US8663303B2 (en) | 2010-11-15 | 2014-03-04 | Aquesys, Inc. | Methods for deploying an intraocular shunt from a deployment device and into an eye |
US8974511B2 (en) | 2010-11-15 | 2015-03-10 | Aquesys, Inc. | Methods for treating closed angle glaucoma |
US9205075B2 (en) | 2006-07-12 | 2015-12-08 | Mobius Therapeutics, Llc | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
WO2008011125A2 (en) | 2006-07-20 | 2008-01-24 | Neurosystec Corporation | Devices, systems and methods for ophthalmic drug delivery |
US20080027371A1 (en) | 2006-07-26 | 2008-01-31 | Higuchi John W | Method and device for minimally invasive site specific ocular drug delivery |
JPWO2008020632A1 (en) | 2006-08-18 | 2010-01-07 | 凸版印刷株式会社 | Microneedle and microneedle patch |
US20080058717A1 (en) | 2006-09-04 | 2008-03-06 | Spector David M | Oral cavity liquid delivery system including pre-angled needle guidance assembly and method for using the same |
US20080065002A1 (en) | 2006-09-07 | 2008-03-13 | Neurosystec Corporation | Catheter for Localized Drug Delivery and/or Electrical Stimulation |
WO2008033426A1 (en) | 2006-09-12 | 2008-03-20 | Psivida Inc. | Injector apparatus and method of use |
US8944069B2 (en) | 2006-09-12 | 2015-02-03 | Vidacare Corporation | Assemblies for coupling intraosseous (IO) devices to powered drivers |
US20080097346A1 (en) | 2006-09-19 | 2008-04-24 | Alcon, Inc. | Trocar cannula |
EP2089423B1 (en) | 2006-09-21 | 2016-10-26 | Vaxil Biotherapeutics Ltd. | Antigen specific multi epitope vaccines |
US20080097390A1 (en) | 2006-09-27 | 2008-04-24 | Alcon Manufacturing, Ltd. | Spring actuated delivery system |
US7849334B2 (en) | 2006-09-29 | 2010-12-07 | Intel Coporation | Transitioning a computing platform to a low power system state |
US20080234625A1 (en) | 2006-10-16 | 2008-09-25 | Bruno Dacquay | Fuse Assembly For Single Use Medical Device |
US8167863B2 (en) | 2006-10-16 | 2012-05-01 | Carefusion 303, Inc. | Vented vial adapter with filter for aerosol retention |
JP5748407B2 (en) | 2006-11-10 | 2015-07-15 | グローコス コーポレーション | Uveal sclera shunt |
US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
EP2091482A2 (en) | 2006-12-01 | 2009-08-26 | Allergan, Inc. | Method for determining optimum intraocular locations for drug delivery systems |
RU2344767C2 (en) | 2006-12-18 | 2009-01-27 | Наталья Александровна Уракова | Method of intra-arterial injection offered by a l urakov |
TWI457336B (en) | 2006-12-28 | 2014-10-21 | Kinex Pharmaceuticals Llc | Composition and methods for modulating a kinase cascade |
EP2124857B1 (en) | 2007-01-09 | 2017-03-29 | Fovea Pharmaceuticals | Apparatus for intra-ocular injection |
US20080177239A1 (en) | 2007-01-18 | 2008-07-24 | Yong Li | Trocar cannula system |
US9144516B2 (en) | 2007-02-08 | 2015-09-29 | Sharpsight B.V. | Device for intraocular administration of a substance, for example a medication, into a human or animal eye by means of a hypodermic needle |
US7883499B2 (en) | 2007-03-09 | 2011-02-08 | Icu Medical, Inc. | Vial adaptors and vials for regulating pressure |
GB0705782D0 (en) | 2007-03-26 | 2007-05-02 | Novartis Ag | Vial assemblies |
DE102007018696A1 (en) | 2007-04-18 | 2008-10-23 | Sanofi-Aventis Deutschland Gmbh | Injection device for dispensing a medicament |
US7975733B2 (en) | 2007-05-08 | 2011-07-12 | Carmel Pharma Ab | Fluid transfer device |
USD590690S1 (en) | 2007-05-24 | 2009-04-21 | Domino S.P.A. | Handlebar hand grip |
US8216312B2 (en) | 2007-05-31 | 2012-07-10 | Zimmer Spine, Inc. | Spinal interbody system and method |
EP2173289A4 (en) | 2007-07-17 | 2010-11-24 | Transcend Medical Inc | Ocular implant with hydrogel expansion capabilities |
US20090030381A1 (en) | 2007-07-23 | 2009-01-29 | Lind Casey J | Arced Hypodermic Needle |
CA2695996A1 (en) | 2007-08-16 | 2009-02-19 | East Carolina University | Smart injection syringe systems providing real-time user feedback of correct needle position |
EP2188004A4 (en) | 2007-08-21 | 2015-06-17 | Yukon Medical Llc | Vial access and injection system |
CA2639322C (en) | 2007-09-07 | 2016-11-08 | Becton, Dickinson And Company | Pen needle hub having increased contact area |
CA2698574A1 (en) | 2007-09-07 | 2009-03-19 | Qlt Plug Delivery, Inc. | Insertion and extraction tools for lacrimal implants |
US20090076463A1 (en) | 2007-09-17 | 2009-03-19 | Jurg Attinger | Trocar Cannula |
US20090082713A1 (en) | 2007-09-20 | 2009-03-26 | Friden Phillip M | Method of enhancing iontophoretic delivery of a peptide |
US20090081277A1 (en) | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Pharmaceutical formulations and methods for treating ocular conditions |
IL186290A0 (en) | 2007-09-25 | 2008-01-20 | Medimop Medical Projects Ltd | Liquid drug delivery devices for use with syringe having widened distal tip |
US8083759B2 (en) | 2007-11-02 | 2011-12-27 | Refocus Ocular, Inc. | Apparatuses and methods for forming incisions in ocular tissue |
JP5461427B2 (en) | 2007-12-17 | 2014-04-02 | ニューワールド ファーマシューティカルズ,エルエルシー | Integrated intradermal delivery, diagnosis and communication system |
US8631935B2 (en) | 2009-06-03 | 2014-01-21 | Medline Industries, Inc. | Catheter tray, packaging system, and associated methods |
US8448786B2 (en) | 2009-06-30 | 2013-05-28 | Medline Industries, Inc. | Catheter tray, packaging system, instruction insert, and associated methods |
US8602959B1 (en) | 2010-05-21 | 2013-12-10 | Robert Park | Methods and devices for delivery of radiation to the posterior portion of the eye |
WO2009087572A1 (en) | 2008-01-09 | 2009-07-16 | Novartis Ag | Unitary withdrawal spike unit suitable for factory fitting |
JP2009183441A (en) | 2008-02-06 | 2009-08-20 | Ken Kondo | Intravenous needle assembly |
EP2254542B1 (en) | 2008-02-18 | 2012-07-04 | ICU Medical, Inc. | Vial adaptor |
US20100081707A1 (en) | 2008-02-21 | 2010-04-01 | Ali Robin R | Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
JP2011513229A (en) | 2008-02-21 | 2011-04-28 | イスタ・ファーマスーティカルズ・インコーポレイテッド | Ophthalmic NSAID as an adjuvant |
US20100152646A1 (en) | 2008-02-29 | 2010-06-17 | Reshma Girijavallabhan | Intravitreal injection device and method |
CA2717605C (en) | 2008-03-11 | 2012-05-15 | Alcon Research Ltd. | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
FR2928536B1 (en) | 2008-03-14 | 2012-04-27 | Inst Nat Sante Rech Med | INJECTION DEVICE IN THE EYE |
US20090259180A1 (en) | 2008-04-11 | 2009-10-15 | Jong Soo Choi | Injection method using injector with length-adjustable needle and injection apparatus using the same |
CN201192452Y (en) | 2008-04-15 | 2009-02-11 | 黄蛟龙 | Air-operated massaging device |
CN101559249A (en) | 2008-04-18 | 2009-10-21 | 崔钟洙 | Injection method and injection device using injector with length-adjustable needle head |
US20090287161A1 (en) | 2008-05-15 | 2009-11-19 | Allergan, Inc | Metered, multiple dose/aliquot syringe |
US20090312782A1 (en) | 2008-06-13 | 2009-12-17 | Maxwell Choongwon Park | Method and apparatus for repairing tendons |
US9022940B2 (en) | 2008-07-18 | 2015-05-05 | Joseph H. Meier | Handheld imaging devices and related methods |
US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
US7886908B2 (en) | 2008-07-21 | 2011-02-15 | Smiths Medical Asd, Inc. | Tray assembly |
JP5854836B2 (en) | 2008-08-30 | 2016-02-09 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Cartridge and needle system therefor |
TWI580441B (en) | 2008-09-19 | 2017-05-01 | 愛爾康研究有限公司 | Stabilized pharmaceutical sub-micron suspensions and methods of forming same |
US8221353B2 (en) | 2008-10-21 | 2012-07-17 | KMG Pharma, Inc | Intravitreal injection device and system |
US20100098772A1 (en) | 2008-10-21 | 2010-04-22 | Allergan, Inc. | Drug delivery systems and methods for treating neovascularization |
US7678078B1 (en) | 2008-10-21 | 2010-03-16 | KMG Pharma LLC | Intravitreal injection device, system and method |
WO2010054660A1 (en) | 2008-11-11 | 2010-05-20 | Herlev Hospital | Double cannula system for anaesthetic needle |
EP2355770A1 (en) | 2008-11-12 | 2011-08-17 | British Columbia Cancer Agency Branch | Vial handling and injection safety systems and connectors |
CN102238926B (en) | 2008-12-05 | 2015-09-16 | 伊万提斯公司 | For ocular implants being transported to the method and apparatus in eyes |
US20110282298A1 (en) | 2008-12-09 | 2011-11-17 | Nadav Agian | Device for injecting fluid isolated from microneedle hub with dead-space-reducing insert |
WO2010066590A1 (en) | 2008-12-12 | 2010-06-17 | Shl Group Ab | Medicament delivery device |
US20100152676A1 (en) | 2008-12-16 | 2010-06-17 | Alcon Research, Ltd. | Drug Loading Through Plunger |
US20100160889A1 (en) | 2008-12-22 | 2010-06-24 | Baxter International Inc. | Vial access spike assembly |
US8512309B2 (en) | 2009-01-15 | 2013-08-20 | Teva Medical Ltd. | Vial adapter element |
US8545554B2 (en) | 2009-01-16 | 2013-10-01 | Allergan, Inc. | Intraocular injector |
US20100191177A1 (en) | 2009-01-23 | 2010-07-29 | Iscience Interventional Corporation | Device for aspirating fluids |
US8425473B2 (en) | 2009-01-23 | 2013-04-23 | Iscience Interventional Corporation | Subretinal access device |
ES2378012B1 (en) | 2009-01-29 | 2013-02-12 | Innova Salud Desarrollos Sanitarios S.L. | DEVICE FOR THE ADMINISTRATION OF INJECTABLE PRODUCTS WITH CONTROLLED FLOW. |
US8162914B2 (en) | 2009-02-10 | 2012-04-24 | Kraushaar Timothy Y | Cap adapters for medicament vial and associated methods |
CN102387753B (en) | 2009-02-10 | 2015-04-15 | 普西维达美国公司 | Ocular trocar assembly |
US8123736B2 (en) | 2009-02-10 | 2012-02-28 | Kraushaar Timothy Y | Cap adapters for medicament vial and associated methods |
US8057483B2 (en) | 2009-02-14 | 2011-11-15 | Ocular Transplantation Llc | Subretinal implantation instrument |
CN201356711Y (en) | 2009-02-23 | 2009-12-09 | 徐学农 | Vitreous chamber flushing syringe needle |
JP5613688B2 (en) | 2009-03-02 | 2014-10-29 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Drug delivery device with foldable finger pad |
WO2010100243A1 (en) | 2009-03-05 | 2010-09-10 | Sanofi-Aventis Deutschland Gmbh | Needle unit |
CA2753939A1 (en) | 2009-03-05 | 2010-09-10 | Sanofi-Aventis Deutschland Gmbh | Drug delivery device with retractable needle |
CA2753919A1 (en) | 2009-03-05 | 2010-09-10 | Sanofi-Aventis Deutschland Gmbh | Drug delivery device |
AU2010220254B2 (en) | 2009-03-05 | 2014-12-04 | Sanofi-Aventis Deutschland Gmbh | Needle assembly |
JP5586633B2 (en) | 2009-03-06 | 2014-09-10 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Drug delivery device with retractable needle |
US8287494B2 (en) | 2009-03-23 | 2012-10-16 | Colin Ma | Intravitreal injection devices and methods of injecting a substance into the vitreous chamber of the eye |
SE0900371A1 (en) | 2009-03-24 | 2010-09-25 | Istvan Bartha | Device for distribution of liquid drugs |
JP4505561B1 (en) | 2009-03-30 | 2010-07-21 | 篤志 今津 | Pressure puncture syringe |
WO2010119392A1 (en) | 2009-04-15 | 2010-10-21 | Koninklijke Philips Electronics N.V. | Needle with integrated fibers in the cutting facets of the bevel |
WO2010125551A2 (en) | 2009-04-29 | 2010-11-04 | Janisys Limited | A micro-needle device and apparatus and a method for applying a micro-needle element to a site on the skin of a subject |
US20120191064A1 (en) | 2009-05-15 | 2012-07-26 | Iscience Interventional Corporation | Methods and apparatus for sub-retinal catheterization |
WO2010149734A1 (en) | 2009-06-25 | 2010-12-29 | Sanofi-Aventis Deutschland Gmbh | Cannula assembly for co-delivery of medicaments |
RU2428956C2 (en) | 2009-07-13 | 2011-09-20 | Александр Дмитриевич Ромащенко | Method of treating optic nerve by transplantation of autologic stem cells |
CN102648016A (en) | 2009-07-23 | 2012-08-22 | 适宜卫生科技项目公司 | Intradermal injection adapter |
US8535333B2 (en) | 2009-07-29 | 2013-09-17 | Transcend Medical, Inc. | Ocular implant applier and methods of use |
JP5865835B2 (en) | 2009-08-12 | 2016-02-17 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Cap for portable drug delivery device and such drug delivery device |
US20120259288A1 (en) | 2009-08-28 | 2012-10-11 | Sanofi-Aventis Deutschland Gmbh | Assembly kit for preparing of a pre-filled syringe |
EP2480270A4 (en) | 2009-09-21 | 2015-07-08 | Harvard Apparatus Regenerative Technology Inc | Methods and apparatus for introducing cells at a tissue site |
MX344382B (en) | 2009-10-23 | 2016-12-14 | Amgen Inc * | Vial adapter and system. |
WO2011057065A1 (en) | 2009-11-06 | 2011-05-12 | The Uab Research Foundation | Apparatuses and methods for delivering substances to the inner eye |
US9254365B2 (en) | 2009-11-11 | 2016-02-09 | Unitract Syringe Pty Ltd | Clinical syringe with replaceable retractable needle |
IL202069A0 (en) | 2009-11-12 | 2010-06-16 | Medimop Medical Projects Ltd | Fluid transfer device with sealing arrangement |
US8480646B2 (en) | 2009-11-20 | 2013-07-09 | Carmel Pharma Ab | Medical device connector |
BR112012015520A2 (en) | 2009-12-22 | 2017-03-14 | Unitract Syringe Pty Ltd | retractable syringe with better delivery efficiency and locking system |
US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
US8343106B2 (en) | 2009-12-23 | 2013-01-01 | Alcon Research, Ltd. | Ophthalmic valved trocar vent |
AU2010340024A1 (en) | 2010-01-05 | 2012-07-26 | Allergan, Inc. | Syringe comprising two plungers with locking means |
CN201591741U (en) | 2010-01-22 | 2010-09-29 | 苏开志 | Sleeve acupuncture pin |
WO2011109388A2 (en) | 2010-03-01 | 2011-09-09 | Medical Instrument Development Laboratories, Inc. | Cannula for intraocular surgery |
EP2364740A1 (en) | 2010-03-09 | 2011-09-14 | Sanofi-Aventis Deutschland GmbH | Arrangement for transferring a translation of a drive means to a plunger |
GB201004102D0 (en) | 2010-03-12 | 2010-04-28 | Liversidge Barry P | Syringe barrels and handling systems |
US9327105B2 (en) | 2010-03-26 | 2016-05-03 | Itrace Biomedical Inc. | Active transdermal drug delivery system and the method thereof |
EP2552349A4 (en) | 2010-03-31 | 2017-12-06 | Ocuject, LLC | Device and method for intraocular drug delivery |
US9320647B2 (en) | 2010-03-31 | 2016-04-26 | Ocuject, Llc | Device and method for intraocular drug delivery |
WO2011123722A1 (en) | 2010-03-31 | 2011-10-06 | Ocuject, Llc | Device and method for intraocular drug delivery |
US9408746B2 (en) | 2010-03-31 | 2016-08-09 | Ocuject, Llc | Device and method for intraocular drug delivery |
US8574217B2 (en) | 2010-04-08 | 2013-11-05 | Kmg Pharma, Llc | Sub-mucosal agent delivery method for the eye |
US8430862B2 (en) | 2010-04-08 | 2013-04-30 | KMG Pharma LLC | Subconjunctival agent delivery apparatus, system and method |
US8652118B2 (en) | 2010-04-08 | 2014-02-18 | Kmg Pharma, Llc | Sub-mucosal agent delivery, apparatus, system and method |
US8632589B2 (en) | 2010-05-04 | 2014-01-21 | Abbott Medical Optics Inc. | IOL insertion system with semi-automatic trailing haptic configuration management |
CA2797207C (en) | 2010-05-04 | 2018-08-14 | Unitract Syringe Pty Ltd | Syringe barrel adapter and needle assembly |
US8932258B2 (en) | 2010-05-14 | 2015-01-13 | C. R. Bard, Inc. | Catheter placement device and method |
US8758306B2 (en) | 2010-05-17 | 2014-06-24 | Icu Medical, Inc. | Medical connectors and methods of use |
US20110295152A1 (en) | 2010-05-25 | 2011-12-01 | Nextier Corporation | Puncture method, incision needle, puncture needle, needle cap and instrument for blood purification treatment |
US8545430B2 (en) | 2010-06-09 | 2013-10-01 | Transcend Medical, Inc. | Expandable ocular devices |
EP2600923B1 (en) | 2010-06-10 | 2018-08-08 | Anthony J. Colantonio | Apparatus and method for safely inserting an introducer needle into epidural space |
US20120004245A1 (en) | 2010-07-02 | 2012-01-05 | Alcon Research, Ltd. | Compounds for the treatment of posterior segment disorders and diseases |
US8475009B2 (en) | 2010-07-08 | 2013-07-02 | Excelitas Technologies Corp. | Tailored side-emitter perimeter beacon |
KR101180032B1 (en) | 2010-07-12 | 2012-09-05 | 인싸이토(주) | Method for manufacturing Hollow Microneedle with Controlled External Appearance Characteristics |
TW201216948A (en) | 2010-07-19 | 2012-05-01 | Sanofi Aventis Deutschland | Medicament cartridges with non-standard dimensions |
PL2600930T3 (en) | 2010-08-05 | 2021-09-06 | Forsight Vision4, Inc. | Injector apparatus for drug delivery |
WO2012044952A2 (en) | 2010-09-30 | 2012-04-05 | Surmodics, Inc. | Drug delivery blade and methods for delivering a drug depot to a target site |
US8864740B2 (en) | 2010-10-01 | 2014-10-21 | Sanofi-Aventis Deutschland Gmbh | Needle assembly with release mechanism |
EP2438939A1 (en) | 2010-10-08 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Arrangement for coupling a plunger to either a syringe or a stopper |
EP2627292B1 (en) | 2010-10-15 | 2018-10-10 | Clearside Biomedical, Inc. | Device for ocular access |
US20120101475A1 (en) | 2010-10-21 | 2012-04-26 | Meridian Medical Technologies, Inc. | High Efficiency Auto-Injector |
EP2632516A1 (en) | 2010-10-25 | 2013-09-04 | Sanofi-Aventis Deutschland GmbH | Device for controlling a penetration depth of injection needle |
EP2446866A1 (en) | 2010-11-02 | 2012-05-02 | Fovea Pharmaceuticals | Apparatus for injection into an eye |
RU2576506C2 (en) | 2010-11-03 | 2016-03-10 | Санофи-Авентис Дойчланд Гмбх | Needle cannula containing medicinal preparation |
US9241701B2 (en) | 2010-11-11 | 2016-01-26 | Depuy Mitek, Inc. | Cannula system and method for partial thickness rotator cuff repair |
JP5704389B2 (en) | 2010-11-29 | 2015-04-22 | ニプロ株式会社 | Medical hollow needle and method for producing medical hollow needle |
US10285852B2 (en) | 2010-12-02 | 2019-05-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd., The Chaim Sheba Medical Center | Subretinal delivery of therapeutic compositions |
US8608710B2 (en) | 2010-12-09 | 2013-12-17 | Becton Dickinson & Company | Pen needle assembly with different gauge needle cannulas |
US9968337B2 (en) | 2010-12-20 | 2018-05-15 | Cook Medical Technologies Llc | Coring tissue biopsy needle and method of use |
AU2011360973A1 (en) | 2011-03-02 | 2013-09-19 | Aquilus Pharmaceuticals, Inc. | Compounds and methods for the treatment of pain and other disorders |
JP2014510526A (en) | 2011-03-15 | 2014-05-01 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | Diagnosis and treatment of vascular-related macular disease and its symptoms |
USD667111S1 (en) | 2011-03-17 | 2012-09-11 | Surgical Innovations Limited | Handle for surgical instrument |
EP2500002A1 (en) | 2011-03-17 | 2012-09-19 | Sanofi-Aventis Deutschland GmbH | Apparatus for intraocular injection |
US20140088552A1 (en) | 2011-03-25 | 2014-03-27 | The Curators Of The University Of Missouri | Intravitreal Injection Device |
US8992503B2 (en) | 2011-03-27 | 2015-03-31 | Microsert Ltd. | Miniature implanted drug delivery devices and inserter systems for introducing such devices |
EP2510911A1 (en) | 2011-04-13 | 2012-10-17 | Sanofi-Aventis Deutschland GmbH | Apparatus for intraocular injection |
EP2510902A1 (en) | 2011-04-15 | 2012-10-17 | Sanofi-Aventis Deutschland GmbH | Intraocular injection device |
IL212420A0 (en) | 2011-04-17 | 2011-06-30 | Medimop Medical Projects Ltd | Liquid drug transfer assembly |
EP2514684A1 (en) | 2011-04-20 | 2012-10-24 | Becton Dickinson France | Packaging for medical containers |
EP2514461A1 (en) | 2011-04-20 | 2012-10-24 | Sanofi-Aventis Deutschland GmbH | Needle assembly for a medical device |
EP2522318A1 (en) | 2011-05-12 | 2012-11-14 | Sanofi-Aventis Deutschland GmbH | Guide device for intraocular injection |
WO2012162459A1 (en) | 2011-05-26 | 2012-11-29 | Pepose Jay | Device and method for administering eye medications |
EP2540261A1 (en) | 2011-06-30 | 2013-01-02 | Sanofi-Aventis Deutschland GmbH | Intraocular medicament delivery device |
US9352084B2 (en) | 2011-08-05 | 2016-05-31 | Unitract Syringe Pty Ltd | Injectable drug delivery arrangement with controlled delivery cannula position relative to point of delivery |
WO2013025696A1 (en) | 2011-08-15 | 2013-02-21 | Teva Pharmaceutical Industries Ltd. | Ophthalmic formulations and processes for their preparation |
US20150110717A1 (en) | 2011-09-07 | 2015-04-23 | Screencell | Methods of increasing the number of target cells recovered from a fluid sample |
EP2755705B1 (en) | 2011-09-13 | 2015-11-25 | Sanofi-Aventis Deutschland GmbH | Injection device |
EP2574355A1 (en) | 2011-09-27 | 2013-04-03 | Sanofi-Aventis Deutschland GmbH | Package for a medicament delivery device |
EP2578190A1 (en) | 2011-10-07 | 2013-04-10 | Sanofi-Aventis Deutschland GmbH | Intraocular injection device |
EP2578189A1 (en) | 2011-10-07 | 2013-04-10 | Sanofi-Aventis Deutschland GmbH | Apparatus for intraocular injection |
EP2578191A1 (en) | 2011-10-07 | 2013-04-10 | Sanofi-Aventis Deutschland GmbH | Apparatus for intraocular injection |
EP2578260A1 (en) | 2011-10-07 | 2013-04-10 | Sanofi-Aventis Deutschland GmbH | Apparatus for intraocular injection |
EP2586407A1 (en) | 2011-10-31 | 2013-05-01 | Sanofi-Aventis Deutschland GmbH | Aid device for intraocular injection |
EP2596826A1 (en) | 2011-11-24 | 2013-05-29 | Sanofi-Aventis Deutschland GmbH | Safety syringe |
EP2601988A1 (en) | 2011-12-08 | 2013-06-12 | Sanofi-Aventis Deutschland GmbH | Syringe carrier |
WO2013086167A1 (en) | 2011-12-08 | 2013-06-13 | Unitract Syringe Pty Ltd | Accurate dose control mechanisms and drug delivery syringes |
EP2601990A1 (en) | 2011-12-08 | 2013-06-12 | Sanofi-Aventis Deutschland GmbH | Syringe carrier |
EP2601992A1 (en) | 2011-12-08 | 2013-06-12 | Sanofi-Aventis Deutschland GmbH | Syringe carrier |
KR20140105820A (en) | 2011-12-15 | 2014-09-02 | 사노피-아벤티스 도이칠란트 게엠베하 | Reservoir or medicated module for a drug delivery system and method of and assembly for filling the same |
ES2533576T3 (en) | 2011-12-30 | 2015-04-13 | Q-Med Ab | Cannula without bruising |
WO2013104642A1 (en) | 2012-01-09 | 2013-07-18 | Fresenius Kabi Deutschland Gmbh | Port cannula for puncturing port catheters |
AU344164S (en) | 2012-02-02 | 2012-09-04 | Terumo Corp | Safety device for indwelling needle |
EP2626096A1 (en) | 2012-02-10 | 2013-08-14 | Sanofi-Aventis Deutschland GmbH | Medicament delivery device with needle assembly removal mechanism |
EP2818190B1 (en) | 2012-02-20 | 2016-11-02 | Terumo Kabushiki Kaisha | Medical device packaging body |
WO2013126498A1 (en) | 2012-02-22 | 2013-08-29 | Schachar Ira H | Device and method for treatment of retinal detachment and other maladies of the eye |
US9265896B2 (en) | 2012-02-23 | 2016-02-23 | Shinmaywa Industries, Ltd. | Method for manufacturing puncture needle |
JP6109203B2 (en) | 2012-02-23 | 2017-04-12 | ユニトラクト シリンジ プロプライエタリイ リミテッドUnitract Syringe Pty Ltd | Instrument for targeted delivery of therapeutic implants |
USD672506S1 (en) | 2012-02-28 | 2012-12-11 | Idea Village Products, Inc. | Exfoliating device |
JP2015508690A (en) | 2012-02-29 | 2015-03-23 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Drawer device for withdrawing drug from container only once |
MX2014010944A (en) | 2012-03-12 | 2014-11-13 | Unitract Syringe Pty Ltd | Fill-finish cartridges for sterile fluid pathway assemblies and drug delivery devices incorporating fill-finish cartridges. |
EP2641629A1 (en) | 2012-03-22 | 2013-09-25 | Sanofi-Aventis Deutschland GmbH | Medical injection device with injection site pain reduction device |
US9421129B2 (en) | 2012-04-02 | 2016-08-23 | Ocuject, Llc | Intraocular delivery devices and methods therefor |
US9833523B2 (en) | 2012-04-24 | 2017-12-05 | The Ohio State University | Pharmacokinetic determination of intravitreal agents |
US9889248B2 (en) | 2012-05-21 | 2018-02-13 | Baxalta GmbH | Syringe storage tray |
US20150157359A1 (en) | 2012-06-14 | 2015-06-11 | Asahi Kasei Medical Co., Ltd. | Puncture needle |
US9956341B2 (en) | 2012-07-03 | 2018-05-01 | Milestone Scientific, Inc. | Drug infusion with pressure sensing and non-continuous flow for identification of and injection into fluid-filled anatomic spaces |
US8727117B2 (en) | 2012-07-16 | 2014-05-20 | Becton, Dickinson And Company | Package for syringe |
WO2014028285A1 (en) | 2012-08-13 | 2014-02-20 | The Brigham And Women's Hospital, Inc. | Methods and devices for inserting a needle |
WO2014036009A1 (en) | 2012-08-27 | 2014-03-06 | Clearside Biomedical, Inc. | Apparatus and methods for drug delivery using microneedles |
USD715125S1 (en) | 2012-10-08 | 2014-10-14 | The Ames Companies, Inc. | Grip |
KR20210133321A (en) | 2012-11-08 | 2021-11-05 | 클리어사이드 바이오메디컬, 인코포레이드 | Methods and devices for the treatment of ocular disease in human subjects |
US20150297609A1 (en) | 2012-12-27 | 2015-10-22 | Sentiss Pharma Pvt. Ltd. | Sterile ophthalmic pharmaceutical suspensions |
US9022968B2 (en) | 2013-01-08 | 2015-05-05 | University Of South Florida | Auto-regulation system for intraocular pressure |
US9211231B2 (en) | 2013-03-14 | 2015-12-15 | Carefusion 303, Inc. | Vial adapter for side engagement of vial cap |
US9968603B2 (en) | 2013-03-14 | 2018-05-15 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
US9597260B2 (en) | 2013-03-15 | 2017-03-21 | Becton Dickinson and Company Ltd. | System for closed transfer of fluids |
USD740098S1 (en) | 2013-03-19 | 2015-10-06 | Tong Yah Electronic Technology Co., Ltd. | Vehicular handle |
US9987163B2 (en) | 2013-04-16 | 2018-06-05 | Novartis Ag | Device for dispensing intraocular substances |
WO2014179698A2 (en) | 2013-05-03 | 2014-11-06 | Clearside Biomedical, Inc. | Apparatus and methods for ocular injection |
US10188550B2 (en) | 2013-06-03 | 2019-01-29 | Clearside Biomedical, Inc. | Apparatus and methods for drug delivery using multiple reservoirs |
JP6430501B2 (en) | 2013-07-16 | 2018-11-28 | スリーエム イノベイティブ プロパティズ カンパニー | Hollow microneedle with beveled opening |
WO2015015467A1 (en) | 2013-08-02 | 2015-02-05 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | A device for delivery of compositions to the eye |
CN105492054A (en) | 2013-08-07 | 2016-04-13 | 尤尼特拉克特注射器公司 | Luer connection adapters for syringes |
RU2016103793A (en) | 2013-08-07 | 2017-09-14 | Юниктракт Сириндж Пти Лтд | LUER'S CONNECTING ADAPTER FOR TYPE-IN Syringes |
USD718602S1 (en) | 2013-09-09 | 2014-12-02 | Midwest Tool And Cutlery Company | Hand grip for hand tools |
WO2015036947A1 (en) | 2013-09-11 | 2015-03-19 | Debiotech S.A. | Needle insertion device |
USD713958S1 (en) | 2013-12-05 | 2014-09-23 | Becton, Dickinson And Company | Pen needle outer cover |
WO2015095772A2 (en) | 2013-12-20 | 2015-06-25 | Emory University | Formulations and methods for targeted ocular delivery of therapeutic agents |
ES2672327T3 (en) | 2014-01-27 | 2018-06-13 | Opia Technologies | Eye iontophoresis device |
USD726908S1 (en) | 2014-02-06 | 2015-04-14 | St. Jude Medical, Cardiology Division, Inc. | Catheter handle |
WO2015126694A1 (en) | 2014-02-12 | 2015-08-27 | Ethicon Endo-Surgery, Inc. | Method and apparatus for suprachoroidal administration of therapeutic agent |
CA2952822A1 (en) | 2014-06-17 | 2015-12-23 | Clearside Biomedical, Inc. | Methods and devices for treating posterior ocular disorders |
CN106794321A (en) | 2014-06-20 | 2017-05-31 | 科尼尔赛德生物医学公司 | Variable-diameter intubation and for controlling the method to the insertion depth of drug delivery |
US9517307B2 (en) | 2014-07-18 | 2016-12-13 | Kaleo, Inc. | Devices and methods for delivering opioid antagonists including formulations for naloxone |
AU2015316709B2 (en) | 2014-09-19 | 2020-03-26 | Oxular Limited | Ophthalmic delivery device |
CN117695204A (en) | 2014-09-19 | 2024-03-15 | 奥叙拉尔有限公司 | Ophthalmic pharmaceutical composition |
JP5828535B1 (en) | 2014-10-10 | 2015-12-09 | 石根 三井 | Contact lenses for straightening corneal cross-linking |
USD750223S1 (en) | 2014-10-14 | 2016-02-23 | Clearside Biomedical, Inc. | Medical injector for ocular injection |
US20160106587A1 (en) | 2014-10-16 | 2016-04-21 | Incept, Llc | Ocular gels or hydrogels and microinjectors |
CN204364577U (en) | 2014-12-26 | 2015-06-03 | 林才桥 | Intramuscular injection device |
AU2016261925B2 (en) | 2015-05-12 | 2020-10-01 | Incept, Llc | Drug delivery from hydrogels |
UA122570C2 (en) | 2015-06-03 | 2020-12-10 | Аквісіс, Інк. | Ab externo intraocular shunt placement |
RU2695505C1 (en) | 2015-09-24 | 2019-07-23 | Бектон, Дикинсон Энд Компани | Needle for use with a device for sampling and/or transfer of blood or other fluids and devices containing such a needle |
WO2017120600A1 (en) | 2016-01-08 | 2017-07-13 | Clearside Biomedical, Inc. | Compositions and methods of treating wet age-related macular degeneration |
WO2017120601A1 (en) | 2016-01-08 | 2017-07-13 | Clearside Biomedical, Inc. | Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics |
EP3413851B1 (en) | 2016-02-10 | 2023-09-27 | Clearside Biomedical, Inc. | Packaging |
KR102381775B1 (en) | 2016-03-16 | 2022-04-04 | 옥슬러 리미티드 | Ophthalmic delivery device and ophthalmic drug composition |
US20190133933A1 (en) | 2016-04-29 | 2019-05-09 | Clearside Biomedical, Inc. | Formulations and methods for reduction of intraocular pressure |
EP3452165A1 (en) | 2016-05-02 | 2019-03-13 | Clearside Biomedical, Inc. | Systems and methods for ocular drug delivery |
WO2018031913A1 (en) | 2016-08-12 | 2018-02-15 | Clearside Biomedical, Inc. | Devices and methods for adjusting the insertion depth of a needle for medicament delivery |
WO2018111862A1 (en) | 2016-12-15 | 2018-06-21 | Clearside Biomedical, Inc. | Systems and methods for delivering drugs to retinal tissue |
US20200061357A1 (en) | 2017-05-02 | 2020-02-27 | Georgia Tech Research Corporation | Targeted drug delivery methods using a microneedle |
US20190269702A1 (en) | 2018-03-05 | 2019-09-05 | Clearside Biomedical, Inc. | Compositions and methods for treating noninfectious uveitis |
US20210366311A1 (en) | 2020-05-22 | 2021-11-25 | Clearside Biomedical, Inc. | Apparatus and methods for fabricating and using a simulated anatomical tissue structure |
US20220280386A1 (en) | 2021-03-02 | 2022-09-08 | Clearside Biomedical, Inc. | Methods and apparatus for extracting fluid from container |
-
2007
- 2007-02-21 US US11/709,941 patent/US20070202186A1/en not_active Abandoned
- 2007-02-22 WO PCT/US2007/004874 patent/WO2007100745A2/en active Application Filing
- 2007-02-22 JP JP2008556462A patent/JP2009531298A/en active Pending
- 2007-02-22 CA CA002643019A patent/CA2643019A1/en not_active Abandoned
- 2007-02-22 EP EP07751620.1A patent/EP1986605B1/en active Active
- 2007-02-22 CN CN2007800145013A patent/CN101426473B/en active Active
- 2007-02-22 AU AU2007221105A patent/AU2007221105A1/en not_active Abandoned
- 2007-02-22 CN CN2011100936446A patent/CN102247239B/en active Active
- 2007-02-22 EP EP18176149.5A patent/EP3446679A1/en not_active Withdrawn
- 2007-02-22 BR BRPI0708133-2A patent/BRPI0708133A2/en not_active Application Discontinuation
- 2007-02-22 KR KR1020087020946A patent/KR20080099285A/en not_active Application Discontinuation
-
2013
- 2013-03-15 US US13/842,218 patent/US20130216623A1/en not_active Abandoned
- 2013-03-15 US US13/842,288 patent/US20130245600A1/en not_active Abandoned
-
2016
- 2016-11-22 US US15/358,908 patent/US20170290702A1/en not_active Abandoned
-
2017
- 2017-01-04 US US15/398,538 patent/US20170340560A1/en not_active Abandoned
-
2020
- 2020-01-13 US US16/741,473 patent/US20200390692A1/en not_active Abandoned
-
2021
- 2021-03-30 US US17/217,455 patent/US20210212940A1/en not_active Abandoned
-
2022
- 2022-04-01 US US17/711,495 patent/US11752101B2/en active Active
-
2023
- 2023-08-03 US US18/365,024 patent/US20230372235A1/en active Pending
Patent Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4377897A (en) * | 1981-08-04 | 1983-03-29 | Ocular Associates | Ophthalmic needle and method for manufacturing the same |
US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
US5273530A (en) * | 1990-11-14 | 1993-12-28 | The University Of Rochester | Intraretinal delivery and withdrawal instruments |
US5632740A (en) * | 1991-01-30 | 1997-05-27 | Ceram Optec Industries, Inc. | Illuminated leading probe device |
US5312361A (en) * | 1991-09-13 | 1994-05-17 | Zadini Filiberto P | Automatic cannulation device |
US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5766242A (en) * | 1993-11-15 | 1998-06-16 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5824072A (en) * | 1993-11-15 | 1998-10-20 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5952378A (en) * | 1994-08-24 | 1999-09-14 | Pharmacia & Upjohn Ab | Methods and means for drug administration |
US5792099A (en) * | 1995-02-14 | 1998-08-11 | Decamp; Dennis | Syringe and cannula for insertion of viscoelastic material into an eye and method of using same |
US20020042594A1 (en) * | 1998-03-30 | 2002-04-11 | Paul Lum | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US6936053B1 (en) * | 1998-07-02 | 2005-08-30 | Jeffrey N. Weiss | Ocular implant needle |
US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
US6397849B1 (en) * | 1998-08-03 | 2002-06-04 | Insite Vision Incorporated | Methods of ophthalmic administration |
US20010008961A1 (en) * | 1998-08-03 | 2001-07-19 | Hecker Karl I. | Injection apparatus and method of using same |
US20030171722A1 (en) * | 2001-01-04 | 2003-09-11 | Michel Paques | Microsurgical injection and/or distending instruments and surgical method and apparatus utilizing same |
US20050089545A1 (en) * | 2002-02-22 | 2005-04-28 | Mitsuaki Kuwano | Drug delivery system for the subconjunctival administration of fine grains |
US20040039253A1 (en) * | 2002-08-20 | 2004-02-26 | Peyman Gholam A. | Treatment of retinal detachment |
US20050137525A1 (en) * | 2003-06-04 | 2005-06-23 | Georgia Tech Research Corporation | Drilling microneedle device |
US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
US20050171507A1 (en) * | 2004-01-23 | 2005-08-04 | Christian Jeffrey J. | Composite ophthalmic microcannula |
US20050244462A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Devices and methods for treating a mammalian eye |
US20060233858A1 (en) * | 2005-03-08 | 2006-10-19 | Allergan, Inc. | Systems and methods providing targeted intraocular drug delivery |
US20080033351A1 (en) * | 2006-08-04 | 2008-02-07 | Allergan, Inc. | Ocular implant delivery assemblies with distal caps |
Cited By (182)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170038284A1 (en) * | 1998-10-23 | 2017-02-09 | Babak Nemati | Systems for augmenting optical transmission through biological tissues |
US10568762B2 (en) | 1999-04-26 | 2020-02-25 | Glaukos Corporation | Stent for treating ocular disorders |
US9789001B2 (en) | 2000-04-14 | 2017-10-17 | Dose Medical Corporation | Ocular implant with therapeutic agents and methods thereof |
US9066782B2 (en) | 2000-04-14 | 2015-06-30 | Dose Medical Corporation | Ocular implant with therapeutic agents and methods thereof |
US10485702B2 (en) | 2000-04-14 | 2019-11-26 | Glaukos Corporation | System and method for treating an ocular disorder |
US9993368B2 (en) | 2000-04-14 | 2018-06-12 | Glaukos Corporation | System and method for treating an ocular disorder |
US20110105987A1 (en) * | 2000-04-14 | 2011-05-05 | Glaukos Corporation | System and method for treating an ocular disorder |
US8348877B2 (en) | 2000-04-14 | 2013-01-08 | Dose Medical Corporation | Ocular implant with therapeutic agents and methods thereof |
US8075511B2 (en) | 2001-04-07 | 2011-12-13 | Glaukos Corporation | System for treating ocular disorders and methods thereof |
US9987472B2 (en) | 2001-04-07 | 2018-06-05 | Glaukos Corporation | Ocular implant delivery systems |
US8062244B2 (en) | 2001-04-07 | 2011-11-22 | Glaukos Corporation | Self-trephining implant and methods thereof for treatment of ocular disorders |
US9155654B2 (en) | 2001-04-07 | 2015-10-13 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US8118768B2 (en) | 2001-04-07 | 2012-02-21 | Dose Medical Corporation | Drug eluting ocular implant with anchor and methods thereof |
US10406029B2 (en) | 2001-04-07 | 2019-09-10 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US20080200860A1 (en) * | 2001-04-07 | 2008-08-21 | Glaukos Corporation | System for treating ocular disorders and methods thereof |
US9572963B2 (en) | 2001-04-07 | 2017-02-21 | Glaukos Corporation | Ocular disorder treatment methods and systems |
US8579846B2 (en) | 2001-04-07 | 2013-11-12 | Glaukos Corporation | Ocular implant systems |
US10828473B2 (en) | 2001-04-07 | 2020-11-10 | Glaukos Corporation | Ocular implant delivery system and methods thereof |
US7857782B2 (en) | 2001-04-07 | 2010-12-28 | Glaukos Corporation | Ocular implant delivery system and method thereof |
US8142364B2 (en) | 2001-05-02 | 2012-03-27 | Dose Medical Corporation | Method of monitoring intraocular pressure and treating an ocular disorder |
US7951155B2 (en) | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US20070118147A1 (en) * | 2002-03-15 | 2007-05-24 | Smedley Gregory T | Combined treatment for cataract and glaucoma treatment |
US8882781B2 (en) | 2002-03-15 | 2014-11-11 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
US20100087774A1 (en) * | 2002-09-21 | 2010-04-08 | Glaukos Corporation | Ocular implant with anchoring mechanism and multiple outlets |
US8007459B2 (en) | 2002-09-21 | 2011-08-30 | Glaukos Corporation | Ocular implant with anchoring mechanism and multiple outlets |
US20070129693A1 (en) * | 2005-11-11 | 2007-06-07 | Hunter Ian W | Controlled needle-free eye injector |
US20220347014A1 (en) * | 2006-02-22 | 2022-11-03 | Clearside Biomedical, Inc. | Ocular injector and methods for accessing suprachoroidal space of the eye |
US11752101B2 (en) * | 2006-02-22 | 2023-09-12 | Clearside Biomedical, Inc. | Ocular injector and methods for accessing suprachoroidal space of the eye |
US8636713B2 (en) | 2006-05-02 | 2014-01-28 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
US10632013B2 (en) | 2006-05-02 | 2020-04-28 | Georgia Tech Research Corporation | Methods and devices for drug delivery to ocular tissue using microneedle |
US8808225B2 (en) | 2006-05-02 | 2014-08-19 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
US10905586B2 (en) | 2006-05-02 | 2021-02-02 | Georgia Tech Research Corporation | Methods and devices for drug delivery to ocular tissue using microneedle |
US9788995B2 (en) | 2006-05-02 | 2017-10-17 | Georgia Tech Research Corporation | Methods and devices for drug delivery to ocular tissue using microneedle |
US10085884B2 (en) | 2006-06-30 | 2018-10-02 | Aquesys, Inc. | Intraocular devices |
US9962290B2 (en) | 2006-11-10 | 2018-05-08 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US8506515B2 (en) | 2006-11-10 | 2013-08-13 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US10828195B2 (en) | 2006-11-10 | 2020-11-10 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US9402767B2 (en) | 2007-09-24 | 2016-08-02 | Ivantis, Inc. | Ocular implant architectures |
US8734377B2 (en) | 2007-09-24 | 2014-05-27 | Ivantis, Inc. | Ocular implants with asymmetric flexibility |
US8961447B2 (en) | 2007-09-24 | 2015-02-24 | Ivantis, Inc. | Glaucoma treatment method |
US11744734B2 (en) | 2007-09-24 | 2023-09-05 | Alcon Inc. | Method of implanting an ocular implant |
US9039650B2 (en) | 2007-09-24 | 2015-05-26 | Ivantis, Inc. | Ocular implants with asymmetric flexibility |
US9610196B2 (en) | 2007-09-24 | 2017-04-04 | Ivantis, Inc. | Ocular implants with asymmetric flexibility |
US9351874B2 (en) | 2007-11-20 | 2016-05-31 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US9226852B2 (en) | 2007-11-20 | 2016-01-05 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8808222B2 (en) | 2007-11-20 | 2014-08-19 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US9050169B2 (en) | 2007-11-20 | 2015-06-09 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8551166B2 (en) | 2007-11-20 | 2013-10-08 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8512404B2 (en) | 2007-11-20 | 2013-08-20 | Ivantis, Inc. | Ocular implant delivery system and method |
US11504275B2 (en) | 2008-03-05 | 2022-11-22 | Alcon Inc. | Methods and apparatus for treating glaucoma |
US10537474B2 (en) | 2008-03-05 | 2020-01-21 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
US9693902B2 (en) | 2008-03-05 | 2017-07-04 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
US8529494B2 (en) | 2008-03-05 | 2013-09-10 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
US9066783B2 (en) | 2008-03-05 | 2015-06-30 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
US8409606B2 (en) | 2009-02-12 | 2013-04-02 | Incept, Llc | Drug delivery through hydrogel plugs |
US8563027B2 (en) | 2009-02-12 | 2013-10-22 | Incept, Llc | Drug delivery through hydrogel plugs |
WO2010132751A1 (en) * | 2009-05-15 | 2010-11-18 | Iscience Interventional Corporation | Methods and apparatus for sub-retinal catheterization |
US11426306B2 (en) | 2009-05-18 | 2022-08-30 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US10813789B2 (en) | 2009-05-18 | 2020-10-27 | Dose Medical Corporation | Drug eluting ocular implant |
US11596546B2 (en) | 2009-07-09 | 2023-03-07 | Alcon Inc. | Ocular implants and methods for delivering ocular implants into the eye |
US11464675B2 (en) | 2009-07-09 | 2022-10-11 | Alcon Inc. | Single operator device for delivering an ocular implant |
US11918514B2 (en) | 2009-07-09 | 2024-03-05 | Alcon Inc. | Single operator device for delivering an ocular implant |
US10406025B2 (en) | 2009-07-09 | 2019-09-10 | Ivantis, Inc. | Ocular implants and methods for delivering ocular implants into the eye |
US9693899B2 (en) | 2009-07-09 | 2017-07-04 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
US9211213B2 (en) | 2009-07-09 | 2015-12-15 | Ivantis, Inc. | Ocular implants and methods for delivering ocular implants into the eye |
US10492949B2 (en) | 2009-07-09 | 2019-12-03 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
US9579234B2 (en) | 2009-10-23 | 2017-02-28 | Ivantis, Inc. | Ocular implant system and method |
US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
US9089392B2 (en) | 2009-12-23 | 2015-07-28 | Transcend Medical, Inc. | Drug delivery devices and methods |
US9549846B2 (en) | 2009-12-23 | 2017-01-24 | Novartis Ag | Drug delivery devices and methods |
WO2011139713A2 (en) | 2010-04-26 | 2011-11-10 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
EP2563429B1 (en) * | 2010-04-26 | 2020-04-15 | Emory University | Device for delivery of a drug to ocular tissue using microneedle |
US9510973B2 (en) | 2010-06-23 | 2016-12-06 | Ivantis, Inc. | Ocular implants deployed in schlemm's canal of the eye |
CN106214321A (en) * | 2010-10-15 | 2016-12-14 | 科尼尔赛德生物医学公司 | For entering the device of eyes |
WO2012051575A3 (en) * | 2010-10-15 | 2012-06-14 | Iscience Interventional Corporation | Device for ocular access |
US10952894B2 (en) | 2010-10-15 | 2021-03-23 | Clearside Biomedical, Inc. | Device for ocular access |
US9980854B2 (en) | 2010-11-15 | 2018-05-29 | Aquesys, Inc. | Shunt placement through the sclera |
US10842671B2 (en) | 2010-11-15 | 2020-11-24 | Aquesys, Inc. | Intraocular shunt placement in the suprachoroidal space |
US10307293B2 (en) | 2010-11-15 | 2019-06-04 | Aquesys, Inc. | Methods for intraocular shunt placement |
US10004638B2 (en) | 2010-11-15 | 2018-06-26 | Aquesys, Inc. | Intraocular shunt delivery |
US20160256320A1 (en) * | 2010-11-15 | 2016-09-08 | Aquesys, Inc. | Intraocular shunt placement in the suprachoroidal space |
US10285852B2 (en) | 2010-12-02 | 2019-05-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd., The Chaim Sheba Medical Center | Subretinal delivery of therapeutic compositions |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
US9155655B2 (en) | 2011-06-14 | 2015-10-13 | Ivantis, Inc. | Ocular implants for delivery into the eye |
US10363168B2 (en) | 2011-06-14 | 2019-07-30 | Ivantis, Inc. | Ocular implants for delivery into the eye |
US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
US20140316326A1 (en) * | 2011-08-16 | 2014-10-23 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Device for the treatment of an ocular disease |
US11363951B2 (en) | 2011-09-13 | 2022-06-21 | Glaukos Corporation | Intraocular physiological sensor |
US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
US20160256323A1 (en) * | 2011-12-08 | 2016-09-08 | Aquesys, Inc. | Intrascleral shunt placement |
US10080682B2 (en) * | 2011-12-08 | 2018-09-25 | Aquesys, Inc. | Intrascleral shunt placement |
US11135088B2 (en) | 2011-12-19 | 2021-10-05 | Ivantis Inc. | Delivering ocular implants into the eye |
US9931243B2 (en) | 2011-12-19 | 2018-04-03 | Ivantis, Inc. | Delivering ocular implants into the eye |
US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
US9066750B2 (en) | 2011-12-19 | 2015-06-30 | Ivantis, Inc. | Delivering ocular implants into the eye |
EP2806853B1 (en) * | 2012-01-23 | 2020-07-08 | Allergan, Inc. | Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation |
IL265620A (en) * | 2012-01-23 | 2019-05-30 | Allergan Inc | Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation |
US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
US11026836B2 (en) | 2012-04-18 | 2021-06-08 | Ivantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
JP2015535293A (en) * | 2012-11-08 | 2015-12-10 | クリアサイド バイオメディカル,インコーポレイテッド | Methods and devices for the treatment of ocular disorders in human subjects |
EP2916827A4 (en) * | 2012-11-08 | 2016-12-07 | Clearside Biomedical Inc | Methods and devices for the treatment of ocular diseases in human subjects |
EA034963B1 (en) * | 2012-11-08 | 2020-04-13 | Клиасайд Байомедикал, Инк. | Method of treating a posterior segment of the eye disorder |
WO2014074823A1 (en) * | 2012-11-08 | 2014-05-15 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
US9572800B2 (en) | 2012-11-08 | 2017-02-21 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
EP3721872A1 (en) * | 2012-11-08 | 2020-10-14 | Clearside Biomedical Inc. | Methods for the treatment of ocular disease in human subjects |
US9931330B2 (en) | 2012-11-08 | 2018-04-03 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
US9636332B2 (en) | 2012-11-08 | 2017-05-02 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
AU2013342275B2 (en) * | 2012-11-08 | 2017-11-09 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
US11712369B2 (en) | 2012-11-28 | 2023-08-01 | Alcon Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
US10617558B2 (en) | 2012-11-28 | 2020-04-14 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
US9022968B2 (en) * | 2013-01-08 | 2015-05-05 | University Of South Florida | Auto-regulation system for intraocular pressure |
US20140194834A1 (en) * | 2013-01-08 | 2014-07-10 | University Of South Florida | Auto-Regulation System for Intraocular Pressure |
US10524959B2 (en) | 2013-02-27 | 2020-01-07 | Aquesys, Inc. | Intraocular shunt implantation methods and devices |
US10849558B2 (en) | 2013-03-13 | 2020-12-01 | Glaukos Corporation | Intraocular physiological sensor |
US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
WO2014159889A1 (en) * | 2013-03-14 | 2014-10-02 | Lumoptik, Inc. | Insertion tool guidance system for ocular access |
US11253394B2 (en) | 2013-03-15 | 2022-02-22 | Dose Medical Corporation | Controlled drug delivery ocular implants and methods of using same |
US9937075B2 (en) | 2013-05-03 | 2018-04-10 | Clearside Biomedical, Inc. | Apparatus and methods for ocular injection |
US20150051581A1 (en) * | 2013-05-03 | 2015-02-19 | Clearside Biomedical, Inc. | Apparatus and methods for ocular injection |
US10517756B2 (en) | 2013-05-03 | 2019-12-31 | Clearside Biomedical, Inc | Apparatus and methods for ocular injection |
EP2991706B1 (en) | 2013-05-03 | 2021-06-23 | Clearside Biomedical, Inc. | Apparatus and methods for ocular injection |
US9180047B2 (en) * | 2013-05-03 | 2015-11-10 | Clearside Biomedical, Inc. | Apparatus and methods for ocular injection |
US10555833B2 (en) | 2013-05-03 | 2020-02-11 | Clearside Biomedical, Inc. | Apparatus and methods for ocular injection |
US9770361B2 (en) | 2013-05-03 | 2017-09-26 | Clearside Biomedical, Inc. | Apparatus and methods for ocular injection |
AU2014259694B2 (en) * | 2013-05-03 | 2018-11-08 | Clearside Biomedical, Inc. | Apparatus and methods for ocular injection |
US11559428B2 (en) | 2013-05-03 | 2023-01-24 | Clearside Biomedical, Inc. | Apparatus and methods for ocular injection |
US9636253B1 (en) | 2013-05-03 | 2017-05-02 | Clearside Biomedical, Inc. | Apparatus and methods for ocular injection |
US9539139B2 (en) | 2013-05-03 | 2017-01-10 | Clearside Biomedical, Inc. | Apparatus and methods for ocular injection |
US10722396B2 (en) | 2013-05-03 | 2020-07-28 | Clearside Biomedical., Inc. | Apparatus and methods for ocular injection |
US10188550B2 (en) | 2013-06-03 | 2019-01-29 | Clearside Biomedical, Inc. | Apparatus and methods for drug delivery using multiple reservoirs |
US10369048B2 (en) | 2013-06-28 | 2019-08-06 | Aquesys, Inc. | Intraocular shunt implantation |
US11298264B2 (en) | 2013-06-28 | 2022-04-12 | Aquesys, Inc. | Intraocular shunt implantation |
US20160143776A1 (en) * | 2013-08-02 | 2016-05-26 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | A device for delivery of compositions to the eye |
WO2015015467A1 (en) * | 2013-08-02 | 2015-02-05 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | A device for delivery of compositions to the eye |
CN105592828A (en) * | 2013-08-02 | 2016-05-18 | 堤乐哈修门医学研究基础建设及服务有限公司 | A device for delivery of compositions to the eye |
US20160270894A1 (en) * | 2013-11-01 | 2016-09-22 | Atrium Medical Corporation | Positioning agent and method of using the same |
US10842604B2 (en) * | 2013-11-01 | 2020-11-24 | Atrium Medical Corporation | Positioning agent and method of using the same |
US10188495B2 (en) * | 2013-11-01 | 2019-01-29 | Atrium Medical Corporation | Positioning agent and method of using the same |
US10470928B2 (en) | 2013-11-14 | 2019-11-12 | Aquesys, Inc. | Intraocular shunt inserter |
US20170172797A1 (en) * | 2013-11-14 | 2017-06-22 | Aquesys, Inc. | Intraocular shunt insertion techniques |
US10653555B2 (en) * | 2013-11-14 | 2020-05-19 | Aquesys, Inc. | Intraocular shunt insertion techniques |
US20160302965A1 (en) * | 2013-12-06 | 2016-10-20 | Forsight Vision4, Inc. | Implantable therapeutic devices |
US10010447B2 (en) | 2013-12-18 | 2018-07-03 | Novartis Ag | Systems and methods for subretinal delivery of therapeutic agents |
WO2015095772A3 (en) * | 2013-12-20 | 2015-08-13 | Emory University | Formulations and methods for targeted ocular delivery of therapeutic agents |
US9205181B2 (en) | 2014-01-09 | 2015-12-08 | Rainbow Medical, Ltd. | Injectable hydrogel implant for treating glaucoma |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
EP3157463A4 (en) * | 2014-06-17 | 2018-02-21 | Clearside Biomedical, Inc. | Methods and devices for treating posterior ocular disorders |
US9956114B2 (en) | 2014-06-20 | 2018-05-01 | Clearside Biomedical, Inc. | Variable diameter cannula and methods for controlling insertion depth for medicament delivery |
US10709547B2 (en) | 2014-07-14 | 2020-07-14 | Ivantis, Inc. | Ocular implant delivery system and method |
US11096822B2 (en) | 2014-09-19 | 2021-08-24 | Oxular Limited | Ophthalmic delivery device |
WO2016042162A1 (en) * | 2014-09-19 | 2016-03-24 | Medterials, Inc. | Ophthalmic delivery device |
AU2015316709B2 (en) * | 2014-09-19 | 2020-03-26 | Oxular Limited | Ophthalmic delivery device |
USD750223S1 (en) | 2014-10-14 | 2016-02-23 | Clearside Biomedical, Inc. | Medical injector for ocular injection |
US11612517B2 (en) | 2015-06-03 | 2023-03-28 | Aquesys, Inc. | Ab externo intraocular shunt placement |
US10470927B2 (en) | 2015-06-03 | 2019-11-12 | Aquesys, Inc. | AB externo intraocular shunt placement |
US10463537B2 (en) | 2015-06-03 | 2019-11-05 | Aquesys Inc. | Ab externo intraocular shunt placement |
US11197779B2 (en) | 2015-08-14 | 2021-12-14 | Ivantis, Inc. | Ocular implant with pressure sensor and delivery system |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
EP3345642A4 (en) * | 2015-09-03 | 2019-07-10 | Pusan National University Hospital | Optically induced injection device |
US11154420B2 (en) | 2015-09-17 | 2021-10-26 | Oxular Limited | Ophthalmic injection device |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
US10390901B2 (en) | 2016-02-10 | 2019-08-27 | Clearside Biomedical, Inc. | Ocular injection kit, packaging, and methods of use |
US11622884B2 (en) | 2016-03-16 | 2023-04-11 | Oxular Limited | Ophthalmic delivery device and ophthalmic drug compositions |
US11318043B2 (en) | 2016-04-20 | 2022-05-03 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
CN109073653A (en) * | 2016-04-22 | 2018-12-21 | 国立癌中心 | For marking the injection composition of lesion |
US11596545B2 (en) | 2016-05-02 | 2023-03-07 | Clearside Biomedical, Inc. | Systems and methods for ocular drug delivery |
US10667947B2 (en) | 2016-06-02 | 2020-06-02 | Aquesys, Inc. | Intraocular drug delivery |
US11504431B2 (en) * | 2016-07-20 | 2022-11-22 | Emory University | Formulations for the suprachoroidal space of an eye and methods |
EP3487586A4 (en) * | 2016-07-20 | 2020-03-04 | Emory University | Formulations for the suprachoroidal space of an eye and methods |
US10973681B2 (en) | 2016-08-12 | 2021-04-13 | Clearside Biomedical, Inc. | Devices and methods for adjusting the insertion depth of a needle for medicament delivery |
US11273072B2 (en) | 2017-01-13 | 2022-03-15 | Gyroscope Therapeutics Limited | Suprachoroidal injection device |
US20190110924A1 (en) * | 2017-10-18 | 2019-04-18 | Jesus Moreno | Opthalmic microsurgical instrument |
US10987247B2 (en) * | 2017-10-18 | 2021-04-27 | Jesus Moreno | Opthalmic microsurgical instrument |
US11576816B2 (en) * | 2017-10-18 | 2023-02-14 | Jesus Moreno | Opthalmic microsurgical instrument |
US11564835B2 (en) * | 2017-10-18 | 2023-01-31 | Jesus Moreno | Opthalmic microsurgical instrument |
US11246753B2 (en) | 2017-11-08 | 2022-02-15 | Aquesys, Inc. | Manually adjustable intraocular flow regulation |
US11135089B2 (en) | 2018-03-09 | 2021-10-05 | Aquesys, Inc. | Intraocular shunt inserter |
US10952898B2 (en) | 2018-03-09 | 2021-03-23 | Aquesys, Inc. | Intraocular shunt inserter |
CN108653818A (en) * | 2018-05-24 | 2018-10-16 | 上海其胜生物制剂有限公司 | A kind of reversible collagen stimulation filler and preparation method thereof |
US11540940B2 (en) | 2021-01-11 | 2023-01-03 | Alcon Inc. | Systems and methods for viscoelastic delivery |
Also Published As
Publication number | Publication date |
---|---|
US20210212940A1 (en) | 2021-07-15 |
EP1986605B1 (en) | 2018-06-06 |
US11752101B2 (en) | 2023-09-12 |
CN101426473B (en) | 2011-06-08 |
CN102247239A (en) | 2011-11-23 |
BRPI0708133A2 (en) | 2011-05-17 |
AU2007221105A1 (en) | 2007-09-07 |
KR20080099285A (en) | 2008-11-12 |
EP1986605A2 (en) | 2008-11-05 |
WO2007100745A2 (en) | 2007-09-07 |
US20130216623A1 (en) | 2013-08-22 |
CA2643019A1 (en) | 2007-09-07 |
CN102247239B (en) | 2013-10-30 |
EP1986605A4 (en) | 2013-02-13 |
US20220347014A1 (en) | 2022-11-03 |
JP2009531298A (en) | 2009-09-03 |
US20200390692A1 (en) | 2020-12-17 |
WO2007100745A3 (en) | 2008-07-24 |
US20130245600A1 (en) | 2013-09-19 |
EP3446679A1 (en) | 2019-02-27 |
US20170290702A1 (en) | 2017-10-12 |
US20230372235A1 (en) | 2023-11-23 |
US20170340560A1 (en) | 2017-11-30 |
CN101426473A (en) | 2009-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11752101B2 (en) | Ocular injector and methods for accessing suprachoroidal space of the eye | |
Einmahl et al. | Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye | |
US20230355431A1 (en) | Ophthalmic Drug Compositions | |
KR20110139772A (en) | Apparatus and method for ocular treatment | |
CN101180086A (en) | Sustained release implants for subretinal delivery | |
JP2007536220A (en) | Use of viscoelastic compositions to treat increased intraocular pressure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ISCIENCE INTERVENTIONAL CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YAMAMOTO, RONALD;CONSTON, STANLEY R.;SIERRA, DAVID;REEL/FRAME:019305/0388 Effective date: 20070424 |
|
AS | Assignment |
Owner name: CLEARSIDE BIOMEDICAL, INC., GEORGIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ISCI HOLDINGS INC. F/K/A/ ISCIENCE INTERVENTIONAL CORPORATION;REEL/FRAME:036385/0377 Effective date: 20150324 Owner name: ISCI HOLDINGS INC., CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:ISCIENCE INTERVENTIONAL CORPORATION;REEL/FRAME:036408/0010 Effective date: 20140121 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
AS | Assignment |
Owner name: SILICON VALLEY BANK, CALIFORNIA Free format text: SECURITY INTEREST;ASSIGNOR:CLEARSIDE BIOMEDICAL, INC.;REEL/FRAME:050217/0270 Effective date: 20190829 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: CLEARSIDE BIOMEDICAL, INC., GEORGIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:SILICON VALLEY BANK;REEL/FRAME:053139/0929 Effective date: 20200706 |